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CHAPTER 1 
Surfactant Metabolism by Alveolar Cells: 
factors affecting lipid uptake in vivo and in vitro 
Davey L. Poelma1, J. Freek van Iwaarden2 and Burkhard Lachmann1 
1 Dept. of Anesthesiology, Erasmus MC-Faculty; Rotterdam, The Netherlands 
2 Dept of Neonatology, University Hospital Maastricht, Maastricht, The Netherlands 
Modified version accepted for publication 
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Introduction 
Kurt von Neergaardll was the first to draw attention to the role of surface tension within the 
lung. In 1929, he demonstrated that the pressure needed to inflate a fluid-filled lung with fluid 
was less than approximately % to 1,4 of the pressure necessary to inflate an air-filled lung with 
the same volume of air (Fig. 11l). From these experiments he concluded that about two-thirds 
of the retractive forces are due to surface tension phenomena acting at the air-liquid interface 
within the lung; and accordingly this surface tension at the alveolar level is reduced by the 
presence of a surface active agent with a low surface tension to allow normal breathing. 
Unfortunately, these findings were published in the German language only and for approxi-
mately 25 years they remained practically unnoticed by other scientists in the field. The next 
description of the presence of a surface active agent within the lung was in 1954 by Macklin 
who described a thin aqueous mucoid film, formed by granular pneumocytes, on the alveolar 
wall and which moved constantly towards bronchioles and phagocytic pneumocytes21 • The 
following year, it was noted by Pattle and colleagues, that the foam and bubbles from lung 
edema and healthy lung cut had a remarkable stability; they concluded that these bubbles 
consisted of a surface active agent, able to lower surface tension towards zero31 • 
In 1957, Clements used the Wilhelmy balance to demonstrate that the surface tension derived 
from the alveolar lining fluid of the lung was not a constant value; with a large surface, surface 
tension was high, but when the surface area was decreased, surface tension fell to values near 
zero41 • 
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Figure 1. Pressure volume diagram of a healthy air-filled lung and an ARDS lung. In 
ARDS higher pressures are required to expand the lung compared to a healthy lung due 
to the high surface tension at the air liquid interface in the alveoli. Which is caused by 
surfactant inactivity. Adapted from von Neergaard1l. 
Avery and Mead made the first steps towards extensive research on this surface active agent, 
called pulmonary surfactant, by demonstrating higher surface tension in very small premature 
infants and infants dying of respiratory failure due to hyaline membrane disease5l. Even today, 
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almost half a century later, small steps are still being made toward a better understanding of 
this surface active agent. 
Pulmonary surfactant 
This pulmonary surfactant, lining the alveolar surface, is a complex of lipids and proteins 
produced in the alveolar type II cells and secreted into the alveolar space. 
Lipids 
The lipid composition is generally the same in both compartments6• ?l. Most of the lipids are 
phospholipids (80-90%), and in decreasing order of content are cholesterol, triacylglycerol and 
free fatty acids7l (Fig. 2). 
Phosphatidylcholine (PC) compromises most of the phospholidids (70-80%), of which 
approximately 50% is disaturated (DPPC) 6• 8l. 
This subgroup of PC is an unusual species, with palmatic acid at both the 1-position and 2-
position rather than a saturated fatty acid at the 1-position and unsaturated fatty acid at the 2-
position of the diacylglycerolphospholipid found in most mammalian tissues; although not 
specific for surfactant (because it is also found in other tissues) it compromises a very high 
percentage of the surfactant phospholipids. 
Already in early fetal gestation, about 20% of the total amount of PC retrieved from the lung 
is DPPGl. This DPPC is the main surface tension lowering phospholipid in the lung. 
Although only a small fraction of the extracellular DPPC is necessary to cover the alveolar wall 
throughout the lung with a monolayer (as calculated by Wright and Clements10l) its pool size 
is tightly regulated. For example, decreases in the amount of DPPC on the short term due to 
an abnormal nutritional state such as fasting11l, fatty acid deficiency12l or choline deficiency13l, 
are replenished rapidly by adaptation mechanisms'4l. 
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Figure 2. Schematic overview of surfactant composition. 
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SP-C 
SP-D 
PPC 
PC, phosphatidylcholine; DPPC, dipalmitoylphosphatidylcholine; PI, phosphatidylino-
sitol; PG, phosphatidylglycerol; PE, phosphatidylethanolamine; Chol, cholesterol. 
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Next, all mammalian pulmonary surfactants have been shown to contain significant amounts 
of phosphatidylglycerol (PG) (7-18%) and phosphatidylinositol (PI) (2-4%) 15l, suggesting a 
specific role of these acidic phospholipids. In adult mammalians, PG is the second major lipid 
component next to PC, comprising approximately 5-l 0% of total surfactant phospholipids in 
humans7· 16.18l and rats6· 19l. However, in preterm fetal lungs the PG component in surfactant is 
extremely low, although its relative absence is compensated by an increased amount of PP· 20'22l 
in the surfactant compartments. 
When DPPC is mixed with PG or PI, adsorption of the lipids in the monolayer is enhanced, 
indicating that these negatively charged lipids may play an important role in the surface 
tension lowering activity of surfactant. For PG, this enhanced adsorption may be caused by a 
specific interaction between PG and SP-B23·24l. 
Finally, the remaining phospholipids consist mainly of phosphatidyl-ethanolamine (PE; 2-3%) 
and some other minor phospholipids, whereas the total surfactant is completed by choles-
teroP5l. 
Proteins 
Pulmonary surfactant contains at least four surfactant proteins (SP), SP-A, SP-B, SP-C and 
SP-D. Of these proteins, SP-A and SP-D are hydrophilic proteins and SP-B and SP-C are 
hydrophobic. 
SP-A has been extensively studied and although its role is not yet completely clear, it is 
suggested that it plays an important role in regulating surfactant function via binding to 
phospholipids25· 26l, modifYing phospholipid structure to tubular myeline27· 28l, maintaining the 
surface properties of surfactanr29l, regulating secretion and clearance of surfactant30·37l, 
regulation of alveolar macrophage function38l, as well as a possible role in the immunological 
properties of surfactant38· 39l. 
SP-B and SP-C are two hydrophobic proteins that are known to play an important role in the 
formation of a stable lipid monolayer. Especially SP-B has been shown to be essential for 
normal surfactant function, lowering surface tension40· 40; absence of SP-B at birth leads to 
death caused by respiratory insufficiency42· 43l, and conditional knockout of SP-B in adult 
animals leads to respiratory failure44l. In addition SP-B is also suggested to play a role in the 
protection of the surfactant system against endotoxin-induced lung inflammation by 
enhancing surfactant function, resulting in reduced lung injury, decreased influx of 
inflammatory cells, and lower cytokine levels45l. 
SP-C also enhances the surface active properties of surfactant40·41·4648l. Although (unlike SP-B) 
its absence at birth is not lethal, it does result in decreased stability of surfactant at low olumes 
despite the fact that surfactant pool sizes and lung morphology were similar in wild type and 
SP-C knockout mice49l. Another function of SP-C is to increase the resistance of surfactant 
against inactivation by plasma proteins50l. On the other hand, elevated expression of SP-C is 
thought to be related to cytotoxicity and, ultimately, altered lung development50. Though SP-
D has been suggested to be the fourth surfactant protein, this protein is not only found within 
the lung but also in other organ systems and its specific contribution with regard to surfactant 
is not completely clear; however, several studies have suggested that, together with SP-A, it has 
an immunomodulatory role in the lun~9· 52-55l. 
Metabolism 
The presence of surfactant within the alveolus is the result of a complex system of production, 
secretion, insertion into the lipid monolayer and tum-over, uptake and recycling (Fig. 3). 
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Figure 3. Diagram showing surfactant metabolism. 
Production and secretion 
Surfactant phospholipids are produced by alveolar type II cells which comprise only 15% of 
the total number of cells in the lung56-581 • The de novo synthesis of surfactant is thought to be 
relatively slow, especially in newborn animals59• 601 as well as in humans as demonstrated by Bunt 
et al. using stable isotopes611 • Bunt and colleagues also demonstrated that the use of prenatal 
corticosteroids increased surfactant synthesis in the preterm infant621 as well as in very 
premature baboons631 • Therefore, most of the surface-active surfactant is produced by recycling. 
Martini and co-workers demonstrated that approximately 50-90% of the PC in surfactant is 
recycled depending on age and species, whereby with increasing age the contribution of 
recycling decreases641 • The surfactant lipids are synthesized in the endoplasmatic reticulum and 
then stored in lamellar bodies65• 661 • In these lamellar bodies surfactant specific proteins A, B and 
C are already present671; however, the content of SP-A is extremely low (1 %) suggesting that 
the SP-A present in the alveolar space might be derived from parts other than lamellar bodies. 
When the alveolar type II cell is stimulated, intracellular effectors diffuse and activate the 
movement of the lamellar bodies to the apical plasma membrane of the alveolar type II cells, 
and the content of the lamellar bodies is secreted into the alveolar space by a process of 
regulated exocyrosis58• 68• 691 (for more details on the regulation of secretion see56• 70• 711). 
After excretion into the alveolar space the lamellar bodies unravel and form tubular myeline 
after association with SP-N8• 721 • Subsequently, the material of the lamellar bodies is absorbed/ 
inserted into the lipid monolayer. This tubular myelin is most likely the immediate precursor 
for lipids inserted into the monolayer; however it should be noted that SP-A knockout mice 
do not produce normal tubular myelin and the structure and in vitro properties of surfactant 
have changed. However, the in vivo function of surfactant in SP-A knockout mice has not 
changed, and thus tubular myeline is not essential for normal lung functiod31 • 
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Turnover of surfactant 
During respiration the surfactant in the lipid monolayer is turned over from large surface 
active aggregates into small inactive surfactant aggregates74-76l. However, little is known about 
the exact mechanism of this turnover. These small aggregates are not surface active and are 
removed from the alveolar space to be reutilized or recycled to ensure the presence of surface 
active aggregates in the lipid monolayer. 
Uptake/removal of small aggregates 
The turned-over, inactivated surfactant is mainly cleared from the alveolar space by uptake by 
alveolar type II cells and alveolar macrophages. However, their relative contribution to the 
uptake of surfactant lipids remains obscure and is dependent on several factors. In vitro studies 
suggested a major role for alveolar macrophages77l, whereas in vivo experiments suggested an 
equal contribution or even a major role for alveolar type II cells in the clearance of surfactanr78· 
80) 
Because of the need of recycling, as suggested previously, re-uptake of surfactant by alveolar 
type II cells is essential and possibly a crucial factor in the surfactant metabolism. 
Unfortunately, little is known about the regulation and mechanisms of removal of surfactant 
from the alveolar space by alveolar type II cells and alveolar macrophages. 
This uptake of surfactant lipids is thought to take place (at least in part) via a coated-pit 
pathwat1"83l. More recently, it was demonstrated that all surfactant phospholipids are 
internalized via the same pathway by alveolar macrophages and alveolar type II cells, though 
alveolar cells have a higher affinity for negatively charged phospholipids84l. In addition, the 
surfactant proteins are known to affect the uptake, especially SP-A34• 36• 80• 85• 86l. 
Measuring the uptake 
Most studies on surfactant metabolism, especially those focused on the uptake of surfactant 
lipids by alveolar type II cells and alveolar macrophages, used radioactive labeled DPPC to 
measure the uptake. In addition, most studies were performed in an in vitro setting, whereas 
the in vivo studies mainly focused on alveolar macrophages. Unfortunately, the use of radio-
activity does not discriminate between uptake or intracellular presence of the label and 
association with the outer cell membrane or adherence. In addition, one cannot specify the 
specific cells involved in the "uptake" as whole lung tissue is tested on radioactivity. 
Recently, we described a method using fluorescent labeled liposomes to study the uptake of 
surfactant-like liposomes both in vivo and in vitro, in both alveolar type II cells and alveolar 
macrophages. Our method mimics the small aggregates of surfactant, as these are the 
surfactant aggregates generally thought to be removed from the alveolar space. In addition, 
using confocal laser microscopy it can be demonstrated that the fluorescent labeled liposomes 
are indeed intracellular located rather than stuck to the outer cell membrane. 
More interestingly, in our method it is not DPPC that is labeled but PE, a minor component 
of surfactant as a part of liposomes consisting of the main lipid components of surfactant, 
providing the opportunity to study the role of the main lipid components in the regulation of 
the uptake of surfactant. 
One of the advantages of the use of fluorescent labeled liposomes is the possibility to focus on 
one particular cell type; with the use of specific fluorescent labeled antibodies one can 
discriminate between different cell types and study their relative contribution or role in the 
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removal of surfactant lipids and possible mutual regulation of the uptake; even more specific, 
one can determine whether all cells or a subpopulation of cells is involved in the uptake. 
Another important advantage of the method described by our group is that it allows to 
measure uptake by alveolar type II cells and alveolar macro phages both in vivo and in vitro. We 
believe we were the first to demonstrate that in vivo a significantly small percentage of the 
alveolar type II cells is involved in the uptake in comparison to in vitro; this indicates the need 
to study uptake both in vitro and in vivo (Fig. 4). 
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Figure 4. Differences in uptake in vivo and in vitro. 
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Cell-associated fluorescence as a measure for the uptake of surfactant-like liposomes was 
determined for different concentrations of labeled liposomes both in vitro (A, C) and in 
vivo (B, D). Additionally the percentage cells involved in the uptake was determined. 
Data derived from Poelma et al. 2002 . ATII, alveolar type II cells; AM, alveolar macro-
phages. 
Effict of lipid composition on uptake 
The composition of surfactant is largely similar across different species, including humans87· 88l; 
however, small differences in the relative concentrations of the individual lipids are observed 
which are also related to age (Table 1). For example, fetal or neonatal surfactant contains a 
larger percentage of phosphatidylinositol and less phosphatidylglycerol, whereas adult 
surfactant contains more phosphatidylglycerol than phosphatidylinositoP5l. In addition, 
neonates have been shown to rely more on recycling and thus uptake than adults59• 64l, which 
suggests a possible effect/role of the lipid composition on the uptake. Moreover, severe lung 
injury (initiated by a wide variety of causes) is known to be related to alternations in lipid 
composition of surfactanrB9• 90l, which could also contribute to a decreased surfactant function, 
implying an effect of the different surfactant lipids on the uptake. However, it remains 
unknown how these alternations in composition are related to the disease. 
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Table 1. Breakdown of lipid composition of surfactant, in percentage 
Mouse 
Rat 
Rabbit 
(neonatal) 
Rabbit 
(adult) 
Human 
Bovine 
Phospholipid composition (%) [% distaturated] 
PC PG PI PS 
72.3 18.1 
82.3 [49.3] 7.5 [32.3] 1.8 [2.2] 0.1 
80.6 [52.8] 4.5 6.8 
80.6 [52.8] 7.2 [38.7] 4 [2.5] 1.9 
80.5 [47.7] 11.5 2.5 
79.2 [49.9] 11.3 [33.3] 3.5 3 
PE Cholesterol 
1.9 9.7 
5.1 7.1 
4.4 
4.4 
12.3 7.3 
PC, Phosphatidylcholine; PG, phosphatidylglycerol; PI, phosphatidylinositol; PS, 
phoshatidylserine; PE, phosphatidylethanolamine. Data derived from Veldhuizen et al. 1998 
[15], Akino et al. 1992 [127] 
Bates et al. and Chander et al. were the first to report on the influence of the individual 
surfactant lipids on the uptake, demonstrating that radio-active labeled PG was cleared more 
rapidly by alveolar type II cells in vitrrr1• 92l. This increased uptake in vitro of PG was also 
demonstrated for alveolar macro phages in comparison to the uptake of D PPG3l. 
More recently, we demonstrated a common pathway for the uptake of surfactant lipids by both 
cell types in vitrcf4l. It was shown that a significantly lower percentage of alveolar type II cells 
than alveolar macrophages is involved in the uptake ofDPPC (29% versus 72%, respectively), 
whereas the number of cells involved in the uptake of PG is approximately the same. The 
presence of a possible phospholipid receptor would simplify the explanation of these results. A 
different distribution of this phospholipid receptor on alveolar macrophages and type II cells 
might be the reason for the difference in the percentage of cells involved in the uptake. The 
uptake of DPPC requires more receptors than the uptake of for instance PG; or, more 
generally, more negatively charged phospholipids are taken up more easily than neutrally 
charged phospholipids. A higher receptor density on alveolar macrophages than on alveolar 
type II cells, and the presence of several subpopulations of type II cells with different receptor 
densities would explain the lower percentage of alveolar type II cells compared to the alveolar 
macro phages. 
These results with regard to the role of individual surfactant lipids indicate that, besides 
surfactant proteins, the phospholipid composition of the small aggregates affects the surfactant 
metabolism. However, these studies were performed in vitro whereas significant differences 
have been demonstrated with regard to the uptake of surfactant-like liposomes by alveolar cells 
between in vivo and in vitro experiments, and extrapolation of these results to the in vivo 
situation should be done cautiously94l. 
The effects of lipid composition in vivo was studied by increasing the amount of PG, the 
second major phospholipid, present in the small aggregates. The incorporation ofPG influen-
ces the uptake of surfactant-like liposomes by alveolar cells, though the effects on both cell 
types differ. The uptake of surfactant-like liposomes by alveolar type II cells is hardly affected 
by different concentrations ofPG. More interesting, however, the influence of the intratracheal 
instillation of PG-containing liposomes on alveolar macro phages is dramatic; in particular, the 
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number of alveolar macrophages obtained in the lung lavage is influenced by the amount of 
PG. In addition, an increase in the amount of PG not only reduces the number of alveolar 
macrophages but this decrease in the number of cells is accompanied by a deterioration in 
arterial oxygenation. Although PG does not interfere with the function of endogenous 
surfactant in vitro, as was tested, its increase does lead to a reduced surface activity in vivo. 
Moreover, these adverse affects of PG on endogenous surfactant function can be avoided by 
adding so-called co-factors like calcium, magnesium, etc. 
The "fatal" effect ofPG on alveolar macrophages, as suggested by our group, is absent in vitro, 
because in that setting the previously mentioned co-factors are already present in the incuba-
tion. However, the effects ofPG on the uptake of surfactant-like liposomes by alveolar type II 
cells in vivo are completely different from those derived from the in vitro experiments, even 
when co-factors are present. In vitro, increased concentrations of PG result in an increased 
uptake of these liposomes by alveolar type II cells, whereas the uptake of these liposomes by 
alveolar type II cells in vivo is hardly affected by the concentration ofPG within the liposomes, 
irrespective of the presence of the suggested "co-factors". These results underline the presence 
of 'enviromental' factors that influence the uptake in vivo and thus emphasize the need to 
study the uptake of lipids and! or surfactant by alveolar type II cells and alveolar macro phages 
both in vivo and in vitro. 
Effect of surfactant proteins 
As previously mentioned, surfactant contains four proteins; SP-A, SP-B, SP-C and SP-D. 
First, SP-A has been extensively studied and is thought to play several roles within surfactant 
homeostasis, especially in the regulation of clearance of surfactant from the alveolar space85l. 
Next, both SP-B and SP-C are known to be important for the surface active surfactant mono-
layer4044'95·96l. On the other hand, regarding the effects on the uptake of surfactant by alveolar 
cells, SP-B is capable of increasing the uptake of lipids by alveolar cell~6· 97l (Poelma et al., 
submitted); however, high concentrations of SP-B are required to induce this increase, which 
raises the question concerning the physiological contribution of SP-B in regulating the uptake 
of surfactant lipids by alveolar cells. On the other hand, SP-C has a similar function to SP-B 
with regard to enhancing surface active properties of surfactant40' 41'4648l, but it should be noted 
that SP-C increases the uptake of surfactant-like liposomes at lower concentrations than SP-B. 
This effect of SP-C is concentration-dependent, with a maximum at 2% SP-C. In addition, 
the presence of co-factors (such as calcium, etc.) within the liposomes decreasing the possibility 
of dilution of the endogenous pool is demonstrated to further increase the effect of SP-C. At 
an incorporation of 1% SP-C the uptake is already increased, but the maximum increase 
remains at 2% (Poelma et al., submitted). However, the effects of SP-C on the uptake of 
surfactant-like liposomes is suggested to be suppressed in vivo because in vitro experiments 
have shown a much larger effect on the uptake; more specifically, a non-saturable effect36• 97l. 
Furthermore, SP-C is known to associate very rapidly with lung tissue and alveolar macro-
phages98·99l. This increased association, even more rapidly than DPPC, might be an explana-
tion for the increased uptake of liposomes containing SP-C. Although other factors, such as 
the conformation changes observed in liposomes after incorporation of SP-C, may also affect 
the binding and uptake of these liposomes by alveolar cells, as was suggested by Rice et al. 100J. 
Finally, the presence of a putative SP-C receptor could also induce an increased uptake. 
However, because its presence has not yet been demonstrated, further studies are needed. 
Effect of surfactant therapy 
Currently, exogenous surfactant is increasingly used in the clinic situation mostly in neonates, 
but the use of exogenous surfactant in adults is now under consideration101l. However, the 
administration of exogenous surfactant is known to influence the endogenous surfactant. Most 
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studies have focused on the effects of exogenous surfactant on the production and/ or secretion 
of D PPC and have produced conflicting results33• 102'105l. In premature infants with respiratory 
distress syndrome, treatment with exogenous surfactant was shown to stimulate the synthesis 
of endogenous surfactant106l. Little is known about the clearance or uptake of surfactant. 
Exogenous surfactant is taken up by alveolar type II cells and alveolar macrophages107' 110l; 
however, the specific effects of exogenous surfactant, that is surface active surfactant on the 
clearance of non-surface active surfactant, either endogenous or exogenous is unknown. Our 
group demonstrated significant effects of exogenous surfactant on the clearance of surfactant-
like liposomes (unpublished data). Nevertheless, the effect of exogenous surfactant on the 
uptake shows significant differences between in vivo and in vitro. 
Effect of surfactant protein analogues 
AB previously mentioned, SP-B is essential for the biophysical properties of pulmonary 
surfactant, and is thus most appreciated to be present in exogenous surfactant. 
The high cost of naturally derived exogenous surfactant increases the demand for a syntheti-
cally-produced surfactant. Therefore, synthetic analogues of SP-B based on the known human 
amino-acid sequence are nowadays tested and have been demonstrated to closely mimic the 
function of natural surfactant proteins111l. In addition these SP-B analogues might be opti-
mized because only essential parts of SP-B are reproduced and further developed to increase 
the efficiency of the SP-B within the exogenous surfactant preparation. 
Synthetic SP-B has been developed and closely mimics the function of natural surfactant 
proteins111). The SP-B analogues are based on the 1-25 sequence of the N-terminal site of 
human SP-B with a modification at position 11; cysteine replaced by alanine ( Cys-11> Ala-
11)112· 113l. A mutant SP-B (serine SP-B-1-25) was synthesized with a site-specific substitution 
of serine for arginine in position 12 and 17 and for lysine in position 16 and 24 of theN-
terminal (Fig. 5). A disulfide linked homodimer of these SP-B analogues was formed by 
oxidizing the monomeric SP -1-25 peptide11z. 113l. The serine-SP-B-1-25 analogues were demon-
strated to be less surface active in comparison to the SP-B-1-25 variants. We showed that the 
less surface active SP-B mimics serine analogues, and reduced the uptake of surfactant-like 
liposomes by alveolar type II cells when incorporated in the liposomes; on the other hand, the 
SP-B-1-25 analogues mimic the effect of native SP-B and do not induce any changes in the 
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SP-Bl-25 monomer 
Phe-Pro-Ile-Pro-Leu-Pro-Tyr-Cys-Trp-Leu-Ala-Arg-Ala-Leu-Ile-Lys-Arg-Ile-Gln-Ala-
Met-Ile-Pro-Lys-Gly 
SP-Bl-25 serine monomer 
Phe-Pro-Ile-Pro-Leu-Pro-Tyr-Cys-Trp-Leu-Ala-Ser-Ala-Leu-Ile-Ser-Ser-Ile-Gln- Ala-
Met-Ile-Pro-Ser-Gly 
Figure 5: Peptide sequences of the SP-B analogues and their serine mutants. The SP-B 1-
25 homodimer consists of two SP-Bl-25 monomers disulfide-linked at Cys8 (not 
shown). The fluorescent label was inserted in all peptides at theN-terminus, shown at 
the left side of the sequence. 
uptake ofliposomes by alveolar type II cells (unpublished data). With regard to the uptake of 
these liposomes with SP-B analogues incorporated by alveolar macrophages, our group 
demonstrated that the surface active SP-B analogues influence the uptake by alveolar macro-
phages (unpublished data). 
It was also shown that SP-C enhances the surface tension lowering properties of surfactant; 
therefore, surfactant preparations intended for clinical use most likely contain not only SP-B 
but also SP-C. The use of recombinant SP-C (rSP-C) in surfactant preparations is under inves-
tigation, to establish the efficiency of this SP-C on the surface tension lowering activities of 
surfactant11 L 114-11GJ. With regard to surface tension lowering activity the rSP-C surfactant 
(Altana, Konstanz, Germany) has similar results to natural surfactant117• 118l. This rSP-C 
surfactant contains an SP-C that is an analogue of human SP-C; it contains phenylalanine 
instead of two cysteines in positions 4 and 5 of the human SP-C sequence, and isoleucine 
instead of methionine in position 32. However, the effects of these SP-C-analogues on the 
uptake, or more generally on the metabolism of surfactant, is unknown. Our group has shown 
that the uptake of surfactant lipids by alveolar type II cells and alveolar macrophages is 
regulated by SP-C (Poelma et al., submitted), and thus the influence of recombinant SP-C on 
the surfactant metabolism needs to be clarified. 
Additional factors influencing surfactant uptake 
Finally, besides factors related directly to surfactant, our group has shown that multiple 
'environmental' factors influence and affect the surfactant metabolism. Some of these factors 
have been described previously; for example, calcium has been shown to influence the 
metabolism, as in its presence PG promotes association of SP-A and DPPC119• 120l, and was 
demonstrated to affect the function of SP-B29• 121l. The effects or influences of these alveolar 
factors (e.g. divalent cations as suggested by the study of our group with regard to the effects 
ofSP-B and SP-C), are also underlined by the fact that significant differences between in vivo 
and in vitro results were demonstrated, even when the absence or dilution of known co-factors 
such as calcium were compensated for. It should be emphasized that in our opinion the use of 
in vitro experiments is indeed useful, although extrapolation of the results to the in vivo 
situation has to be made carefully. Using a similar technique to conduct studies both in vivo 
and in vitro enables the researcher to compare the results and might help to clarify the complex 
mechanism of the regulation of the uptake of surfactant lipids by alveolar cells in vivo. 
In addition, although most studies on the uptake of surfactant have focused on healthy 
animals, many different diseases can disturb the surfactant system, and the presence of 
cytokines and other inflammatory parameters are known to affect the presence of surface active 
surfactant in the lung. For example, tumor necrosis factor (TNF)-a, interleukin (IL) -1, 
interferon (IFN)-y are known to influence the production of SP-A, SP-B and SP-C, which 
regulates the uptake of surfactant by alveolar cells, and thus affects the total metabolism 122-126l. 
In addition, prenatal steroids have been demonstrated to increase surfactant synthesis62l. 
Future studies 
Because the uptake of surfactant in healthy adult animals has to some extent been clarified, 
future research could focus on the uptake of surfactant-like liposomes in diseased animals, 
using different models for diseased animals. Possible irregularities in the uptake and thus the 
endogenous surfactant metabolism might be elucidated. The known regulatory factors, at least 
those clarified up to now, will then provide options to restore normal metabolism by influen-
cing the uptake. For example, if uptake of surfactant is reduced in a certain disease state, it 
might be beneficial to increase the concentration ofPG within the surfactant preparation used 
for therapy. In other words, clarifying regulating factors in the surfactant uptake and 
uncovering irregularities in the metabolism, or more specifically in the uptake of surfactant, 
17 
allows to develop an exogenous surfactant preparation that is disease specific by modifying the 
composition depending on the underlying deviation from the normal situation. 
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Abstract 
The uptake of fluorescent-labeled liposomes (with a surfactant-like composition) by alveolar 
macrophages and alveolar type II cells was studied using flow cytometry: in vivo by instillation 
of the labeled liposomes in the trachea of ventilated rats followed by isolation of the alveolar 
cells and determination of the cell-associated fluorescence and in vitro by incubation of isolated 
alveolar cells with the fluorescent liposomes. The results show that the uptake of liposomes by 
the alveolar cells is time- and concentration dependent. In vivo alveolar macrophages inter-
nalize more than three times as many liposomes as alveolar type II cells, whereas in vitro the 
amount of internalized liposomes by these cells is approximately the same. In vitro practically 
all the cells (70 to 75o/o) internalize liposomes, whereas in vivo only 30% of the alveolar type 
II cells ingest liposomes versus 70% of the alveolar macrophages. These results indicate that in 
vivo only a small subpopulation of alveolar type II cells is able to internalize surfactant 
liposomes. 
Introduction 
Pulmonary surfactant lines the alveolar capillary membrane and plays an essential role in 
normal lung function. It is a complex oflipids and proteins synthesized by alveolar type II cells 
and stored in lamellar bodies until it is secreted into the alveolar space1l. Within the alveolus, 
surfactant transforms to tubular myelin, which unfolds, and the surfactant lipids are rapidly 
inserted in the lipid monolayer present at the air-liquid interfacell. During a breathing cycle, 
lipids are squeezed out of the monolayer. In order to maintain the primary function of the 
monolayer, i.e. reduction of the surface tension, the loss of lipids from the monolayer has to 
be compensated by renewed insertion of lipids. AB the de novo synthesis of surfactant is 
insufficient to correct the natural loss (i.e. inactivation of surfactant) the alveolar type II cell 
not only produces newly synthesized surfactant but also reutilizes inactivated surfactant, 
derived from the alveolar space. 
The recycling of surfactant is a major pathway for surfactant in the alveolar space2l; clearance 
by the mucociliar pathwafl or degradation by alveolar type II cells and alveolar macrophages 
appears to be less important in the removal of surfactant lipids from the alveolar space. 
One important factor in the complex system of surfactant synthesis, secretion, recycling, 
clearing and degradation, is the uptake of surfactant lipids by alveolar type II cells and alveolar 
macrophages. Numerous in vitro studies have demonstrated that both cell types can internalize 
surfactant lipids, though their relative contribution in the uptake of surfactant lipids in the 
lung remains obscure. According to Miles et al., based on in vitro studies, alveolar macrophages 
may be responsible for all the catabolism of surfactant lipids4l. 
In contrast, results of in vivo experiments suggest a primary role of alveolar type II cells in the 
uptake of surfactant lipids rather than alveolar macrophages5• GJ, however, a recent study 
suggests an equal contribution of both alveolar type II cells and alveolar macro phages in the 
uptake of surfactant lipids in vivo in the presence of SP-A?J. 
Though differences in methodology may underlie these contradictory findings, another 
explanation may be the difference between in vivo and in vitro experiments. Study of the 
uptake oflipids by alveolar cells in vivo and in vitro using a similar technique has the advantage 
that the contribution of the alveolar type II cells and alveolar macrophages in the uptake of 
lipids in the lung can be assessed, as can the influence of cell isolation and environmental 
factors. In the present study, we have studied the uptake of fluorescent-labeled liposomes by 
alveolar type II cells and alveolar macrophages in vivo as well as in vitro using flow cytometry. 
In contrast to most studies on the uptake of surfactant lipids by type II cells or alveolar 
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macrophages which focused on its main component, saturated phosphatidylcholine (PC) (i.e. 
dipalmitoyl phosphatidylcholine; DPPC) 5• 6• 81 , in the present study we used fluorescent lipo-
somes with a composition similar to natural surfactant: DPPC, PC, phosphatidyl glycerol 
(PG), phosphatidyl inositol (PI), phosphatidyl ethanolamine (PE) and cholesterol (weight 
ratio 5 5:21 :8:2:6:8)31 • 
An advantage of using flow cytometry to study the uptake oflipids by alveolar type II cells and 
alveolar macrophages is that it allows to determine whether all the cells are able to internalize 
lipids or only subpopulations. To date, it is not known whether all alveolar macrophages 
and/ or alveolar type II cells are involved in the uptake of lipids. We have developed a new 
method to study the uptake of surfactant lipids by alveolar type II cells and alveolar macro-
phages in vivo as well as in vitro using fluorescent-labeled surfactant-like liposomes. 
Materials and methods 
Ethical Guidelines 
This study was approved by the Institutional Animal Committee at the Erasmus University 
Rotterdam. 
Liposome preparation 
To prepare surfactant-like liposomes, the following lipids were mixed; dipalmitoyl phosphati-
dylcholine (DPPC), phosphatidyl choline (PC), phosphatidylglycerol (PG), phosphatidyl 
inositol (PI), and rhodamine labeled phosphatidyl ethanolamine (PE)(Rhodamine DHPE; 
Molecular Probes, Leiden, The Netherlands) and cholesterol in a weight ratio of55:21:8:2:6:8 
and dried under a stream of nitrogen gas. The lipids were purchased from Sigma, Zwijndrecht, 
The Netherlands, unless stated otherwise. The liposomes were suspended in PBS at a concen-
tration of 1 mg lipids/rnl using glass pearls and vortexing. Immediately prior to use, the lipo-
some suspension was sonicated for 2 min on ice using an ultrasonic disintegrator (Branson 
Sonifier 250, Danbury, USA) to prepare small unilamellar liposomes. These liposomes were 
used, unless stated otherwise. Large multilamellar liposomes were prepared by sonicating the 
liposome suspension in a water bath sonicator (Branson 5210, Danbury, USA) at 3TC for 3 
min. The size of the liposomes was determined by dynamic light scattering at 2YC with a 
Malvern 4700 system using a 25 m W He-Ne laser (NEC, Tokyo, Japan) and the automeasure 
version 3.2 software (Malvern Ltd, UK). As a measure of particle size distribution of the 
dispersion, the system reports a polydispersity index (p.d.). This index ranges from 0.0 for a 
monodisperse and up to 1.0 for an entirely polydisperse dispersion.The 'small' liposomes had 
a size of 161 nm p.d. 0.35 and the 'large liposomes had a size of 1455 nm p.d. 0.65, signifi-
cantly larger than the 'small' liposomes. 
Intratracheal imtillation of fluorescent liposomes 
The studies were performed with male Sprague-Dawley rats (IFFA Credo, The Netherlands) 
with a bodyweight of 314 ± 18 g. After induction of anesthesia with a mixture of nitrous oxide 
(66%), oxygen (33%) and isoflurane (1-2%) a sterile polyethylene catheter (0.8 mm o.d.) was 
inserted into one of the carotid arteries. The animals were then tracheotomized and a sterile 
metal cannula was inserted into the trachea. 
After these surgical procedures, gaseous anesthesia was ended and replaced with an intra-
peritoneal injection of pentobarbital sodium (60 mg/rnl, Nembutal®, Algin BV, Maassluis, The 
Netherlands) at a dose of 30 mg/kg bodyweight every hour. 
Muscle relaxation was induced and maintained by an hourly intramuscular injection of 
pancuronium bromide (2 mglkg, Pavulon; Organon Technika, Boxtel, The Netherlands). The 
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animals were then mechanically ventilated with a Servo® ventilator 300 (Siemens-Elema, 
Solna, Sweden) set to pressure control mode using a frequency of 30/min, an inspiratory/ 
expiratory ratio of 1:2, a positive end-expiratory pressure (PEEP) of 2 em H 20, a peak 
inspiratory pressure (PIP) of 12 em H 20 and Fi02 was set to 1. 
Before instillation of the labeled liposomes, PEEP was increased to 6 em H20 and PIP was 
increased to 26 em H 20. After disconnection from the ventilator, the liposomes were 
administered intratracheally at the indicated doses. The suspension of liposomes (1 mg 
lipids/ml, unless stated otherwise) was administered as a bolus of 3 ml!kg followed by a bolus 
of air (12 ml/kg), directly into the endothracheal tube via a syringe, and the animals were 
immediately reconnected to the ventilator. Thirty min after instillation of the liposomes PEEP 
was reduced to 2 em H 20 and PIP to 12 em H 20. 
Arterial blood gases were measured with conventional methods (ABL 505, Radiometer, 
Copenhagen, Denmark) at start of ventilation, immediately after instillation of the liposomes 
and every 30 minutes thereafter. One hour after ventilation (unless stated otherwise) the 
animals were sacrificed by exsanguination via the abdominal aorta and the alveolar cells were 
isolated to determine the cell-associated fluorescence. Control animals were sacrificed 
immediately after anesthesia and their isolated alveolar type II cells and alveolar macrophages 
were used to correct for auto-fluorescence. 
Instillation of a large volume (30 mllkg) of the liposomes 
After the surgical procedures one group of animals was instilled with a large volume of 
fluorescent-labeled liposomes (30 ml/kg; 1 mg lipids/ml). The liposomes were retrieved from 
the lungs immediately after instillation (recovery 90%). One hour after instillation, the 
animals were sacrificed and alveolar type II cells and alveolar macrophages were isolated and 
cell-associated fluorescence was determined. 
Isolation of alveolar type II cells and alveolar macrophages 
Prior to isolation of the cells, the thorax was opened and the blood cells were removed from 
the lungs by perfusing the pulmonary artery with saline (3TC) supplemented with 20 IE 
heparin (Leo Pharma, Weesp, The Netherlands). The lungs were removed from the thoracic 
cavity en bloc and lavaged with 10 ml of solution 1 [140 mM NaCl, 5 mM KCl, 2.5 mM 
Na2HP04.2H20, 10 mM HEPES (N-2-hydroxyethylpiperazine-N'-2-ethaesulfonic acid), 6 
mM glucose, 0.2 mM EGTA (ethylene glycol-his- (~-amino ethyl ether) N,N' -tetra-acetic 
acid), pH 7.40] at 22oC. This procedure was repeated four times. The lung lavages were pooled 
per animal and centrifuged (100x g, 10 min; 4°C). The cellular pellet, i.e. alveolar macro-
phages, were suspended in solution 2 (140 mM NaCl, 5 mM KCl, 2.5 mM phosphate buffer, 
10 mM HEPES, 6 mM glucose, 2.0 mM CaC12 and 1.3 mM MgS04) to a concentration of 
2x106 cells/ml and stored on ice until further use. The alveolar type II cells were isolated accor-
ding to Dobbs et al. 91 • Alveolar type II cells were suspended in solution 2 at a concentration of 
2x106 cells/ml and stored on ice until further use. Alveolar macrophages were identified using 
monoclonal antibodies specific for rat macrophages (ED9) and alveolar type II cells were 
identified using an alkaline phosphatase assay as described by Edelson et al. 101 • The average 
yield of alveolar type II cells was 16x106 and 5x106 alveolar macrophages per rat. 
In vitro assay to determine the uptake of fluorescent-labeled liposomes 
Alveolar type II cells and alveolar macro phages were isolated from control animals as described 
above and were suspended in solution 2 to a concentration of 2x106 cells/mi. A total of 3xl05 
cells were incubated with various concentrations of liposomes at 3TC (final volume 500 p.l) 
in a shaking water bath. After 1 hour, the incubation was terminated by addition of 2 ml of 
ice-cold PBS. The cell suspension was centrifuged at 100x g for 10 min at 4oC. The super-
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natant was removed and the cells were suspended in 2 ml of ice-cold PBS and centrifuged 
again. This wash procedure was repeated twice. Finally, the pellet was resuspended in 200 )ll 
cold PBS and cell-associated fluorescence was determined as described below. 
Flow cytometry 
Cell-associated fluorescence of the alveolar type II cells and alveolar macro phages as a measure 
for internalized liposomes was determined using flow cytometry (FACSCalibur; Becton 
Dickinson; Mountain View, USA). The cell-associated fluorescence of 15,000 cells was deter-
mined. Alveolar macro phages and alveolar type II cells derived from control animals were used 
in each experiment to determine the autofluorescence of the cells. Subsequently, the mean cell-
associated fluorescence was determined only for those cells that had a higher fluorescence than 
that caused by auto-fluorescence (gated cells). For the cell sorting experiment, the 
FACSCalibur was set to the sorting mode, and only those cells with a mean fluorescence higher 
than the autofluorescence were collected and analyzed. 
Localization of cell-associated fluorescence 
To inspect the localization of the cell-associated fluorescence confocal micrographs of alveolar 
cells were obtained using a confocal microscope (Zeiss LSM 410, Jena Germany). Images were 
created with standard objectives and photomultiplier tubes dedicated to the appropriate 
excitation and emission spectra of rhodamine (excitation 541 nm and emission 572 nm). 
Images of alveolar cells were serial sectioned at a depth of 0.5 Jlm, to distinguish cell-
membrane associated fluorescence from true intra cellular fluorescence. 
Statistical analysis 
Differences in blood gas values over time were analysed usmg a repeated measurement 
ANOVA followed by an independent t-test. Differences between animals that received 
fluorescent-labeled liposomes and the control group were determined using an independent 
samples t-test. Differences between the animals receiving a normal volume of liposomes and 
the animals receiving a high volume of liposomes were analyzed using an independent t-test. 
Differences were considered statistically significant at a p <0.05. Values are expressed as mean 
±SEM 
Results 
Isolated alveolar type II cells and alveolar macrophages. 
The forward and sideward scatter plots in Fig. 1 demonstrate that alveolar type II cells and 
alveolar macrophages isolated from controls consist of heterogeneous cell populations. The 
cell-associated fluorescence of alveolar cells isolated from rats one 1 hour after intratracheal 
instillation of fluorescent-labeled liposomes, was clearly higher than the control cells. The cell-
associated fluorescence of the alveolar macrophages is higher than the fluorescence of the 
alveolar type II cells, suggesting more uptake of fluorescent liposomes by alveolar macro phages. 
Instillation of the fluorescent-labeled liposomes had no significant effect on oxygenation levels 
of the animals during ventilation (results not shown). 
In vivo uptake of fluorescent liposomes by alveolar cells 
To characterize the in vivo uptake of fluorescent-labeled liposomes by alveolar cells, the cells 
were isolated at different time points (0.5 to 3 hours) after instillation of the fluorescent-
labeled liposomes. The cell-associated fluorescence of alveolar type II cells and of alveolar 
macrophages demonstrated a time-dependent increase reaching a plateau in 1 hour (Fig. 2). In 
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Alveolar type II cells (A,C,E) and alveolar macrophages (B,D,F) were isolated from control 
animals (A-D) and from animals one hour afrer intratracheal instillation of fluorescent 
liposomes (E,F). The forward and sideward scatter plots demonstrate the presence of 
heterogeneous populations of alveolar type II cells (A) and alveolar macrophages (B). Auto-
fluorescence of control alveolar type II cells (C) and control alveolar macrophages (D) was 
determined. Total cell-associated fluorescence was determined of alveolar type II cells (E) 
and alveolar macro phages (F) isolated from animals that were intra tracheally instilled with 
fluorescent liposomes. Marker Ml (C-F) indicates the mean cell-associated fluorescence of 
the cells that have internalized the fluorescent liposomes (gated cells). 
addition, concentration dependency was determined by instilling fluorescent-labeled 
liposomes of different concentrations (0.5, 1, 2, 3, 5 mg/ml) and isolating the alveolar cells 1 
hour after instillation (Fig. 3). At a concentration of 1 mg/ml the cell-associated fluorescence 
of the alveolar type II cells was half maximal whereas for alveolar macrophages the half 
maximal uptake was observed at an intratracheal dose of 2 mg/ml fluorescent liposomes. 
The percentage alveolar cells involved in the uptake of fluorescent liposomes (gated cells) 
reached a maximum at a concentration of 1 mg/ml (Fig. 3). Approximately 30% of the alveolar 
type II cells participated in the uptake of fluorescent-labeled liposomes. In contrast, about 
70% of the alveolar macrophages internalize the fluorescent-labeled liposomes (Fig. 3). At an 
intratracheal dose of 3 mg fluorescent liposomes, the uptake by the alveolar cells was maximal. 
The mean cell-associated fluorescence of the alveolar macrophages involved in the uptake was 
3.26 ± 1.24 times higher than that of the alveolar type II cells; this indicates 3.26 times more 
uptake of liposomes by alveolar macro phages than alveolar type II cells. 
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At every time point (30 min, 1, 2 and 3 hours after instillation of the liposomes), 5 
animals were sacrificed, alveolar type II cells (A) and macrophages (B) isolated, and mean 
cell-associated fluorescence was determined. At all time points fluorescence differed 
significantly from the control group (values are mean ± SEM). 
Uptake of unilamellar vs. multi lamellar liposomes 
As demonstrated by Griese et al.U1, smaller sized particles are preferentially taken up by the 
alveolar type II cells. We studied the effect of the size of the labeled liposomes on the uptake 
in vivo by instilling either small unilamellar liposomes, created by ultrasonification, or large 
multilamellar liposomes, sonicated in a warm water bath sonicator'21 • No differences were 
observed in the uptake ofboth types ofliposomes, unilamellar or multilamellar (Table 1). 
Localisation of the cell-associated fluorescence 
Confocal laser microscopy was used to ascertain that the measured cell-associated fluorescence 
was caused by intracellular presence of fluorescent labeled liposomes. Confocal scans through 
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the middle of the cell (Fig. 4) show that the fluorescence is not limited to the circumference 
of the cell and shows a punctuate fluorescence throughout the cell except for the nucleus. 
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Fig 3. Concentration-dependent uptake of liposomes in vivo 
One hour after instillation of the indicated concentrations of fluorescent liposomes, the 
alveolar cells were isolated. The mean cell-associated fluorescence of the gated alveolar 
type II cells (A) and alveolar macrophages (C) was determined. In addition, the percen-
tage gated alveolar type II cells (B) and alveolar macrophages (D) was determined. At all 
concentrations fluorescence and percentage gated cells differed significantly from the 
control groups (n=4 rats at every concentration; values are mean± SEM). 
Identification of cells that internalize the fluorescent liposomes 
We found that in vivo only 30o/o of the type II cells isolated from rats intratracheally instilled 
with fluorescent liposomes were involved in the uptake of fluorescent liposomes. The average 
percentage of cells identified as alveolar type II cells in the alveolar type II cell isolate was 
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Fig 4. Confocal microscopic images of alveolar type II cells and alveolar macrophages 
Alveolar type II cells (A) and alveolar macrophages (B) isolated one hour after instillation 
of fluorescent-labeled liposomes were mounted on glass cover slips. Confocal laser micro-
scopy demonstrated a punctuate distribution of fluorescent label not limited to the cell 
surface, which did not localize to the nuclei, indicating internalization of the fluorescent 
liposomes by both cell types. Since untreated control cells did not show this fluorescence 
at the same microscope settings, we conclude that the observed internal fluorescence of 
treated cells was due to the uptake of fluorescencly labeled liposomes. Bar indicates 5 [.tm. 
approximately 80%. Theoretically, it is possible that a substantial number of the cells that 
internalize fluorescent liposomes in alveolar type II cell isolate are not type II cells but 
contaminating cells such as macrophages, etc. To exclude this possibility, rats were intra-
tracheally instilled with fluorescent liposomes. The alveolar type II cells and alveolar macro-
Table 1. Size-dependent uptake of fluorescent liposomes 
Alveolar type II cells Alveolar macrophages 
Mean Gated Mean Gated 
fluorescence cells fluorescence cells 
Control 2 ± 1 2 ± 1 4±1 1 ± 1 
Small 66 ± 8 28 ± 4 liposomes 112 ± 17 70 ± 15 
Large 44 ± 10 16 ± 7 liposomes 117 ± 36 52± 5 
Alveolar cells were isolated one hour after instillation of the indicated fluorescent liposomes. 
Smallliposomes: unilamellar fluorescent liposomes; large liposomes: multilamellar fluorescent 
liposomes. Mean fluorescence: mean cell-associated fluorescence; gated cells: percentage gated 
cells (n = 3 rats; values are mean± SEM). 
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Table 2. Identification of fluorescent cells 
Type II cells isolate Macrophage isolate 
o/o type II cell 80 ± 5 N.D. 
o/o Macrophage 1.7 ± 2.1 92 ± 5 
Alveolar cells were isolated one hour after instillation of fluorescent liposomes; fluorescent cells 
were collected and identified. N.D.: not detected (n = 3 rats, values are mean± SEM). 
phages were isolated. The alveolar cells with a mean fluorescence higher than the auto-
fluorescence of the control cells were sorted and collected. As shown in Table 2, 80 ± 5% (n=3) 
of these fluorescent cells present in the alveolar type II cell isolate were identified as alveolar 
type II cells using alkaline phosphatase assay, whereas 92 ± 5% (n=3) of the alveolar macro-
phages could be identified as macrophages as was demonstrated using a monoclonal antiserum 
directed against macrophages (ED9). 
Distribution of the liposomes 
To determine whether the low number of alveolar type II cells internalizing the liposomes was 
due to an inhomogeneous distribution of liposomes in the lungs, one group of animals was 
instilled with a high volume of fluorescent-labeled liposomes. 
Instillation of a large volume ofliposomes which was immediately redrawn from the lungs, did 
not result in a significant difference in the percentage of cells responsible for the fluorescence, 
nor was there any significant difference in the level of fluorescence between the animals 
receiving the liposomes as a bolus and the animals receiving a high volume ofliposomes (Table 
3). Interestingly, the number of alveolar macrophages involved in the uptake ofliposomes was 
significantly lower in the high volume group than in the low volume, standardly used, group. 
Table 3. Distribution of fluorescent liposomes 
Alveolar type II cells Alveolar macrophages 
Mean Gated Mean Gated 
fluorescence cells fluorescence cells 
Control 2±1 2 ± 1 4±1 1 ± 1 
Low 66 ± 8 28 ± 4 112 ± 17 70 ± 15 
volume 
Large 62 ± 7 18 ± 6 123 ± 19 38 ± 5* 
volume 
Alveolar cells were isolated one hour after instillation of fluorescent liposomes with the 
indicated method. Low volume: 3 ml!kg liposomes followed by bolus of air; large volume: 30 
ml/kg liposomes immediately withdrawn from the lungs (recovery 90%). Mean fluorescence: 
mean cell-associated fluorescence; gated cells: percentage gated cells (n = 3 rats; values are mean 
± SEM). 
* Significantly smaller than low volume value, p < 0.05 (by unpaired t-test). 
In vitro measurement of uptake 
In vitro experiments with different concentrations of fluorescent-labeled liposomes demon-
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strated an apparent maximal uptake at 20 pg/ml for both cell types (Fig. 5). The percentage 
alveolar type II cells responsible for the uptake was maximal at 100 pg/ml at 67.6 ± 11.1 %. 
The percentage alveolar macrophages reaches its maximum of73 ± 34.7% at 20 pg/ml (Fig. 
5). The mean cell-associated fluorescence did not significantly differ between the alveolar type 
II cells and the alveolar macrophages. 
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Fig 5. Concentration-dependent uptake of liposomes in vitro 
Alveolar cells were isolated from control animals and incubated for 1 hour at 3TC with 
the indicated concentrations of fluorescent liposomes. The mean cell-associated fluor-
escence of gated alveolar type II cells (A) and alveolar macrophages (C) was determined. 
In addition, the percentage gated alveolar type II cells (B) and alveolar macrophages (D) 
was determined. At all concentrations fluorescence and percentage gated cells differed 
significantly from the control group. (n= 4 incubations at every concentration; values are 
mean± SEM). 
The mean fluorescence of the alveolar macrophages in vitro is 5.12 ± 1.01 times lower in 
comparison to the fluorescence of the alveolar macrophages in vivo. 
In order to get an impression of the amount of lipids that are only bound to the cellular 
membranes of the cells, we have incubated the cells on ice with the fluorescent liposomes for 
1 hour. For alveolar type II cells, 12 ± 4% (n=3) of the total cell population had a mean 
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fluorescence [28 ± 7 (n=3)] higher than the autofluorescence, for alveolar macrophages 18 ± 
3% (n==3) of the cells had a mean fluorescence [36 ± 5 (n=3)] higher than the autofluorescence. 
Discussion 
In the present study we used fluorescent-labeled liposomes to study the uptake of lipids by 
alveolar cells. For the in vivo experiments, these liposomes were intratracheally instilled in 
mechanically ventilated rats. The choice to mechanically ventilate the animals was made on the 
basis of ensuring that the liposomes are instilled in a completely opened lung, rather than in a 
lung in which atelectesis are present. The used ventilator settings, peak of 26 em H 20 and a 
PEEP of 6 em H 20, resulted in a mean airway pressure of 13 em H 20. It has been demon-
strated that ventilating with mean airway pressure up to 15 em H 20 does not affect the 
surfactant metabolism, and does not induce lung injury13l. 
By using different concentrations we have demonstrated a concentration-dependent uptake, 
reaching a maximum at 3 mg/ml. A time-dependent uptake was demonstrated by isolating the 
alveolar cells at different time points after instillation of the liposomes, similar to previous 
studies using radioactive-labeled liposomes5· 14' 15l. Using a composition similar to natural 
surfactant diminishes the effects of single components and allows to study the uptake of 
surfactant as a whole complex of different lipids. 
The use of confocal laser microscopy allows to demonstrate the intracellular presence of the 
fluorescent-labeled liposomes. The cell-associated fluorescence was therefore caused by 
internalized liposomes rather than by liposomes associated with the cell membrane of the 
alveolar cells. 
The use of fluorescence enabled to quantitate the fluorescence per individual cell, which leads 
to intriguing results. Interestingly, only 30% of the alveolar type II cells is involved in the 
uptake of liposomes. After instillation ofliposomes with different concentrations, the number 
of cells taking part in the uptake of the liposomes does not increase above ± 30%. 
Identification of the isolated cells demonstrated a similar amount of type II cells in the type II 
cell isolate as reported in other studies5• 6· 16l. The cells with a fluorescence higher than the auto-
fluorescence were identified as type II cells, demonstrating that the measured cell-associated 
fluorescence was indeed caused by type II cells. The low number of alveolar type II cells 
involved in the uptake of lipids in vivo is intriguing, as the in vitro experiments demonstrated 
a much larger number of type II cells (70%) participating in the uptake. Instillation of a high 
volume of labeled liposomes, distributing the liposomes throughout the lung, did not result in 
an increase in type II cells taking up the liposomes. Hence, the low number of participating 
type II cells in vivo is not caused by an insufficient distribution or by cells other than alveolar 
type II cells in the cell isolate. In other words, the difference is either caused by the isolation 
procedure, or is due to the absence of environmental influences in vitro. It seems unlikely that 
the isolation procedure stimulates the alveolar type II cells to take up lipids. It has been 
observed that a stressful isolation procedure can cause secretion of lamellar bodies17l; in 
addition, the turnover, degradation and resecretion continues during the 1 hour incubation. 
Therefore, the measured fluorescence in vivo is an underestimation of the actual uptake of the 
fluorescent labeled liposomes. On the other hand, the fluorescence per cell is only slightly 
increased in vitro, whereas the number of cells participating in the uptake is significantly 
increased. Therefore, these results suggest a possible regulating effect of the alveolar 
environment on the uptake of lipids by alveolar type II cells, as well as the presence of a sub-
population of alveolar type II cells which are activated either during the isolation procedure or 
by the absence of the environmental factors, or degredate, c.q. resecrete the fluorescent labeled 
liposomes more rapidly. Alveolar type II cells have been shown to interact with alveolar 
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macrophages18• 201 , although it remains unclear if these cells regulate each others uptake of lipids. 
In addition, an important role of the environment is also seen in the uptake of lipids by 
alveolar macrophages. Both in vivo and in vitro, the same number of alveolar macrophages 
takes part in the uptake (70%), although most interestingly the alveolar macrophages take up 
more lipids in vivo than in vitro. The instillation of liposomes with different concentrations 
demonstrated that the uptake of liposomes by alveolar macro phages reaches a plateau phase, 
both in vivo and in vitro. When comparing the mean fluorescence per cell at this plateau it is 
obvious that in vivo the alveolar macrophages take up approximately 5 times as many lipo-
somes than in vitro. In other words, both the alveolar type II cell and alveolar macrophage 
interact with the environment. 
Additionally the results of the instillation of a high volume of liposomes suggest the presence 
of subpopulations within the alveolar macrophages. When a high volume of liposomes (30 
ml!kg) is instilled and removed from the lung, a number of alveolar macrophages is removed 
as in a lung lavage. One hour after instillation and withdrawal of the high volume the alveolar 
cells were isolated and cell-associated fluorescence was determined. The alveolar type II cells 
showed no significant difference compared with the cells derived from animals instilled with 
the normal volume (1 ml). In contrast, the alveolar macrophages showed a significant decrease 
in the number of cells taking up the liposomes. The mean fluorescence per cell did not differ 
significantly, suggesting that a part of the cells that are involved in the uptake of fluorescent 
liposomes were removed by the instillation and withdrawal of a high volume of liposomes. In 
this primary 'lavage' the most mobile cells are removed, whereas the more resident cells are not 
likely to be removed. Although there might be influx of new alveolar macrophages by chemo-
taxis, their contribution in the clearance of the liposomes from the alveolar space is time-
dependent as demonstrated in the present study; we therefore conclude that the relatively short 
time of exposure to the liposomes of recently influxed cells can explain the minor contribution 
of these newly influxed cells. The mean fluorescence per cell did not differ, indicating that the 
cells were not negatively influenced by this lavage, although the low number of cells involved 
suggest that the liposomes are preferentially taken up by the mobile macrophages rather than 
by the resident, adherent cells. 
To date, their relative contribution is under discussion, some studies indicate a minor role of 
the alveolar macrophages in the uptake oflipids51, others indicate a larger contribution of these 
cells to the clearance of surfactant4• 71 • We have found comparing the alveolar type II cells with 
the alveolar macrophages, that the alveolar macrophages take up approximately 2-3 times more 
liposomes. When correcting for the number of cells within the lung, it is clear that the alveolar 
type II cells contribute± 60-70% of the clearance of surfactant from the alveolar space. There 
are about 10-15 times as many type II cells than macrophages (calculations using re£211), 
although only 30% of the type II cells are involved in the clearance of the liposomes compared 
to 70% of the alveolar macro phages, the alveolar type II cells still outnumber macrophages 5-
7 times with regard to the number of cells involved in the clearance of liposomes. The macro-
phages take up 2-3 times more liposomes than the alveolar type II cells. Therefore, the alveolar 
type II cells contribute about 2-3 times more than the alveolar macrophages. 
In the present study we used fluorescent-labeled liposomes with a composition similar to that 
of natural surfactant, without surfactant proteins. Although studies in the past have demon-
strated a possible role of the apoproteins, especially SP-A, on the uptake of surfactant by both 
alveolar type II cells and alveolar macrophages71, the present study focuses on the method on 
measuring the uptake rather than studying the role of the apoproteins. The absence of the 
surfactant proteins might account for the different findings in the contribution of alveolar 
macrophages in the present study, although the inter-species variation is another option. 
In summary, using fluorescent-labeled liposomes, we have demonstrated an important role of 
the environment on the uptake of surfactant liposomes by alveolar cells, as well as the presence 
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of possible subpopulations alveolar type II cells and macrophages, that are involved in the 
uptake. 
References 
1. Fehrenbach H Alveolar epithelial type II cell: defender of the alveolus revisited. Respir Res 2001;2:33-46. 
2. Nicholas TE. Pulmonary suifactant: no mere paint on the alveolar wall. Respirology 1996;1:247-57. 
3. Veldhuizen R, Nag K, Orgeig S, Possmayer F The role of lipids in pulmonary suifactant. Biochim 
Biophys Acta 1998;1408:90-108. 
4. Miles PR, Ma JY, Bowman L. Degradation of pulmonary suifactant disaturated phosphatidylcholines 
by alveolar macrophages. J Appl Physiol1988;64:2474-81. 
5. Rider ED, Ikegami M, jobe AH. Localization of alveolar suifactant clearance in rabbit lung cells. Am 
J Physiol1992;263:L201-9. 
6. Rider ED, Ikegami M, jobe AH Intrapulmonary catabolism of suifactant-saturated phosphatidylcho-
line in rabbits. j Appl Physio/1990;69:1856-62. 
7. Gurel 0, Ikegami M, Chroneos ZC, ]obe AH Macrophage and type II cell catabolism of SP-A and 
saturated phosphatidylcholine in mouse lungs. Am J Physiol Lung Cell Mol Physio/200 1 ;280:Ll266-72. 
8. Rider ED, Pinkerton KE, jobe AH Characterization of rabbit lung lysosomes and their role in 
suifactant dipalmitoylphosphatidylcholine catabolism. J Bioi Chem 1991;266.·22522-8. 
9. Dobbs LG, Gonzalez R, Williams MC An improved method for isolating type II cells in high yield and 
purity. Am Rev Respir Dis 1986;134:141-5. 
10. Edelson ]D, Shannon JM, Mason Rf Alkaline phosphatase: a marker of alveolar type II cell differen-
tiation. Am Rev Respir Dis 1988;138:1268-75. 
11. Griese M, Reinhardt D. Smaller sized particles are preferentially taken up by alveolar type II pneumo-
cytes. J Drug Target 1998;5:471-9. 
12. van Iwaarden JE Claassen E, jeurissen SH, Haagsman HP, Kraal G. Alveolar macrophages, suifactant 
lipids, and suifactant protein B regulate the induction of immune responses via the airways. Am j Respir 
Cell Mol Bio/2001;24:452-8. 
13. Ikegami M, Horowitz AD, Whitsett ]A, ]obeAH Clearance of SP-C and recombinant SP-C in vivo 
and in vitro. Am j Physiol1998;274:L933-9. 
14. Griese M, Beck], Feuerhake F Suifactant lipid uptake and metabolism by neonatal and adult type II 
pneumocytes. Am] Physiol1999;277:L901-9. 
15. Muller Wj, Zen K, Fisher AB, Shuman H Pathways for uptake of fluorescently labeled liposomes by 
alveolar type II cells in culture. Am J Physiol1995;269:Ll 1-9. 
16. Gregory TJ, Longmore Wj, Moxley l\.1A., Whitsett ]A, Reed CR, Fowler AA, 3rd, et al. Suifactant 
chemical composition and biophysical activity in acute respiratory distress syndrome. j Clin Invest 
1991;88:1976-81. 
17. Wissel H, Zastrow S, Richter E, Stevens PA. Internalized SP-A and lipid are differentially resecreted by 
type II pneumocytes. Am j Physiol Lung Cell Mol Physiol2000;278:L580-90. 
18. Mason Rj, Leslie CC, McCormick-Shannon K, Deterding RR, Nakamura T, Rubin ]S, et aL Hepatocyte 
growth factor is a growth factor for rat alveolar type II cells. Am j Respir Cell Mol Bio/1994; 11:561-7. 
19. Leslie CC, McCormick-Shannon K, Shannon JM, Garrick B, Damm D, Abraham ]A, et al. Heparin-
binding EGF-like growth factor is a mitogen for rat alveolar type II cells. Am J Respir Cell Mol Bioi 
1997;16:379-87. 
20. Miller CR, Bondurant B, McLean SD, McGovern KA, O'Brien DE Liposome-cell interactions in vitro: 
effect of liposome suiface charge on the binding and endocytosis of conventional and sterically stabilized 
liposomes. Biochemistry 1998;37.·12875-83. 
21. Crapo ]D, Peters-Golden M, Marsh-Sa/in], Shelburne ]S. Pathologic changes in the lungs of oxygen-
adapted rats: a morphometric analysis. Lab Invest 1978;39:640-53. 
38 
CHAPTER 
A common pathway for the uptake of surfactant lipids 
by alveolar cells 
Davey L. Poelma1, Michel R. Jui, Sjoerd C. Bakker1, 
Luc ]. Zimmermann2, Burkhard F. Lachmann1 
and J. Freek van Iwaarden2 
1 Dept. of Anesthesiology, Erasmus MC- Faculty, Rotterdam, The Netherlands 
2 Dept. of Neonatology, University Hospital Maastricht, Maastricht, The Netherlands 
In: Am J Respir Cell Mol BioL 2004;30(5):751-8 
39 
Abstract 
The uptake of different surfactant lipids: dipalmitoylphosphatidylcholine (DPPC), 
phosphatidylglycerol (PG) or phosphatidylinositol (PI) and liposomes with a surfactant-like 
composition by alveolar type II cells (alveolar type II cells) and macrophages (alveolar macro-
phages) was studied in vitro. 
Fluorescent labeled liposomes containing either 86% of the studied lipid i.e. DPPC, PG, PI 
and 6% labeled phosphatidylethanolamine (PE) and 8% cholesterol or a lipid mixture similar 
to surfactant (DPPC, PG, PI, phosphatidylcholine, PE and cholesterol in a weight ratio of 
55:8:2:21:8:6) were incubated with alveolar macrophages and alveolar type II cells. The cell-
associated fluorescence assessed by flow cytometry, demonstrated a higher uptake of PG and 
PI by both alveolar macrophages and alveolar type II cells, and a lower uptake of DPPC by 
alveolar macrophages. In addition, less alveolar type II cells take up DPPC whereas there are 
no differences for the alveolar macrophages in the number of cells involved in the uptake. 
Competition experiments with Texas-Red labeled liposomes and either DPPC liposomes or PI 
liposomes labeled with Bodipy indicated that all these liposomes are internalized via the same 
pathway by alveolar cells. Thus, lipid composition direcdy influences the (re)uptake of 
surfactant. 
Introduction 
The alveolus is lined with a thin layer of lipids and proteins, called surfactant and this surface 
active agent has an essential role in maintaining normal lung function. Pulmonary surfactant 
is produced by alveolar type II cells. By weight, approximately 90% of surfactant consists of 
lipids. Although, the lipid composition varies in different species, its major component is 
phosphatidylcholine (PC; 70-80%) of which nearly 50% is saturated dipalmitoylphosphati-
dylcholine (DPPC). DPPC is the major surface tension-reducing component of surfactant. In 
addition, surfactant contains variable amounts of phosphatidylglycerol (PG; 7-18%), 
phosphatitylinositol (PI; 2-4%) and phosphatidylethanolamine (PE; 2-3%) 0 • The remaining 
percentage consists of other phospholipids and cholesterol0 • 
The presence of surfactant within the alveolus is the result of a complex system of production, 
secretion, uptake and recycling. The production of newly synthesized surfactant has been 
suggested to be relatively slow, especially in newborn animals2• 3l. Therefore, inactivated 
surfactant is reutilized, i.e. recycled. It has been demonstrated that 50-90% of the PC is 
recycled depending on age and species, where with an increasing age the contribution of 
recycling decreases4l. Inactivated surfactant is cleared from the alveolar space mainly by alveolar 
type II cells5l. This uptake of surfactant by alveolar type II cells is essential to enable recycling 
of surfactant. Therefore uptake or reuptake of surfactant plays an important role in the 
homeostasis of the surfactant metabolism. 
It has been shown that there are essential differences in the composition of surfactant between 
neonates and adults regarding the phospholipids which, combined with the fact that neonates 
rely more on recycling, suggests an effect of the composition on the uptake of surfactant. 
Previous studies have demonstrated an effect of surfactant proteins, especially SP-A, on the 
uptake by alveolar cellsG-9l. However, litde is known on the effect oflipid composition on the 
clearance of surfactant from the alveolar space by alveolar cells, since most studies have focused 
on internalization ofDPPC by both alveolar type II cells and alveolar macrophages. Quintero 
et al. have shown a more rapid clearance of PG by alveolar macrophages in contrast to 
DPPC'0l, indicating an effect of the lipid composition on the uptake. It remains unclear, how-
ever, whether the uptake of surfactant by alveolar type II cells is also affected by lipid compo-
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sition. Therefore, we studied the uptake of the major surfactant lipids by alveolar type II cells 
as well as alveolar macro phages using fluorescent labeled liposomes11l. In addition, we 
examined how the different lipids influence each other's uptake by alveolar cells. 
Material & methods 
Ethical Guidelines 
This study was approved by the Institutional Animal Committee at the Erasmus University 
Rotterdam and complied with NIH guidelines. A total of 30 male Sprague Dawley rats (IFFA 
Credo, The Netherlands) with an average weight of 280 ± 41 g were used. 
Materials 
Dipalmitoylphosphatidylcholine (D PPC), egg phosphatidylcholine (PC), phosphatidylglyce-
rol (PG), phosphatidylinositol (PI), phosphatidylethanolamine (PE) and cholesterol were 
purchased from Sigma (Zwijndrecht, The Netherlands). PE labeled with Bodipt' and PE 
labeled with Texas Red® were obtained from Molecular Probes (Leiden, The Netherlands). 
Both labeled PE lipids are labeled in the head-group. 
Liposome preparation 
To prepare liposomes, the indicated concentrations of the different lipids were mixed. The 
mixture of lipids was dried under a stream of nitrogen gas. The liposomes were suspended in 
PBS at a concentration of 0.5 mg lipids/ml using glass pearls and vortexing. Immediately prior 
to use, the liposome suspension was sonicated for 2 min on ice using an ultrasonic disinte-
grator (Branson Sonifier 250, Danbury, USA) to prepare small unilamellar liposomes10• The 
size of the liposomes was determined by dynamic light scattering at 25oC with a Malvern 4700 
system using a 25 m W He-Ne laser (NEC, Tokyo, Japan) and the automeasure version 3.2 
software (Malvern Ltd, UK). As a measure of particle size distribution of the dispersion, the 
system reports a polydispersity index (p.d.). This index ranges from 0.0 for a monodisperse and 
up to 1.0 for an entirely polydisperse dispersion. After ultrasonification the liposomes size 
ranged from 140 to 165 nm and the polydispersity indexe ranged from 0.2 to 0.35. 
Isolation of alveolar cells 
Prior to isolation of the cells, the thorax was opened and the blood cells were removed from 
the lungs by perfusing the pulmonary artery with saline (3TC) supplemented with 20 IE 
heparin (Leo Pharma, Weesp, The Netherlands). The lungs were removed from the thoracic 
cavity en bloc and lavaged with 10 ml of solution 1 [140 mM NaCl, 5 mM KCl, 2.5 mM 
Na2HP04.2H20, 10 mM HEPES (N-2-hydroxyethylpiperazine-N'-2-ethaesulfonic acid), 6 
mM glucose, 0.2 mM EGTA [ethylene glycol-his- (f3-amino ethyl ether) N,N'-tetra-acetic 
acid), pH 7.40] at 22oC. This procedure was repeated four times. The lung lavages were pooled 
per animal and centrifuged (IOOx g, 10 min; 4°C). The cellular pellet, i.e. alveolar macro-
phages, were suspended in solution 2 (140 mM NaCl, 5 mM KCl, 2.5 mM phosphate buffer, 
10 mM HEPES, 6 mM glucose, 2.0 mM CaC12 and 1.3 mM MgS04) to a concentration of 
2x1 06 cells/ml and stored on ice until further use. The alveolar type II cells were isolated accor-
ding to Dobbs et al. 12J. Alveolar type II cells were suspended in solution 2 at a concentration 
of 2x106 cells/ml and stored on ice until further use. Alveolar macrophages were identified 
using monoclonal antibodies specific for rat macrophages (ED9) and alveolar type II cells were 
identified using an alkaline phosphatase assay as described by Edelson et al. 13J. The average 
yield per rat of alveolar type II cells was 16x106 and 5x106 alveolar macrophages. The purity of 
the alveolar type II cells was determined and 80 ± 5% of the cells in the type II cell isolate were 
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identified as alveolar type II cells. The alveolar macrophage isolate had a purity of 92 ± 2% 
alveolar macrophages as determined by ED9 antibodies. 
Uptake of liposomes by alveolar cells 
Alveolar type II cells and alveolar macrophages were isolated as described above and were 
suspended in solution 2 to a concentration of 2x106 cells/mi. A total of 3x105 cells were 
incubated with various concentrations of the different liposomes at 3TC (unless stated other-
wise) (final volume 500 p.l) in a shaking water bath. After 1 hour, the incubation was 
terminated by addition of 2 ml of ice-cold PBS11l. The cell suspension was centrifuged at 1 OOx 
g for 10 min at 4oC. The supernatant was removed and the cells were suspended in 2 ml of 
ice-cold PBS and centrifuged again. This wash procedure was repeated twice. Finally, the pellet 
was resuspended in 200 pl cold PBS and cell-associated fluorescence was determined as 
described below. 
Flow cytometry 
As a measure for the amount of internalized liposomes, cell-associated fluorescence of a total 
of 15,000 alveolar type II cells or alveolar macrophages was determined using flow cytometry 
(FACSCalibur; Becton Dickinson; Mountain View, USA). The Bodipy® fluorescence was 
determined in the FL 1 channel whereas the Texas Red® fluorescence was determined in the 
FL 4 channel. The spill-over of Bodipy in the FL 4 channel as well as Texas Red in the FL 1 
channel, was less than 1% and was not corrected for in the double labeling experiments. 
Control alveolar macrophages and alveolar type II cells were used in each experiment to deter-
mine the autofluorescence of the cells. Subsequently, the mean cell-associated fluorescence was 
determined only for those cells that had a higher fluorescence than that caused by auto-
fluorescence (gated cells) 11l. Cells with a higher fluorescence than that caused by auto-fluo-
rescence were collected and identified using the methods described above, showing similar 
results for all types of liposomes, 81 ± 6% of the cells were type II cells within the type II cell 
isolate and 93 ± 5% were alveolar macrophages in the alveolar macrophage isolate. 
Localization of cell-associated fluorescence 
Confocal laser miscoscopy was performed using a Zeiss LSM 410, with standard objectives and 
photomultiplier tubes dedicated to the appropriate excitation and emission spectra of the used 
fluorescent label (Bodipy excitation 503 nm emission 512 nm, Texas Red excitation 589 nm 
emission 615 nm). Images were serial sectioned at a depth of 0.5 pm to distinguish cell-
membrane associated fluorescence from true intracellular fluorescence. 
Statistical analysis 
The differences in uptake of different components were analyzed using an AN OVA followed 
by a Bonferroni post hoc test. 
Differences were considered statistically significant at a p <0.05. Values are expressed as mean 
±SEM. 
Results 
Concentration dependent uptake of liposomes 
To study the uptake of the phospholipid components of surfactant, DPPC, PC, PG and PI, 
isolated alveolar cells were incubated for 1 hour with liposomes of different compositions. The 
mean cell-associated fluorescence, as a measurement for uptake of liposomes, of the alveolar 
type II cells and alveolar macrophages demonstrates a concentration-dependent increase. With 
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exception of the uptake of PI liposomes by alveolar macrophages and the uptake of PG 
liposomes by alveolar type II cells, the uptake of all individualliposomes reaches an apparent 
maximum at 25 jlg/ml (Fig. 1A, B). However, the maximum cell-associated fluorescence, e.g. 
maximal uptake, at the plateau differs between the various liposome compositions. 
The 86% PG and 86% PI liposomes are internalized significantly more by alveolar type II cells 
than normal liposomes (PC, DPPC, PG, PI, PE and cholesterol in weight ratio of 
21:55:8:2:6:8). The uptake of 86% PC liposomes and 86% DPPC liposomes does not differ 
from the normalliposomes, except at a higher lipid concentration of 50 jlg/ml, more 86% PC 
liposomes are internalized (Fig 1A). 
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Figure 1. Concentration-dependent uptake of liposomes 
Alveolar type II cells (A) and macrophages (B) were isolated and incubated for 1 hour at 
3TC with the indicated concentrations of either 86% PG (PG:Chol: PE-Bodipy; weight 
ratio: 86:8:6) or 86% PI (PI:Chol:PE-Bodipy; 86:8:6) or 86% DPPC (DPPC:Chol:PE-
Bodipy; 86:8:6) or 86% PC(PC: Chol: PE-Bodipy; 86:8:6) or normal 
(DPPC:PC:PG:PI:Chol:PE-Bodipy; 55:21:8:2:8:6) liposomes. The mean cell-associated 
fluorescence was determined. of those cells with a higher fluorescence than the auto-
fluorescence (n = 4 incubations of 3x105 cells each at every concentration; values 
expressed as mean± SEM). #indicates a significant difference compared to the normal 
liposomes. 
There is a significant difference in the uptake of 86% PG liposomes, 86% PI, 86% PC, and 
normalliposomes by alveolar macrophages at a concentration of 50 jlg/ml. The internalization 
of 86% PG liposomes is significantly higher than that of normalliposomes whereas the uptake 
of 86% DPPC liposomes by alveolar macrophages is significantly lower than normal lipo-
somes. These results may indicate that uptake of liposomes by alveolar macrophages and 
alveolar type II is effected by the charge of the liposomes (i.e. 86% PG and 86% PI liposomes 
are more negatively charged). 
Percentage alveolar type II cells and alveolar macrophages involved in the uptake 
The percentage gated alveolar type II cells and alveolar macrophages involved in the uptake of 
liposomes also demonstrate a concentration-dependent increase, reaching a plateau for all 
groups ofliposomes (Fig. 2 A, B). The percentage alveolar macrophages involved in the uptake 
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of liposomes is not significantly affected by the charge of the liposomes (Fig. 2B). In contrast, 
the number of alveolar type II cells internalizing liposomes is affected by the charge of the 
liposomes; although only the 86% PI liposomes are capable of significantly increasing the 
number of alveolar type II cells taking up the liposomes. More interesting, however, is the 
significantly lower percentage of alveolar type II cells taking part in the uptake of 86% DPPC 
liposomes; 29 ±4.5% versus 72.7 ± 2.3% involved in the internalization of normalliposomes 
at a concentration of 50 rg/ml (Fig. 2A). 
Localization of cell-associated fluorescence 
To ascertain that the cell-associated fluorescence was located within the cell rather than 
aspecific binding to the outer membrane of the cell, confocal laser microscopy was used. The 
confocal scans through the middle of the cell show a punctuate fluorescence throughout the 
cell limited to its circumference with the exception of its nucleus. Both labels, the TexasRed-
labeled PG liposomes (Fig. 3 A,C) and Bodipy-labeled DPPC liposomes (Fig. 3 B, D) were 
internalized by the alveolar type II cells and alveolar macrophages as untreated cells did not 
show any fluorescence at the same microscopic settings. 
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Alveolar cells type II cells (A) and macrophages (B) were isolated and incubated for 1 
hour at 3TC with the same fluorescent liposomes as described in the legend of figure 1. 
The percentage cells with a cell-associated fluorescence higher than the autofluorescence 
was determined (= Gated Cells) (n = 4 incubations of 3xl05 cells each at every concen-
tration; values expressed as mean± SEM). #indicates a significant difference compared 
to the normalliposomes. 
Effect of 86% PG Texas Red labeled liposomes on the uptake of 86% PI Bodipy labeled 
liposomes 
The increased uptake of negatively charged PI and PG liposomes combined with an increased 
percentage alveolar type II cells involved in this uptake, raised the question whether these two 
types ofliposomes are taken up via the same "charge" dependent pathway. Therefore, the effect 
of 86% PG-Texas Red labeled liposomes on the uptake of 86% PI-Bodipy labeled liposomes 
by alveolar type II cells and alveolar macrophages was studied by keeping the Bodipy-labeled 
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Figure 3. Localization of cell-associated fluorescence 
Both alveolar type II cells (A, B) and alveolar macrophages (C, D) were isolated and 
incubated with 86% Bodipy-labeled DPPC liposomes and 86% Texas Red-labeled PG 
liposomes. One hour after incubation cells were washed 3 times with cold PBS and the 
cells were mounted on glass coverslips. Confocal laser microscopy demonstrates a punc-
tuate distribution ofTexasRed labeled PG liposomes (A, C) and Bodipy labeled DPPC 
liposomes (B, D) that is not limited to the cell surface, and is not localized in the nucleus 
of the cell. This distribution of fluorescence throughout the cell indicates internalization 
ofliposomes, strengthened by the fact that untreated cells did not show any fluorescence 
at the same microscopic settings. 
PI liposomes constant and increasing the concentration of added Texas Red labeled PG 
liposomes. In both cell types, alveolar type II cells and alveolar macrophages, Bodipy-asso-
ciated mean fluorescence, i.e. uptake of 86% PI liposomes, significantly decreases with an 
increasing concentration of 86% PG liposomes. On the other hand, the cell-associated Texas 
Red mean fluorescence, i.e. uptake of 86% PG liposomes, increases significantly with an 
increasing concentration of 86% PG liposomes (Fig 4 A, B). 
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Figure 4. Competition between Plliposomes and PG liposomes (Mean fluorescence) 
Alveolar cells were isolated and incubated for 1 hour at 3TC with 12.5 p.g Bodipy 
labeled PI liposomes (PI:Chol:PE-Bodipy; 86:8:6) and the indicated concentrations of 
Texas Red labeled PG liposomes (PG:Chol:PE-Texas Red; 86:8:6). The mean cell-
associated Bodipy fluorescence (PI; squares) as well as the mean cell-associated Texas Red 
fluorescence (PG; triangles) was determined in alveolar type II cells (A) and alveolar 
macrophages (B). Subsequently, the cell-associated Bodipy fluorescence in the presence 
of PG-Texas Red was expressed as percentage of the cell-associated Bodipy fluorescence 
of the incubation with 12.5 p.g PI-Bodipy alone (Cell-associated PI (%)). The cell-
associated Texas Red fluorescence in the presence of PI-Bodipy was expressed as percen-
tage of the cell-associated Texas Red fluorescence of the incubation with 50 p.g PG-Texas 
Red alone (Cell-associated PG (%)).Values are expressed as mean± SEM (n = 4). # indi-
cates a significant difference compared to 0 p.g/ml Texas Red labeled PG liposomes. 
In addition, when the concentration of 86% PG liposomes is increased, significantly less cells 
take up preferentially 86% PI liposomes; there is a significant increase in alveolar cells, either 
alveolar type II cells or alveolar macrophages, that take up both 86% PI liposomes and 86% 
PG liposomes (Fig. 5A, B). There are hardly any alveolar cells that internalize only 86% PG 
liposomes, except at the highest PG concentration, 50 p.g/ml, where there is a significant 
percentage (3%) of the alveolar type II cells that internalize only 86% PG liposomes. The total 
amount of alveolar cells involved in the uptake does not change significantly (83% for alveolar 
macrophages and 79% for alveolar type II cells) (Fig 5A, B). These results may indicate that 
both types of liposomes are taken up via the same pathway. Next, the question rose whether 
this pathway was the same for DPPC. 
Effect of 86% PG Texas Red labeled liposomes on the uptake of 86% DPPC Bodipy 
labeled liposomes 
To determine if 86% DPPC liposomes are taken up via the same pathway as 86% PG, alveolar 
cells were incubated with 86% DPPC-Bodipy labeled liposomes and increasing concentrations 
of 86% PG-Texas Red labeled liposomes. Increasing the concentration of 86% PG-Texas Red 
labeled liposomes results in a significant increase ofTexas Red- associated mean fluorescence, 
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Figure 5. Competition between PI liposomes and PG liposomes (Gated cells) 
Alveolar cells type II cells (A) and macrophages (B) were isolated and incubated for 1 
hour at 3TC with the same fluorescent liposomes as described in the legend of figure 3. 
The squares (o/oPI+, PG- cells) are the percentage cells whose Bodipy cell-associated 
fluorescence is higher than the autofluorescence and whose fluorescence caused by Texas 
Red is within the range of the autofluorescence. The triangles (o/oPG+, PI- cells) are the 
percentage cells that have a Texas Red cell-associated fluorescence higher than the auto-
fluorescence and a Bodipy fluorescence is within the range of the autofluorescence. The 
circles (o/oPG+, PI+) are the percentage cells which have a Texas Red cell-associated 
fluorescence higher than the autofluorescence, as well as a Bodipy cell-associated 
fluorescence higher than the autofluorescence. The dotted line and asterisks are the total 
percentage of cells with a fluorescence higher than the autofluorescence, either by Bodipy 
or Texas Red. Values are expressed as mean ± SEM (n = 4). # indicates a significant 
difference compared to 0 rg/ml Texas-Red labeled PG liposomes. 
together with a significant decrease in Bodipy-associated mean fluorescence (Fig. 6A, B). 
Raising the concentration of 86% PG liposomes results in a significant increase in double 
labeled alveolar macrophages, together with a significant decrease in Bodipy labeled alveolar 
macro phages. 
At a concentration of 12.5 rg/ml 86% PG liposomes, the amount of double labeled alveolar 
macrophages decreases again and the amount of alveolar macrophages that take up only 86% 
PG liposomes increases (Fig. 7B). The alveolar type II cells demonstrate a similar change in 
cells involved in the uptake, first the amount of double labeled cells increase, and at a 
concentration of 5 rg/ ml, which is lower than for alveolar macro phages, the amount of double 
alveolar type II cells decreases, together with an increase in alveolar type II cells that take up 
only 86% PG liposomes (Fig 7A). 
Effect of 86% DPPC Texas Red labeled liposomes on the uptake of 86% PG Bodipy 
labeled liposomes 
To determine whether 86% DPPC liposomes can inhibit the uptake of 86% PG liposomes, 
suggesting a similar pathway for uptake of liposomes, alveolar cells were incubated with 86% 
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Figure 6. Uptake of DPPC liposomes in presence of Texas-Red labeled PG liposomes (Mean 
fluorescence) 
Alveolar cells were isolated and incubated for 1 hour at 3TC with 12.5 ]lg Bodipy 
labeled DPPC liposomes (DPPC:Chol:PE-Bodipy; 86:8:6) and the indicated concen-
trations ofTexas Red labeled PG liposomes (PG:Chol:PE-Texas Red; 86:8:6). The mean 
cell-associated Bodipy fluorescence (DPPC; squares) as well as the mean cell-associated 
Texas Red fluorescence (PG; triangles) was determined in alveolar type II cells (A) and 
alveolar macrophages (B). Subsequently, the cell-associated Bodipy fluorescence in the 
presence of PG-Texas Red was expressed as percentage of the cell-associated Bodipy 
fluorescence of the incubation with 12.5 ]lg DPPC-Bodipy alone (%Cell-associated 
DPPC). The cell-associated Texas Red fluorescence in the presence ofDPPC-Bodipy was 
expressed as percentage of the cell-associated Texas Red fluorescence of the incubation 
with 50 ]lg PG-Texas Red alone (% Cell-associated PG). Values are expressed as mean 
± SEM (n = 4). # indicates a significant difference compared to 0 ]lg/ml Texas-Red 
labeled PG liposomes. 
PG-Bodipy labeled liposomes and increasing concentrations of 86% DPPC-Texas Red labeled 
liposomes. Increasing the concentration of 86% DPPC-Texas Red labeled liposomes results in 
a significant decrease of Bodipy-associated mean fluorescence per alveolar type II cell, but no 
changes were seen in cell-associated fluorescence per alveolar macrophages (Table 1). 
Increasing the concentration of 86% DPPC liposomes results in a significant decrease in 
single-labeled, Bodipy associated, alveolar cells, and a concomitant increase in double-labeled, 
Bodipy and Texas-Red associated, alveolar cells. There is a slight, non-significant, increase in 
alveolar cells that are only Texas-Red labeled and thus took up only 86% DPPC liposomes. 
Discussion 
In the current study we investigated the uptake of the main phospholipid components of 
surfactant in vitro by alveolar type II cells and alveolar macrophages. We used fluorescent 
labeled liposomes containing 86% of the studied component, 8% cholesterol and 6% labeled 
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Figure 7. Uptake ofDPPC liposomes in presence ofTexas-Red labeled PG liposomes (Gated 
cells) 
Alveolar cells type II cells (A) and macrophages (B) were isolated and incubated for 1 
hour at 3TC with the same fluorescent liposomes as described in the legend of figure 5. 
The squares (o/oDPPC+, PG- cells) are the percentage cells which have a Bodipy cell-
associated fluorescence higher than the autofluorescence and a Texas Red fluorescence 
not higher than the autofluorescence. The triangles (o/oPG+, DPPC- cells) are the 
percentage cells which have a Texas Red cell-associated fluorescence higher than the auto-
fluorescence and a Bodipy fluorescence not higher than the autofluorescence. The circles 
(o/oPG+, DPPC+) are the percentage cells which have a Texas Red cell-associated 
fluorescence higher than the autofluorescence as well as Bodipy cell-associated 
fluorescence higher than the autofluorescence. The dotted line and asterisks are the total 
percentage of cells with a fluorescence higher than the autofluorescence, either by Bodipy 
or Texas Red. Values are expressed as mean ± SEM (n = 4). # indicates a significant 
difference compared to 0 J-lg!ml Texas-Red labeled PG liposomes. 
phosphatidylethanolamine. Confocal laser microscopy demonstrated the intracellular presence 
of cell-associated fluorescence, indicating that the fluorescent labeled liposomes are indeed 
taken up by the alveolar cells (Fig. 3). The uptake of the liposomes shows a concentration-
dependent increase in cell-associated fluorescence (Fig. 1), reaching a plateau at 25 J-lg!ml, 
similar to the results of our previous study11l. The uptake of the more negatively charged 
liposomes, i.e. 86% PG and 86% PI liposomes, by alveolar type II cells and alveolar macro-
phages is significantly higher than that of the more neutrally charged liposomes, i.e. 86% PC, 
86% DPPC and normalliposomes. These results indicate that the alveolar cells have a higher 
affinity for negatively charged liposomes. 
The mechanism of internalization ofliposomes by the alveolar cells is not clear at the moment. 
For macro phages as well as alveolar type II cells at least part of the uptake of liposomes seems 
to be mediated by the coated-pit pathway1+16l, suggesting a receptor-mediated process, but for 
which the receptor and the specificity of the receptor are unknown. For arguments sake we 
assume that the uptake of liposomes by alveolar cells is receptor mediated. A receptor with a 
high affinity for negatively charged liposomes per se and which does not discriminate between 
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Table 1. Uptake ofPG liposomes in the presence of increasing concentrations DPPC liposomes 
110 p.g/ml PG Fluorescence PG+ cells (o/o) DPPC+ cells (o/o) PG+ DPPC+ cells 
PG (%) (o/o) 
DPPC ATII AM ATII AM ATII AM ATII AM 
(p.g/ml) 
0 100 100 83 81 0 0 5 4 
10 86 90 63* 47* 0 1 14 37* 
25 59 84 52* 25* 1 1 20 53* 
50 63 81 43* 15* 1 2 27 62* 
100 56* 78 36* 13* 5 5 26 59* 
Isolated alveolar cells were incubated with 10 p.g/ ml Bodipy labeled PG and increasing 
concentration TexasRed labeled DPPC. Mean cell-associated fluorescence per cell was deter-
mined and expressed as percentage of mean fluorescence in absence of DPPC (Fluorescence 
PG (o/o)). 
Definition of abbreviation: ATII, alveolar type II cells; AM, Alveolar macro phages; PG+ cells, 
Bodipy fluorescence associated positive cells; DPPC+cells, TexasRed fluorescence associated 
positive cells; PG+DPPC+ cells, both Bodipy and TexasRed fluorescence associated positive 
cells. (* p<0.05). 
PG and PI liposomes, as was shown by competition experiments with 86% PI and 86% PG 
containing liposomes. 
The receptor is not specific for negatively charged liposomes. The competition experiments of 
PG and DPPC liposomes demonstrate that the uptake of DPPC by the alveolar cells can be 
fully blocked by PG leading to uptake of PG instead, whereas the other way around, 
competing PG with DPPC, leads to only a partial reduction in the PG uptake by alveolar cells 
(Table 1). Therefore the receptor affinities for DPPC and PG and/or PI liposomes seem to 
differ; the highest affinity being for PG followed by PI and DPPC. There seems to be very few 
differences in the uptake of phospholipids by alveolar macrophages and alveolar type II cells, 
but from our experiments it can not be concluded that the "phospholipid receptor" of alveolar 
macrophages and alveolar type II cells is the same. The only striking difference is the number 
of cells involved in the uptake of DPPC liposomes. The number of alveolar type II cells that 
internalize DPPC liposomes is significantly lower than the number of alveolar macrophages 
(29% versus 72%), whereas the number of cells involved in the uptake of PG liposomes is 
approximately the same for alveolar macrophages and type II cells (75-80%). A possible 
explanation can be that the distribution of receptors on alveolar macrophages and type II cells 
differs. Most of the alveolar macrophages may have a high density of receptors, whereas the 
alveolar type II cell population consists of several subpopulations of cells with different 
receptor densities. Hence, adding DPPC liposomes to alveolar cells will lead to association of 
DPPC with practically all macrophages and, in the case of type II cells, association will occur 
only with the subpopulation of type II cells with the highest receptor density. PG or PI lipo-
somes will also associate with the subpopulations of alveolar type II cells with lower receptor 
densities due to the high affinity of the receptor for these two phospholipids. This hypothesis 
may explain the competition experiments ofDPPC with PG and vice versa using alveolar type 
II cells (Figs. 6, 7 and Table 1). By competing DPPC with PG a rapid drop in the cell-
associated DPPC is observed, whereas competing PG with DPPC only a slight reduction in 
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the cell-associated PG is observed which is indicative for a higher affinity of the alveolar cells 
for PG than for DPPC. The maximal number of alveolar type II cells that can internalise 
DPPC is approximately 30%, adding PG to the incubation results in a rapid decline in the 
number of cells that contain only DPPC with a concomitant increase in PG+ cells. The double 
positive cells increase initially, but at higher PG concentrations the number decreases. 
Apparently, at relatively low PG concentrations, PG competes with DPPC for the cells with 
the highest receptor density leading to cells which internalise both lipids as well as small 
numbers of PG+ and DPPC+ cells. At higher PG concentrations, the PG uptake by the cells 
with the high receptor density is saturated, leading to the uptake of PG by the sub population 
of cells with the low receptor density; the cells which cannot internalise DPPC. Therefore, 
there are more alveolar type II cells that can take up PG, which consist of the subpopulations 
of cells with the high as well as with the low receptor densities, and less cells which can inter-
nalise DPPC, namely the subpopulation with the high receptor density. The results of the 
competition berween PG and DPPC can be explained in a similar way. In the absence of 
DPPC the number of PG+ cells is approximately 80%, which consist of the subpopulations 
with high as well as low receptor densities. Including DPPC in the incubations leads to a 
reduction in the number of the PG+ cells that stabilizes at 30-40% PG+ cells at a 10-fold 
higher concentration ofDPPC over PG. This cell population reflects the low receptor density 
cells. Hence, about 40-50% of the alveolar type II cells have a low receptor density and cannot 
internalise DPPC, and about 30-40% of the alveolar type II cells have a high receptor density 
and are able to internalise both DPPC and PG. 
Up to now, the focus has been on the role of the surfactant proteins in the uptake of DPPC 
by alveolar cells in vitro. At least three of the four surfactant proteins, SP-A, SP-B and SP-C, 
were implicated in the internalization of surfactant lipids by alveolar cells. SP-A and SP-C were 
shown to stimulate the uptake of liposomes by alveolar cells6·9• 16• 17), whereas the influence of 
SP-B on the uptake ofliposomes is more complex. SP-B was reported to stimulate the uptake 
by alveolar cells18-20l, whereas others have shown that SP-B can inhibit the SP-C mediated 
uptake by alveolar type II cells7• s). In vivo the role of the surfactant proteins becomes more 
complex and unclear. In SP-A knock out mice the uptake of surfactant by alveolar cells appears 
to be normal21 • 22l, whereas one would expect that based on the vitro results the uptake would 
be disturbed in these animals, only under inflammatory conditions are differences in lipid 
uptake between SP-A (+I+) and SP-A(-/-) mice observed23l. In contrast, for SP-D no influence 
on lipid uptake could be demonstrated in vitrom, while the surfactant lipid metabolism in SP-
D (-/-) mice was disturbed24• 25l. Therefore, in spite of numerous studies, the role of the 
surfactant proteins in the surfactant lipid metabolism in vivo still needs to be further clarified. 
The influence of the surfactant phospholipid composition, in particular the charge of the 
phospholipids, on the uptake of surfactant liposomes by alveolar cells is also not clear. The first 
data are derived from in vivo experiments by Jacobs et al.26•27l, demonstrating the disappearance 
of radiolabeled PG in the lungs of neonatal and adult rabbits after intratracheal injection. Bates 
and Chandler have shown that radiolabeled PG containing vesicles are internalized more 
rapidly by alveolar type II cells in vitro28' 29l. Recently, a study by Quintero et al. indicated that 
alveolar macrophages internalize PG more readily than DPPC in vitro10l. The present study 
indicates that, besides alveolar macro phages, also alveolar type II cells have a higher affinity for 
PG or PI containing liposomes than for the more neutrally charged liposomes. In addition, the 
pathway of uptake of PG, PI, and DPPC by alveolar cells appears to be the same. Uptake of 
surfactant lipids by alveolar cells is an important step in the recycling of surfactant. Surfactant 
recycling itself is crucial to maintain normal lung functions. Therefore, changes in the 
surfactant lipid composition, for instance, more or less PG or other negatively charged lipids, 
may not only alter the uptake of these lipids but also of DPPC, the most important surface 
tension lowering component of surfactant. In various diseases, such as respiratory distress 
51 
syndrome (RDS), extrms1c allergic alveolites and respiratory infections changes in the 
surfactant lipid composition were observed30• 3n. Whether an altered uptake of surfactant lipids 
by alveolar cells plays a role in the pathogenesis of respiratory diseases is not yet known. 
Further studies on the role of the surfactant lipid composition on the uptake of surfactant by 
alveolar cells are therefore warranted. In particular, the influence of the lipid composition on 
the in vivo uptake of surfactant and the effects on lung mechanics. Not only will this infor-
mation expand our knowledge on the surfactant metabolism but it might also provide new 
tools for therapeutic interventions for various respiratory diseases. 
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Abstract 
The effect of phosphatidylglycerol on the uptake by alveolar type II cells and alveolar macro-
phages as well as the effect on endogenous surfactant function was studied in vivo. Healthy 
ventilated rats were intratracheally instilled with fluorescent labeled liposomes with different 
concentrations phosphatidylglycerol. Lung function was determined by monitoring arterial 
oxygenation and, at the end of the experiment, by static pressure-volume curves. In addition, 
alveolar cells were isolated and cell-associated fluorescence was determined using flow 
cytometry. The results show that in the presence of cofactors (Ca 2+, Mg 2+) phosphatidylglyce-
rol stimulates the uptake by alveolar macrophages, but hardly affects the uptake by alveolar 
type II cells. High concentrations phosphatidylglycerol reduce the amount of alveolar macro-
phages in the alveolar space and induce a deterioration of lung function. On the other hand, 
the presence of cofactors protects the lung against the negative effects of phosphatidylglycerol 
on endogenous surfactant and alveolar macrophages. 
This study indicates that the phosphatidylglycerol concentration may play a fundamental role 
in the surfactant function and metabolism; though further investigations are needed to clarify 
the mechanism. 
Introduction 
The alveolus is lined with a thin layer oflipids and proteins, called surfactant, and this surface 
active agent has an essential role in maintaining normal lung function. Pulmonary surfactant 
is produced by alveolar type II cells. By weight, approximately 90% of surfactant consists of 
lipids. Although, the lipid composition varies in different species, its major component is 
phosphatidylcholine (PC; 70-80%) of which nearly 50% is saturated dipalmitoylphosphati-
dylcholine (DPPC). DPPC is the major surface tension-reducing component of surfactant. In 
addition, surfactant contains variable amounts of phosphatidylglycerol (PG; 7-18%), 
phosphatitylinositol (PI; 2-4%) and phosphatidylethanolamine (PE; 2-3%) 11 • 
The remaining percentage of lipids consists of other phospholipids and cholesteroP1• The 
additional 10% consists of surfactant specific proteins (SP), SP-A, SP-B, SP-C and SP-D. 
It has been demonstrated that these surfactant proteins, although only a small part of 
surfactant, play an essential role in the homeostasis of surfactant. This homeostasis consists 
mainly of production, secretion, formation of lipid monolayer, turnover, re-uptake and 
recycling. Especially SP-A has been shown to affect the uptake of surfactant by alveolar cells2• 
51
• However, recent in vitro studies have demonstrated that, aside from these surfactant 
proteins, the different lipid components also affect the uptake6• 71 • In the past significant 
differences in lipid composition between adults and neonates have been described8-111 • In 
addition, the use of exogenous surfactant is now widely accepted as a treatment of surfactant 
dysfunction in neonates and is even under consideration as a therapy in adults121 • Considering 
the natural differences in surfactant lipid composition between adults and neonates, as well as 
the fact that neonates rely more on recycling of surfactant than adults13• 141, the role of the single 
lipid components on the uptake of surfactant by alveolar cells has to be elucidated. 
Phosphatidylglycerol is the second major component after PC, and in vitro studies have 
demonstrated a significant effect of phosphatidylglycerol on the uptake6• 7l_ However, extra-
polation of the results of in vitro experiments regarding the uptake of liposomes to the in vivo 
situation is not always valid, since we were able to demonstrate significant differences in uptake 
of surfactant-like liposomes in vitro in comparison to in vivo151 • Therefore, in the current study 
the effect of different concentrations phosphatidylglycerol incorporated in the liposome on the 
uptake was determined in mechanically ventilated rats using flow cytometry. In addition, we 
also investigated possible effects of these different concentrations on lung mechanics. 
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Materials and methods 
Ethical Guidelines 
This study was approved by the Institutional Animal Committee at the Erasmus MC 
Rotterdam. The studies were performed in 72 male Sprague-Dawley rats (IFFA Credo, The 
Netherlands) with a bodyweight of 310 ± 10 g. 
Materials 
Dipalmitoylphosphatidylcholine (DPPC), egg phosphatidylcholine (PC), phosphatidylglyce-
rol (PG), phosphatidylinositol (PI), phosphatidylethanolamine (PE) and cholesterol were 
purchased from Sigma (Zwijndrecht, The Netherlands). Head-group rhodamine labeled 
phosphatidylethanolamine (PE) (Rhodamine DHPE) was obtained from Molecular Probes 
(Leiden, The Netherlands). 
Liposome preparation 
To prepare liposomes, the different lipids (Sigma, Zwijndrecht, The Netherlands) were mixed 
at the indicated weight ratio (Table 1). The mixture of lipids was dried under a stream of 
nitrogen gas. The liposomes were either suspended in PBS or solution 2 (140 mM NaCl, 5 
mM KCl, 2.5 mM phosphate buffer, 10 mM HEPES, 6 mM glucose, 2.0 mM CaC12 and 1.3 
mM MgS04), to a concentration of 1.0 mg lipids/rnl using glass pearls and vortexing. 
Table 1. Composition of the fluorescent labeled liposomes 
0% PG Normal 20% PG 40% PG 60% PG 86% PG 
(8% PG) 
DPPC 61 55 46 32 17.4 0 
PC 23 21 18 12 6.6 0 
PG 0 8 20 40 60 86 
PI 2 2 2 2 2 0 
PE (labeled) 6 6 6 6 6 6 
Cholesterol 8 8 8 8 8 8 
Weight ratio of the individual lipids used for the composition of the different liposomes; 
DPPC: dipalmitoylphosphatidylcholine; PC: phosphatidylcholine; PG: phosphatidylglycerol; 
PI phosphatidylinositol; PE: phosphatidylethanolamine. 
Immediately prior to use, the liposome suspension was sonicated for 2 min on ice using an 
ultrasonic disintegrator (Branson Sonifier 250, Danbury, USA) to prepare small unilamellar 
liposomes15l. The size of the liposomes was determined by dynamic light scattering at 25oC 
with a Malvern 4700 system using a 25 m W He-Ne laser (NEC, Tokyo, Japan) and the auto 
measure version 3.2 software (Malvern Ltd, Malvern, UK). & a measure of particle size 
distribution of the dispersion, the system reports a polydispersity index (p.d.). This index 
ranges from 0.0 for a monodisperse and up to 1.0 for an entirely polydisperse dispersion. After 
ultrasonification the liposomes size ranged from 140 to 165 nm and the polydispersity index 
ranged from 0.2 to 0.35. 
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Intratracheal instillation of fluorescent liposomes 
After induction of anesthesia with a mixture of nitrous oxide (66%), oxygen (33%) and 
isoflurane (1-2%) a sterile polyethylene catheter (0.8 mm o.d.) was inserted into one of the 
carotid arteries. The animals were then tracheotomized and a sterile metal cannula was inserted 
into the trachea. 
After these surgical procedures, gaseous anesthesia was ended and replaced with an intra-
peritoneal injection of pentobarbital sodium (60 mg/ml, Nembutal®, Algin BV, Maassluis, The 
Netherlands) at a dose of 30 mg/kg bodyweight every hour. 
Muscle relaxation was induced and maintained by an hourly intramuscular injection of 
pancuronium bromide (2 mg/kg, Pavulon; Organon Technika, Boxtel, The Netherlands). The 
animals were then mechanically ventilated with a Servo® ventilator 900 (Siemens-Elema, 
Solna, Sweden) set to pressure control mode using a frequency of 30/min, an inspiratory/ 
expiratory ratio of 1:2, a positive end-expiratory pressure (PEEP) of 2 em H 20, a peak 
inspiratory pressure (PIP) of 12 em H 20 and Fi02 was set to 1. 
Before instillation of the labeled liposomes, PEEP was increased to 6 em H 20 and PIP was 
increased to 26 em H 20. After disconnection from the ventilator, the liposomes were 
administered intratracheally as a bolus of 3 ml/kg followed by a bolus of air (12 ml/kg), 
directly into the endothracheal tube via a syringe, and the animals were immediately 
reconnected to the ventilator. Thirty min after instillation of the liposomes PEEP was reduced 
to 2 em H 20 and PIP to 12 em H 20. 
Arterial blood gases were measured with conventional methods (ABL 555, Radiometer, 
Copenhagen, Denmark) at start of ventilation, immediately after instillation of the liposomes 
and every 30 minutes thereafter. One hour after ventilation the animals were sacrificed by 
exsanguination via the abdominal aorta and the alveolar cells were isolated to determine the 
cell-associated fluorescence. Control animals were sacrificed immediately after anesthesia and 
their isolated alveolar type II cells and alveolar macrophages were used to correct for auto 
fluorescence. 
Isolation of alveolar type II cells and alveolar macrophages 
Prior to isolation of the cells, the thorax was opened and the blood cells were removed from 
the lungs by perfusing the pulmonary artery with saline (3TC) supplemented with 20 IE 
heparin per ml (Leo Pharma, Weesp, The Netherlands). The lungs were removed from the 
thoracic cavity en bloc and lavaged with 10 ml of solution 1 [140 mM NaCl, 5 mM KCl, 2.5 
mM Na2HP04.2H20, 10 mM HEPES (N-2-hydroxyethylpiperazine-N'-2-ethaesulfonic 
acid), 6 mM glucose, 0.2 mM EGTA (ethylene glycol-bis- (~-amino ethyl ether) N,N'-tetra-
acetic acid), pH 7.40] at 2rc. This procedure was repeated four times. The lung lavages were 
pooled per animal and centrifuged (100x g;, 10 min; 4°C). The cellular pellet, i.e. alveolar 
macrophages, were suspended in solution 2 to a concentration of2x106 cells/ml and stored on 
ice until further use. The alveolar type II cells were isolated according to Dobbs et al. 16l. 
Alveolar type II cells were suspended in solution 2 at a concentration of 2x106 cells/ml and 
stored on ice until further use. Alveolar macrophages were identified using monoclonal anti-
bodies specific for rat macrophages (ED9) and alveolar type II cells were identified using an 
alkaline phosphatase assay as described by Edelson et al.m. The average yield of alveolar type 
II cells was 16x1 06 a purity of 81 ± 4% and 5x1 06 alveolar macro phages with a purity of 90 ± 
6% per rat. 
Flow cytometry 
Cell-associated fluorescence of the alveolar type II cells and alveolar macro phages as a measure 
for internalized liposomes was determined using flow cytometry (FACSCalibur; Becton 
Dickinson; Mountain View, USA). The cell-associated fluorescence of 15,000 cells was deter-
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mined. Alveolar macrophages and alveolar type II cells derived from control animals were used 
in each experiment to determine the auto fluorescence of the cells. Subsequently, the mean 
cell-associated fluorescence was determined only for those cells that had a higher fluorescence 
than that caused by auto-fluorescence (gated cells). 
Determination of lung mechanics 
Due to severe deterioration in blood gas values in the animals receiving 86% PG liposomes, 
additional experiments were performed to study the effect of these liposomes on lung 
mechanics. A total of 36 animals were subjected to procedures identical to those described 
above (ventilation and instillation of the liposomes) and after 1 hour the animals were 
sacrificed by an overdose of pentobarbital (60 mg/kg). Next, thorax and diaphragm were 
opened (to eliminate the influence of chest wall compliance and intra-abdominal pressure) and 
a static pressure-volume (PIV) curve from the lungs was recorded using conventional tech-
niques'8l. Maximal compliance (Cmax) was defined as the steepest part of the PN deflation 
curve, and was determined for each animal. The Gruenwald index, which characterizes the 
surfactant system in situ'9l, was calculated from the PN curve, defined as (2V5+ V10)/2V max' 
where V5, V10 and V max are the lung volumes at transpulmonary pressures of respectively 5, 
10 and 35 em H 20 from the deflation limb. Thereafter, broncho-alveolar lavage (BAL) was 
performed with saline (30 ml/kg heated to 3TC) five times and its percentage recovery was 
calculated. Cell debris was removed from the BAL by centrifugation at 400 x gfor 10 min. The 
protein concentration of the BAL fluid was determined using the Bradford method (Bio-Rad 
protein assay, Munich, Germany) with bovine serum albumin (Sigma, StLouis, MO, USA) as 
a standard20J. 
Histological sampling 
To study the presence of histological changes in lung morphology, one hour after instillation 
of the liposomes, blood was removed from the lungs by perfusion of the pulmonary arteries 
with warmed saline (3TC) supplemented with 20 IE heparin per ml (Leo Pharma, Weesp, The 
Netherlands). Next, the lungs were fixated as previously described (17). Briefly, after perfusion 
the lungs were fixated with a fixation solution, consisting of 3.6% formaldehyde and 0.25% 
glutaraldehyde. Prior to fixation, the airway pressure was momentarily increased to 10 cmH20 
and thereafter maintained at 10 cmH20. Blocks of tissue were taken from the center of the 
upper and middle lobe and from the ventral and dorsal part of the lower lobe. The specimens 
were embedded in paraffin, sectioned and stained with hematoxylin and eosin and lung 
morphology was analyzed using light microscopy. 
Statistical analysis 
Differences in blood gas values over time and differences between the groups that received 
liposomes with a different composition were analyzed using a repeated measurement AN OVA 
followed by a Bonferroni post-hoc test. Differences in mean fluorescence per cell and percen-
tage of cells involved in the uptake (gated cells) were analyzed using ANOVA followed by a 
Bonferroni post-hoc test, as were differences in maximal compliance, Gruenwald index, 
maximal volume at 35 em H 20, protein concentration in the BAL and number of macro-
phages retrieved by BAL. Differences were considered statistically significant at a p <0.05. 
Values are expressed as mean± SD. 
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Results 
Influence of the phosphatidylglycerol content of fluorescent labeled liposomes on the uptake 
fu described previously, incorporation of a higher concentration of phosphatidylglycerol in the 
labeled liposomes increases the uptake of these liposomes by alveolar macro phages and alveolar 
type II cells in vitro7l. To determine if these effects of phosphatidylglycerol on the uptake are 
also present in vivo, ventilated rats were intratracheally instilled with fluorescent labeled lipo-
somes that contained various concentrations phosphatidylglycerol. One hour after instillation 
of these liposomes, the animals were sacrificed and alveolar cells were isolated. The uptake of 
liposomes by alveolar type II cells decreased significantly when the amount of PG was 
increased to 20% in comparison to the uptake of normalliposomes, containing only 8% PG. 
However, further increment of the amount of PG did not have a significant effect on the 
uptake of these liposomes by alveolar type II cells in comparison to the 'normal' liposomes; 
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Fluorescent labeled liposomes with different concentrations of PG, either suspended in 
PBS (dotted line) or solution 2 (solid line), were intratracheally instilled in mechanically 
ventilated rats (3 mg/kg). One hour after instillation alveolar type II cells were isolated 
and the mean cell-associated fluorescence of gated alveolar type II cells (A) and alveolar 
macrophages (C) was determined. In addition, the percentage gated alveolar type II cells 
(B) and alveolar macrophages (D) was determined (n = 4 rats at each concentration; 
values are mean ± SEM). * indicates a significant difference (p < 0.05) in comparison to 
the normal (8% PG) liposomes. # indicates a significant difference (p < 0.05) in 
comparison to the same liposomes resuspended in PBS. t, at a concentration of86% PG 
liposomes no macrophages were detected in the bronchoalveolar lavage. 
however, the uptake tends to increase compared to the uptake of20% PG liposomes (Fig. IA). 
When the liposomes are resuspended in solution 2, containing cofactors known to effect the 
uptake (e.g. calcium and magnesium) no significant differences are observed in comparison to 
the same liposomes resuspended in PBS. The number of alveolar type II cells involved in the 
uptake is unaffected by the amount of PG within the liposome in comparison to the normal 
liposomes (Fig IB). 
As surfactant-like liposomes are taken up by both alveolar type II cells and alveolar macro-
phages, the effects of the concentration PG on the uptake was also studied in alveolar macro-
phages. An increase in the amount ofPG within the liposomes results in an increased uptake, 
with an optimum at 40% PG, where the increase is significantly higher in comparison to 
normal liposomes containing 8% PG. When the PG concentration is raised to 60% no 
significant differences with normalliposomes are observed; however, further increment of the 
amount PG within the liposomes (86%) results in an absence of alveolar macrophages in the 
BAL and thus no cell-associated fluorescence can be determined with the use of 86% PG lipo-
somes (Fig. 1 C). Increasing the amount of PG tends to increase the amount of macro phages 
taking part in the uptake with an apparent optimum at 20%, although this increase is not 
significant. Higher PG concentrations result in a decline of the number of cells involved in the 
uptake accumulating at a PG concentration of 86% in the total absence of alveolar macro-
phages in the lung lavage. 
However, suspending the liposomes in solution 2 instead of PBS, as was done in the previous 
experiment, an increase in the amount of PG within the liposomes results in an enhanced 
uptake for all concentrations with a possible optimum at 20% PG in comparison to normal 
liposomes (8% PG); though this increased uptake is not significant. Also, the number of 
alveolar macrophages involved in the uptake depends on the PG concentration. An apparent 
optimum is observed at 20%, increasing the concentration PG results in a gradual decrease in 
the number of cells which internalize liposomes (Fig ID). 
Alveolar macrophages and protein concentration in BAL 
As mentioned previously, the presence of high amounts ofPG, i.e. 86%, in the liposomes leads 
to an absence of alveolar macrophages in the BAL. Therefore, we were interested at which 
concentration of PG this effect occurs. However, when the amount of PG is increased to a 
concentration as high as 20%, the number of alveolar macrophages already decreases signifi-
cantly. This decrease is also observed for the liposomes with 40 and 60% PG incorporated. 
However, with the exception of liposomes containing 60% PG, when the liposomes are 
resuspended in solution 2, normal amounts of alveolar macrophages are found in BAL of 
animals instilled with the different liposomes (Fig. 2A). The BAL which were performed at the 
end of the experiment to collect alveolar macrophages were also used to determine protein-
concentration in the BAL. The influx of protein in the lungs is increased when the PG 
concentration in the liposomes is raised for liposomes suspended in PBS, whereas no effect on 
the protein content of the BAL is observed when liposomes are suspended in solution 2 (Fig. 
2B). 
Histological changes with 86% phosphatidylglycerolliposomes 
As mentioned above, no alveolar macrophages could be retrieved by alveolar lavage when the 
liposomes were suspended in PBS. To study whether alveolar macro phages were indeed absent 
in the alveolar space when the lungs were instilled with 86% PG liposomes, histological 
samples of the lungs of these animals were obtained and analyzed using light microscopy. The 
samples were acquired from animals instilled intratracheally with normal (8% PG) liposomes 
and animals that had received 86% PG liposomes. The histological samples from the latter 
animals showed patchy interstitial infiltrate causing severe wall thickening indicating early 
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Figure 2. Effect of different 
concentrations PG on lavage 
parameters 
One hour after instillation of 
the fluorescent labeled lipo-
somes, either suspended in 
PBS (dotted line) or solution 2 
(solid line), the rats were sacri-
ficed and bronchoalveolar 
lavages were obtained. After 
centrifuging the lavages at 
1 OOxg the number of alveolar 
macrophages in the pellet (A) 
and the amount of proteins in 
the supernatant was deter-
mined (B) (n = 4 rats at each 
concentration; values are mean 
± SEM). * indicates a signifi-
cant difference (p < 0.05) in 
comparison to the normal (8% 
PG) liposomes. # indicates a 
significant difference (p < 
0.05) in comparison to same 
liposome resuspended in PBS. 
diffuse alveolar damage. In addition no alveolar macrophages could be detected within the 
alveolar space (Fig. 3). 
Lung mechanics after instillation of fluorescent labeled liposomes with a different 
concentration phosphatidylglycerol 
During the experiment, blood gas values were determined to study the effects of the liposomes 
on the arterial oxygenation. Instillation of 86% PG liposomes results in a significant decrease 
over time and, after 1 hour, the arterial blood gas values meet international criteria for acute 
respiratory failure21l. 
This dramatic effect of PG liposomes is concentration-dependent, because increasing the 
amount of PG within the liposomes leads to a concomitant decrease in arterial oxygenation 
(Fig. 4). However, when the liposomes are resuspended in solution 2 no significant deteriora-
tion in alveolar oxygenation is observed. 
To determine if this dramatic decrease in gas-exchange is caused by a diminished surfactant 
function, static P /V curves were performed at the end of the experiment. The Gruenwald 
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Figure 3. Slices of the left lung lobe after instillation of liposomes 
Representative coupes of the left lobe of an animal instilled with normalliposomes (A) 
and of an animal instilled with 86% PG liposomes (B). Lung slices were H stained and 
are shown at 400x magnification. 
index, as a measure oflung stability191 , demonstrates significantly lower values for allliposomes 
with a PG content higher than 8% suspended in PBS (Fig. SA). When the liposomes are 
resuspended in solution 2 no significant decrease is present, except for the liposomes 
containing 60% PG (Fig SA). 
These results are corroborated by the changes in maximal compliance; instillation of liposomes 
with a PG concentration higher than the physiological concentration of 8%, and suspended in 
PBS results in a significant decrease of the maximal compliance (Fig. SB). However, when the 
liposomes are resuspended in solution 2, only for 60% and 86 % PG liposomes are significant 
change observed. The maximal lung volume at 3S em H 20 is not affected by the amount of 
PG within the liposomes nor by the solution the liposomes are resuspended in (Fig. SC). 
Discussion 
Pulmonary surfactant is essential for normal physiological lung function. To maintain a low 
variable surface tension, surfactant forms a lipid monolayer, lining the alveolo-capillary 
membrane. As a result of normal breathing, the radius of the alveolus increases and decreases, 
causing lipids to be squeezed out of the lipid monolayer during expiration. In addition, the 
surfactant in the alveolus is turned over from active into inactive surfactant. In other words, 
the amount of surface-active surfactant within the alveolus would decrease if the alveolar type 
II would not compensate the loss, by secreting pulmonary surfactant. As de novo synthesis of 
surfactant has been suggested to be insufficient to compensate for the constant "loss" of active 
surfactant, alveolar type II cells rely on recycling inactivated surfactantl3• 14l. To ensure recycling, 
the inactivated surfactant is cleared from the alveolar space by alveolar type II cells and in 
addition inactive surfactant is also cleared by alveolar macrophages131 • 
This process of uptake or re-uptake of surfactant lipids is thought to be essential in the 
surfactant metabolism. Both alveolar type II cells as well as alveolar macrophages have been 
demonstrated to take up surfactant, though their relative contribution to the clearance remains 
under discussion as results are somewhat contradictorf2'24l. However, most of the studies have 
focused on the uptake of surfactant's main component DPPC, or on the effects of the 
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Figure 4. Effect of different concentrations PG on arterial oxygenation 
Arterial oxygenation was monitored throughout the experiment by drawing arterial 
blood samples at start of the experiment, immediately after instillation of the fluorescent 
labeled liposomes, and then after 30 min and 60 min . 0, 0% PG; II normal; , A lipo-
some suspended in PBS [20% (A), 40o/o(B), 60% (C), 86o/o(D)]; J::,.liposomes resuspen-
ded in solution 2. 
surfactant proteins on the uptake ofDPPC. Both SP-A and SP-C have been shown to enhance 
the uptake ofliposomes by alveolar cells2•5• 25• 2GJ. Besides surfactant proteins and DPPC, also the 
other individual surfactant lipids can influence the uptake; Quintero et al. and Poelma et al. 
demonstrated the enhanced uptake of PG containing liposomes by isolated alveolar macro-
phages and alveolar type II cells6· 7l. However, these studies were performed in vitro and 
significant differences between in vivo and in vitro experiments have been reported15l. 
Since surfactant therapy is nowadays more common in clinical practice, and studies on 
surfactant therapy mostly focus on the addition of surfactant proteins27-29l, very little infor-
mation is available with regard to the influences of the individual surfactant lipids on uptake 
or on lung function. 
Therefore, the current study investigated the effects of the second major component of 
surfactant, PG, on the uptake in ventilated rats, as well as the effects on endogenous surfactant 
function by monitoring arterial oxygenation and determining lung mechanics (protein in 
lavages fluid, Gruenwald index). The study was performed in healthy animals, as the normal 
function/role ofPG has to be clarified to provide a basis for changes possibly found in diseased 
animals. 
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Figure 5. Effect of different concentra-
tions PG on lung mechanics 
One hour after instillation of the 
fluorescent labeled liposomes suspen-
ded either in PBS (dotted line) or in 
solution 2 (solid line), the rats were 
sacrificed and static pressure-volume 
curves were assessed. As a measure of 
lung mechanics, the Gruenwald index 
(A), maximal compliance (MaxC; B) 
and maximal volume at 35 em H 20 
(V max; C) were determined (n=4 rats 
at each concentration; values are 
mean ± SEM). * indicates a signifi-
cant difference (p < 0.05) in compa-
rison to the normal (8% PG) lipo-
somes. 
As demonstrated by the results of the current study, incorporation of PG does influence the 
uptake of surfactant-like liposomes by alveolar cells, although the effects on both cell types 
differ. Only at a 20% PG concentration is a significant decrease in the uptake of liposomes by 
alveolar type II cells seen, whereas at the other PG concentrations no effects were observed. For 
alveolar macro phages the influence of intratracheal instillation of PG containing liposomes is 
more dramatic; in particular, on the number of alveolar macrophages obtained from the BAL 
after instillation of PG containing liposomes. Even the incorporation of 20% PG, which is 
approximately twice that of the normal PG concentration (8%), within the liposomes resulted 
in a decreased number of macrophages collected from the BAL. Histological samples of the 
lungs of animals that were instilled with liposomes containing 86% PG revealed complete 
absence of alveolar macrophages in the lung. The cells might have migrated to bronchial 
associated lymphatic tissue or elsewhere, or perhaps the cells did not leave but were killed by 
overstimulation. From the current results, although it cannot be excluded that the alveolar 
macrophages migrated elsewhere, we hypothesize that they were overstimulated and killed in 
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the process_ On the other hand, in vitro an increase in the concentration PG does not induce 
a decrease of alveolar macrophages71 ; nevertheless, it has to noted that the incubation of the 
alveolar macro phages and labelled liposomes takes place in solution 2, and thus 'essential' 
cofactors are already present. 
The relation between the decrease/absence of alveolar macrophages in the alveolar lavages fluid 
and the deterioration in surfactant function, i.e. a worsening arterial oxygenation, increased 
amounts of proteins in the BAL and a decreased Gruenwald index, might be explained by at 
least two options: First, the presence of a variety of cytokines, inflammatory mediators and 
proteolytic enzymes301 produced by stimulated alveolar macro phages of which some have been 
suggested to be related to respiratory failure31-351 might relate the absence of alveolar macro-
phages to the deteriorated surfactant function. Next, the increased PG content of the lipo-
somes leads to overstimulation of the alveolar macrophage and consequently bursting of the 
macrophage, releasing its contents into the alveolar space. However, after this expulsion of the 
contents of macrophages has taken place, these substances are removed very rapidly and can 
hardly be measured. However, damage to the surfactant monolayer is already made and a 
vicious circle is initiated. Protein concentration will rise in the alveolar space and result in a 
dose-dependent inactivation/inhibition of surfactant361 : surfactant is rate-limiting for the 
transfer of protein over the alveolar capillary membrane, loss of surfactant function will result 
in more protein influx, which in turn will inactivate/inhibit even more surfactant36-381 _ Further 
evidence that the surfactant system is damaged and that there is no additional fibrosis present 
comes from the Vmax data, which is similar in both groups (Fig. 5C). This demonstrates that 
when sufficiently high pressures are applied, collapsed alveoli can still be recruited. 
Despite these severe effects ofPG on the surfactant metabolism, more interestingly the adverse 
consequences of increasing amounts of PG can be avoided. When the liposomes are suspen-
ded in solution 2, rather than in PBS, the amount of alveolar macrophages is not decreased in 
contrast to the similar liposomes resuspended in PBS, except for liposomes containing 60% 
PG. In addition, when the amount of PG is increased and the liposomes are resuspended in 
solution 2, a significant increase in uptake by alveolar macrophages is observed, showing a 
maximum uptake at a PG concentration of 20%. This increased uptake of liposomes with a 
high content of PG incorporated and suspended in solution 2 are similar to the results 
obtained by Poelma et al. with regard to the influence of PG on the uptake of liposomes, 
suspended in solution 2, by alveolar macrophages in vitro71• In the present study, resuspending 
the liposomes in solution 2 has hardly no influence on the uptake of these liposomes by 
alveolar type II cells, whereas in vitro the uptake of liposomes by alveolar type II cells is 
stimulated by the incorporation of PG in these liposomes suspended in solution 2. Although 
both studies were performed using the same technique, the effects of a high PG concentration 
on the uptake by alveolar type II cells is different. It can thus be concluded that, besides the 
presence of the substances in solution 2, in both the current study and the previously one, 
additional environmental factors affect the uptake of surfactant-like liposomes by alveolar type 
II cells in vivo. 
The protection obtained by suspending the liposomes in solution 2 may be explained in several 
ways. Obviously, the presence of divalent cations (Mg, Ca) in solution 2 might 'neutralize' the 
negative charge ofPG. Another explanation could be that the presence of components necessary 
for alveolar macrophages and normal lung function in solution 2 (e.g. Ca, Mg and glucose), 
replenishes the dilution of these factors in vivo caused by the intratracheal instillation of 1 ml 
liposome suspension. Since the volume of the liquid phase is estimated to be approximately 200 
!-!1 in the rat, instillation of 1 ml will lead to a six-fold dilution of the intra alveolar solutes. 
In summary, the present study shows that varying the PG concentration in intratracheally 
instilled liposomes may have serious consequences for alveolar macrophages as well as normal 
lung functioning. A practical implication may be that not only the presence of the hydro-
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phobic surfactant proteins are important for surfactant therapy, but also the PG concentration 
in the applied surfactant may play an important role in surfactant therapy. Therefore, further 
studies are needed to elucidated the complex mechanism(s) that underlie the results described 
above not only to improve our knowledge of the surfactant homeostasis but also to achieve 
improved therapeutic interventions. 
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Abstract 
The effects of SP-B and SP-C on the uptake of surfactant like liposomes by alveolar type II 
cells and alveolar macrophages were studied both in vivo and in vitro. In vivo, mechanically 
ventilated rats were intra tracheally instilled with fluorescent labeled liposomes that had SP-B 
and/or SP-C incorporated in different concentrations. Consequently the alveolar cells were 
isolated and cell-associated fluorescence was determined using flow cytometry. The results 
show that the incorporation of SP-B does not influence the uptake, nor in the presence of 
essential co-factors. The inclusion of SP-C in the liposomes enhanced the by alveolar type II 
cells at a SP-C to lipid ratio of 2:100. If divalent cations (calcium and magnesium) were 
present at physiological concentrations in the liposomes suspension, uptake of liposomes by 
alveolar macrophages was also enhanced. In vitro, the incorporation of SP-B affected uptake 
only at a protein to lipid ratio of 8:100, whereas the inclusion of SP-C in the liposomes leads 
to an increased uptake at a protein to lipid ratio of 1:100. From these results it can be 
concluded that SP-B is unlikely to affect uptake of surfactant, whereas SP-C in combination 
with divalent cations and other solutes are capable of increasing the uptake. 
Introduction 
Pulmonary surfactant is a complex mixture of proteins and phospholipids synthesized and 
secreted by alveolar type II cells. Alveolar surfactant is metabolized and removed from the lung 
by reuptake of inactive surfactant, by both alveolar macrophagcs and alveolar type II cells. At 
least four proteins are known to exist in endogenous surfactant, surfactant protein A (SP-A), 
SP-B, SP-C and SP-D. From these surfactant specific proteins, SP-B and SP-C, two small 
hydrophobic proteins, have been demonstrated to play a role in the formation of a stable 
surfactant monolayer. Especially SP-B has been shown to be essential for normal surfactant 
function, lowering surface tensionL 2l, as the absence of SP-B at birth leads to death caused by 
respiratory insufficiency3• 4l and conditional knockout of SP-B in adult animals leads to 
respiratory failure5l. In addition, previous studies have demonstrated altered concentrations of 
SP-B in broncho-alveolar lavages fluids of patients suffering ARDS6• 7l. 
SP-C also enhances surface active properties of surfactant'· 2' s-lol, although absence of SP-C at 
birth is not lethal like SP-B, but experiments performed in specific SP-C knock-out mice 
demonstrated that despite the fact that surfactant pool sizes and lung morphology were similar 
in wild type and SP-C-knock-out mice, the absence of SP-C lead to a decreased stability of the 
surfactant at low volumes10• Another function of SP -C is increasing the resistance of surfactant 
against inactivation by plasma proteins121 • 
Nowadays, exogenous surfactant is used in clinical practice in neonates, while the use of 
exogenous surfactant in adults is under consideration13l. These exogenous surfactant prepara-
tions commonly contain SP-B and/or SP-C as these proteins play an important role in 
lowering surface tension. Though the beneficial effects of addition of the proteins on surface 
tension lowering activity will not be a point of discussion, their effects on the uptake of 
surfactant have to be clarified. Uptake of surfactant is an important step in the recycling of 
surfactant, which is known to be crucial in the maintenance of surfactant homeostasis. 
Though both these hydrophobic surfactant proteins have been demonstrated to participate in 
the re-uptake of inactive surfactant14• 15l by alveolar type II cells, these studies were done in in 
vitro. Recently we were able to show the influence of the local environment on the uptake of 
surfactant by alveolar cells'6l, indicating the need of studying surfactant metabolism, especially 
uptake not only in vitro but also in vivo. 
Therefore we examined, the effect of SP-B and SP-C on the uptake oflipids by both alveolar 
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type II cells and alveolar macrophages in vivo in ventilated rats as well as in vitro usmg 
fluorescent labeled liposomes, flow cytometry and confocal laser scanning microscopy. 
Materials and methods 
Ethical Guidelines 
This study was approved by the Institutional Animal Committee at the Erasmus University 
Rotterdam. 
Liposome preparation 
Both SP-B and SP-C were purified from lipid extracts of porcine lung lavage to homogeneity 
by Sephadex LH-60 chromatography (Pharmacia, Uppsala, Sweden) 17l. Surfactant-like lipo-
somes were prepared by mixing the following lipids; dipalmitoyl phosphatidylcholine (DPPC), 
phosphatidyl choline (PC), phosphatidylglycerol (PG), phosphatidyl inositol (PI), and phos-
phatidyl ethanolamine (PE) labeled with Rhodamine in the head group (Rhodamine DHPE; 
Molecular Probes, Leiden, The Netherlands) and cholesterol in a weight ratio of55:21:8:2:6:8 
and the indicated concentrations of surfactant proteins. Subsequently, this mixture was dried 
under a stream of nitrogen. The lipids were purchased from Sigma, Zwijndrecht, The 
Netherlands, unless stated otherwise. The liposomes were either suspended in PBS or in 
solution 2 (140 mM NaCl, 5 mM KCl, 2.5 mM phosphate buffer, 10 mM HEPES, 6 mM 
glucose, 2.0 mM CaC12 and 1.3 mM MgS04) at a concentration of 1 mg lipids/ml using glass 
pearls and vortexing. Immediately prior to use the liposome suspension was sonicated for 2 
min on ice using an ultrasonic disintegrator (Branson Sonifier 250, Danbury, USA) to prepare 
small unilamellar liposomes16l. The size of the liposomes was determined by dynamic light 
scattering at 2YC with a Malvern 4700 system using a 25 m W He-Ne laser (NEC, Tokyo, 
Japan) and the automeasure version 3.2 software (Malvern Ltd, UK). As a measure of particle 
size distribution of the dispersion, the system reports a polydispersity index (p.d.). This index 
ranges from 0.0 for a monodisperse and up to 1.0 for an entirely polydisperse dispersion. After 
ultrasonification the liposomes size ranged from 140 to 165 nm and the polydispersity index 
ranged from 0.2 to 0.35. 
Intratracheal instillation of fluorescent liposomes 
The studies were performed with male Sprague-Dawley rats (IFFA Credo, The Netherlands) 
with a bodyweight of 318 ± 16 g. After induction of anesthesia with a mixture of nitrous oxide 
(66%), oxygen (33%) and isoflurane (1-2%) a sterile polyethylene catheter (0.8 mm o.d.) was 
inserted into one of the carotid arteries. The animals were then tracheotomized and a sterile 
metal cannula was inserted into the trachea. 
Mter these surgical procedures, gaseous anesthesia was ended and replaced with an intra-
peritoneal injection of pentobarbital sodium (60 mg/ml, Nembutal®, Algin BV, Maassluis, The 
Netherlands) at a dose of 30 mg/kg bodyweight every hour. 
Muscle relaxation was induced and maintained by an hourly intramuscular injection of 
pancuronium bromide (2 mg/kg, Pavulon; Organon Technika, Boxrel, The Netherlands). The 
animals were then mechanically ventilated with a Servo® ventilator 900C (Siemens-Elema, 
Solna, Sweden) set to pressure control mode using a frequency of 30/min, an inspiratory/ 
expiratory ratio of 1:2, a positive end-expiratory pressure (PEEP) of 2 em H 20, a peak 
inspiratory pressure (PIP) of 12 em H 20 and Fi02 was set to 1. 
Before instillation of the labeled liposomes, PEEP was increased to 6 em H 20 and PIP was 
increased to 26 em H 20. After disconnection from the ventilator, the liposomes were 
administered intratracheally at the indicated dosage. The suspension of liposomes (1 mg 
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lipids/ml, unless stated otherwise) was administered as a bolus of 3 ml/kg followed by a bolus 
of air (12 mllkg), directly into the endothracheal tube via a syringe, and the animals were 
immediately reconnected to the ventilator. Thirty min after instillation of the liposomes PEEP 
was reduced to 2 em H 20 and PIP to 12 em H 20. 
Arterial blood gas values were measured with conventional methods (ABL 555, Radiometer, 
Copenhagen, Denmark) at start of ventilation, immediately after instillation of the liposomes 
and every 30 minutes thereafter. One hour after ventilation the animals were sacrificed by 
exsanguination via the abdominal aorta and the alveolar cells were isolated to determine the 
cell-associated fluorescence. Untreated animals were sacrificed immediately after anesthesia 
and their isolated alveolar type II cells and alveolar macrophages were used to correct for auto-
fluorescence. 
Isolation of alveolar type II cells and alveolar macrophages 
Prior to isolation of the cells, the thorax was opened and the blood cells were removed from 
the lungs by perfusing the pulmonary artery with warmed saline (3TC) supplemented with 
20 IE heparin per ml (Leo Pharma, Weesp, The Netherlands). The lungs were removed from 
the thoracic cavity en bloc and lavaged with 10 ml of solution 1 [140 mM NaCl, 5 mM KCl, 
2.5 mM Na2HP04.2H20, 10 mM HEPES (N-2-hydroxyethylpiperazine-N'-2-ethaesulfonic 
acid), 6 mM glucose, 0.2 mM EGTA (ethylene glycol-his- (~-amino ethyl ether) N,N'-tetra-
acetic acid), pH 7.40] at 3TC. This procedure was repeated four times. The lung lavages were 
pooled per animal and centrifuged (100x g, 10 min; 4°C). The cellular pellet, i.e. alveolar 
macro phages, were suspended in solution 2 to a concentration of 2x 106 cells/ ml and stored on 
ice until further use. The alveolar type II cells were isolated according to Dobbs et al.18l; using 
enzymatic digestion as previously described16l. Alveolar type II cells were suspended in solution 
2 at a concentration of2x106 cells/ml and stored on ice until further use. Alveolar macrophages 
were identified using monoclonal antibodies specific for rat macrophages (ED9) and alveolar 
type II cells were identified using an alkaline phosphatase assay as described by Edelson et al.19l. 
The average yield of alveolar type II cells was 16x106 with a purity of 80 ± 5% and 5x106 
alveolar macrophages with a purity of 92 ± 5% per rat. 
In vitro uptake ofSP-B and SP-C containing liposomes 
Alveolar cells of untreated animals were isolated as described above and suspended in solution 
2 to a concentration of2x106 cells/ml. A total of3*105 cells were incubated with the indicated 
concentration of the specified liposomes at 3TC (final volume 500 ~J.l) in a shaking water 
bath. After 1 hour, the incubation was terminated by addition of 2 ml of ice-cold PBS (4oC). 
The cell-suspension was centrifuged at 100x g for 10min at 4oC. The supernatant was 
removed, and the cells were suspended in 2 ml ice-cold PBS and centrifuged again. This wash 
procedure was repeated twice. Finally, the pellet was resuspended in 200 !J.l of cold PBS, and 
cell-associated fluorescence was determined as described below. 
Flow cytometry 
Cell-associated fluorescence of the alveolar type II cells and alveolar macro phages as a measure 
for internalized liposomes was determined using flow cytometry (FACSCalibur; Becton 
Dickinson; Mountain View, USA). The cell-associated fluorescence of 15,000 cells was 
determined. Alveolar macro phages and alveolar type II cells derived from control animals were 
used in each experiment to determine the auto fluorescence of the cells. Subsequently, the 
. mean cell-associated fluorescence was determined only for those cells that had a higher 
fluorescence than that caused by auto-fluorescence (gated cells). 
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Localization of cell-associated fluorescence 
To localize the cell-associated fluorescence, intra-cellular or extra-cellular, confocal laser micro-
graphs were obtained using a confocal microscope (LSM510NLO, Carl Zeiss Jena, Germany). 
Images were created with plan apochromat 63x 1.4 n.a., objectives and photomultiplier tubes 
and emission filter set at 500-550 nm. (Rhodamine, excitation 543 nm HeNe laser). Images 
of alveolar cells were serially sectioned pinhole at 1 airy unit with an interval of 0.5 ~-tm to 
distinguish cell membrane-associated fluorescence from the intracellular fluorescence. 
Statistical analysis 
Differences between the different groups that received liposomes with a different composition 
were analyzed using an ANOVA followed by a Tukey post-hoc test. The unpaired t-test was 
used for analysis of the effect of calcium. Blood gas values were analyzed using a repeated 
measurement AN OVA. 
Differences were considered statistically significant at a p <0.05. Values are expressed as mean 
± SD. 
Results 
Effect of surfactant protein B and C on the uptake in vivo 
Though SP-B and SP-C have been shown to influence the uptake by alveolar cells20-22J, most 
studies were performed in vitro21.22l, and due to the methods used no comparison between in 
vivo and in vitro results can easily be made. Therefore in the current study mechanically 
ventilated rats were intratracheally instilled with fluorescent labeled liposomes containing 
surfactant proteins B and/ or C. Since it has been described that divalent cations effect the 
function of these surfactant proteins, additional groups were included which were instilled 
with liposomes suspended in solution 2; which includes calcium and magnesium.The 
inclusion of SP-B and! or SP-C in the liposome does not influence the uptake by alveolar cells 
when these liposomes are suspended in PBS (Fig. IA, C). However, suspending the liposomes 
in solution 2 leads to a significant increase in uptake by alveolar macrophages of liposomes 
with SP-C or both SP-B and SP-C incorporated. (Fig. 1 C). 
The use of flow cytometry to measure the uptake of these fluorescent labeled liposomes also 
provides the opportunity to measure the percentage of cells involved in the uptake. Hence, the 
current experiments demonstrate that the incorporation of SP-B and! or SP -C in the liposome 
does not affect the number of alveolar cells involved in the uptake (Fig 1B, D), though 
suspending the liposomes in solution 2 results in a significant increase in the percentage 
alveolar type II cells involved in the uptake of SP-C containing liposomes and the amount of 
alveolar macrophages taking up liposomes containing both SP-B and SP-C (Fig 1 B, D). 
Effect of increasing SP-B/lipid ratio on the uptake in vivo 
The absence of any effect with the inclusion of SP-B in the liposomes raised the question if 
the amount of SP-B was sufficient or not. Therefore the SP-B/lipid ratio in the liposomes was 
varied. Higher SP-Bilipid ratios however did not affect the amount of liposomes taken up by 
individual alveolar type II cells nor the number of alveolar type II cells involved in the uptake 
(Fig 2A, B) 
In addition, increasing the SP-B/lipid ratio did not have an effect on the uptake of the lipo-
somes by alveolar macro phages, as cell-associated fluorescence, as a measure for the amount of 
liposomes internalized, did not differ significantly from standard liposomes (Fig 2C). The 
number of alveolar macrophages, taking up the labeled liposomes, tends to decrease with 
higher SP-B/lipid ratios though this decrease is not significant (Fig 2 D). 
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One hour after instillation of the indicated fluorescent liposomes (protein to lipid ratio 
:100), the alveolar cells were isolated. The mean cell-associated fluorescence of the gated 
alveolar type II cells (A) and alveolar macrophages (C) was determined. In addition, the 
percentage gated alveolar type II cells (B) and alveolar macrophages (D) were deter-
mined. (n = 6 rats at every concentration; values are mean ± SD). *, p<O.OS versus 
standard,#, p<O.OS versus same liposome suspended in PBS. 
Resuspending the liposomes in solution 2 did not have any effect on the uptake by either-
alveolar type II cells nor by alveolar macrophages (Fig 2). 
Effect of SP-C/lipid ratio on the uptake in vivo 
To determine the presence of an optimal SP-C/lipid ratio for internalization of these liposomes 
by alveolar cells, liposomes with different SP-C!lipid ratios were instilled. SP-C has a maximal 
effect on the uptake by alveolar type II cells at a SP -C /lipid ratio of 2:100 (Fig. 3A). Increasing 
the SP-C/lipid ratio did not affect the number of alveolar type II cells involved in the uptake 
(Fig. 3C). 
Interestingly, uptake of liposomes by alveolar macrophages is unchanged with increasing SP-
C!lipid ratios when these liposomes are resuspended in PBS. However when the liposomes are 
resuspended in solution 2, significant increases in uptake are demonstrated when SP-C is 
incorporated in the liposome, with a maximal uptake at a SP-C/lipid ratio of2:100 (Fig 3C). 
Though, the number of alveolar macrophages involved in the uptake remains unaffected by 
74 
100 
~ Q 50 
rr-, 5 
150 
Figure 2. Effect of increasing the SP-B: lipid ratio's on the uptake 
One hour after instillation of the fluorescent liposomes with indicated concentrations 
SP-B, the alveolar cells were isolated. The mean cell-associated fluorescence of the gated 
alveolar type II cells (A) and alveolar macrophages (C) was determined. In addition, the 
percentage gated alveolar type II cells (B) and alveolar macrophages (D) were deter-
mined. (n = 6 rats at every concentration; values are mean ± SD). *, p<0.05 versus SP-
B. #, p<0.05 versus same liposome suspended in PBS. 
the incorporation of SP-C in the liposome or resuspension of the liposomes in solution 2 (Fig. 
3D). 
Effect of SP-B, SP-C containing liposomes on gas exchange 
The instillation of the fluorescently labeled liposomes did not have any effect on gas exchange 
as determined by arterial blood gas values (Table 1). Nor was there any effect on arterial 
oxygenation by the incorporation of the studied surfactant proteins or suspending the lipo-
somes in solution 2. 
In vitro effects on the uptake ofliposomes with SP-B or SP-C incorporated 
A possible explanation for the absence of any effects of the inclusion of SP-B in the liposomes 
on the uptake might be that in the healthy lung the amount of SP-B is sufficient or optimal 
and additional SP-B, added by instillation ofliposomes with SP-B incorporated does not affect 
uptake. To study the effects of the inclusion of SP-B in the liposome in the absence of any 
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Figure 3. Effect of increasing the SP-C: lipid ratio's on the uptake 
One hour after instillation of the fluorescent liposomes with indicated concentrations 
SP-C, the alveolar cells were isolated. The mean cell-associated fluorescence of the gated 
alveolar type II cells (A) and alveolar macrophages (C) was determined. In addition, the 
percentage gated alveolar type II cells (B) and alveolar macrophages (D) were deter-
mined. (n = 6 rats at every concentration; values are mean± SD). *, p<0.05 versus SP-
C; #, p<0.05 versus same liposome suspended in PBS. 
Table 1. Arterial oxygenation 
Start AL 5' 30' 60' 
Standard 540 +1- 33 523 +1- 36 551 +1- 40 522 +1- 28 501 +1- 41 
Values are means ± SE. Bloodgas values of animals intratracheally instilled with normallipo-
somes (n = 5 rats). 
natural SP-B, alveolar cells of untreated animals were isolated and 3*105 cells were incubated 
with different concentrations liposomes in the presence of solution 2. These liposomes had SP-
B incorporated in a SP-lipid ratio of 1:100. Uptake of these liposomes was unchanged in 
comparison to liposomes without SP-B. Neither uptake per cell (Fig 4 A, C) or the number of 
cells involved in the uptake (Fig 4 B, D) was affected by the incorporation of SP-B in the lipo-
somes. 
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For SP-C, liposomes with incorporated SP-C in a protein/lipid ratio of 1:100, were added at 
different concentrations to isolated alveolar cells and incubated for one hour. At the highest 
used liposomes concentration (50 f,.tg/ml) inclusion of SP-C results in an approximately 4-fold 
increase in uptake by alveolar type II cells (Fig. 5A). In addition, the incorporation ofSP-C in 
the liposome not only increased uptake of these liposomes by alveolar type II cells, but induced 
also a significantly higher uptake of these liposomes by alveolar macrophages. 
Furthermore, the incorporation of SP-C does not affect the number of cells involved in the 
uptake at an SP-Cilipid ratio of 1:100 (Fig 5B, D). 
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Figure 4. Concentration-dependent uptake of liposomes with SP-B in vitro 
Alveolar cells were isolated from control animals and incubated for 1 hour at 3TC with 
the indicated concentrations of fluorescent liposomes dependent on the group 
containing SP-B or no surfactant proteins. The mean cell-associated fluorescence of 
gated alveolar type II cells (A) and alveolar macrophages (C) was determined. In 
addition, the percentage gated alveolar type II cells (B) and alveolar macrophages (D) 
were determined. No significant differences were observed at any concentration (n = 4 
incubations at every concentration; values are mean± SEM). 
Localization of cell-associated fluorescence 
To ascertain that the cell-associated fluorescence was located within the cell rather than 
binding to the outer membrane of the cell, confocal laser scanning microscopy was used. One 
hour after intratracheal instillation of the liposomes containing SP-B, SP-C in mechanically 
ventilated rats, the alveolar cells were isolated and confocal scans were made. These confocal 
scans through the middle of the cell show a punctuate fluorescence throughout the cell limited 
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Figure 5. Concentration-dependent uptake of liposomes with SP-C in vitro 
Alveolar cells were isolated from control mimals and incubated for 1 hour at 3TC with 
the indicated concentrations of fluorescent liposomes dependent on the group 
containing SP-C or no surfactmt proteins. The mem cell-associated fluorescence of 
gated alveolar type II cells (A) and alveolar macro phages (C) was determined. In 
addition, the percentage gated alveolar type II cells (B) and alveolar macrophages (D) 
were determined. (n = 4 incubations at every concentration; values are mem ± SEM). *, 
p<0.05 versus stmdard. 
to its circumference with the exception of its nucleus, demonstrating the intracellular presence 
of the fluorescent liposomes. By scmning the cells at different levels each 1 f-lm apart it was 
ensured that the used confocal scm was indeed through the middle of the cell, in addition, 
light microscopy of the same cell at the same setting, demonstrated the limitation of the cell-
associated fluorescence to the cytoplasm (Fig. 6). 
Effect of SP-B/lipid ratio on the uptake in vitro 
Though in the current study no effect of inclusion of SP-B in the liposomes on the uptake by 
alveolar cells was observed, Rice et al. have demonstrated a significmt increase in uptake of 
liposomes by alveolar type II cells with SP-B incorporated14l. However in their study higher 
protein/lipid ratios were used. Therefore using our method of fluorescent labeled liposomes, 
isolated alveolar cells of untreated mimals were incubated with 50 f.lg/mlliposomes that had 
m increasing amount of SP-B included, varying from 1:100 to 8:100. Increasing the SP-
B/lipid ratio results in a significantly enhmced uptake of liposomes by alveolar type II cells at 
m SP-B: lipid ratio of 8:100.(Fig. 7A). In addition, the inclusion of SP-B in the liposome at 
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Figure 6. Localization of cell-associated fluorescence 
Mechanically ventilated rats were intratracheally instilled with fluorescent labeled 
liposomes containing either SP-B (A, C) or SP-C (B, D). One hour after instillation 
alveolar macrophages (C, D) and alveolar type II cells (A, B) were isolated and confocal 
scans were made. All scans were made using the same microscopic settings. 
this particular ratio resulted in an increased number of alveolar type II cells involved in the 
uptake (Fig. 7B) 
The effect of an increased SP-B/lipid ratio on the uptake ofliposomes by alveolar macrophages 
demonstrated a similar significant increase at a SP-B/lipid ratio of 8:100. An increased ratio 
however did not influence the number of alveolar macrophages involved in the uptake of these 
liposomes. 
Discussion 
In the current study we investigated the effects of both SP-B and SP-C on the uptake of 
surfactant like liposomes in vivo and in vitro. 
As demonstrated in this study, SP-B does not influence the uptake of liposomes in vivo, not 
even at a SP-B/lipid ratio of 4:100. However, these liposomes were suspended in PBS prior to 
79 
A 
200 
* 
o+-----------,----------,-
0 4 
SP-B (%) 
B 
~ 
~ 
1 
l? 
100 
* 
50 
0 
0 4 
SP-B (%) 
c D 
200 
* 
o+-----------.----------,-
0 4 
SP-B (%) 
100 
e 
~ 50 
-o 
H 
" l? 
Figure 7. Effect of increased SP-B: lipid ratio's on the uptake in vitro 
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Isolated alveolar cells of untreated animals were incubated with 25 ]lg/ml of liposomes 
with a different SP-B/liposome ratio, varying from 1:100 to 8:100. Both alveolar 
macrophages (C, D) and alveolar type II cells (A, B) were analyzed and mean cell 
associated fluorescence (A, C) and percentage gated cells (B, D) were determined (n = 4 
incubations at every concentration; values are mean± SEM) *, p<0.05 
instillation in trachea of the rats. Since the intra-alveolar fluid phase in rats is estimated to be 
around 200 ~-tl, and the liposomes instilled were suspended in 1 rnl PBS, this might lead to 
dilution of the intra-alveolar pool of solutes in the lung including calcium. 
Previous studies have demonstrated a crucial role of calcium on the biophysical function ofSP-
B as well in interaction with PG or formation of tubular myeline23• 24l. Therefore, to ensure 
more physiological circumstances the liposomes were resuspended in solution 2 containing 
calcium, magnesium, potassium and glucose in similar concentrations as the endogenous pool. 
However, despite resuspending the liposomes in solution 2, the incorporation of SP-B in the 
liposome did not affect the uptake of lipids by alveolar cells. 
Another explanation might be that the physiological amount of SP-B present in vivo is the 
optimal concentration for the SP-B mediated lipid uptake by alveolar cells, in other words, 
raising the SP-B concentration by using SP-B incorporated liposomes does not further 
influence the uptake. Therefore, the uptake of liposomes by isolated alveolar cells was studied 
in vitro using liposomes with and without incorporated SP-B. These experiments clearly 
demonstrate that at the physiological SP-B/lipid ratio of 1:100 no effect on the uptake of lipo-
somes by alveolar type II cells was observed compared to the uptake of liposomes devoid of 
SP-B. However, "Rice et al. demonstrated a significant increase in uptake of liposomes by 
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alveolar type II cells in vitro due to the presence of SP-B14l, though at higher SP-B:lipid ratio's. 
To determine if these results could be repeated and extended to alveolar macro phages using our 
method, we isolated alveolar cells and incubated these cells with a fixed concentration oflipids 
while increasing SP-B/lipid ratio up to 8:100. At the highest ratio, a significant increase in 
uptake was observed indicating that SP-B is indeed able to increase uptake, in accordance with 
the results of the previous studies14• 15l. 
Uptake of liposomes is suggested to take place via a receptor mediated pathwaf5•28l though not 
exclusively; where these "phospholipid" receptors tend to have a higher affinity for negatively 
charged lipids in comparison to neutrally charged lipids28l. However the increase in uptake due to 
the incorporation of SP-B, though in a high protein/lipid ratio (8:100), seems unlikely to be 
caused by the presence of a specific SP-B receptor. The relatively high concentrations of SP-B 
necessary to induce an effect on the uptake, make a specific receptor physiologically unlikely or 
suggest a receptor with a very low affinity. Summarizing, the SP-B containing liposomes are inter-
nalized by the "phospholipid receptors, and not by additional SP-B receptors on the alveolar cells. 
The increment in uptake caused by SP-B at the high protein to lipid ratio could also be 
explained by changes in lipid conformation of the liposomes, because SP-B is able to change 
lipid conformation of surfactant29l. 
In vivo alveolar type II cells internalize more liposomes when SP-C is incorporated in the lipo-
somes at a protein to lipid ratio of2:100. At other protein to lipid ratio's no effect ofSP-C was 
detected even when the liposomes were suspended in solution 2. In contrast, significant 
stimulation of the uptake of liposomes containing SP-C by alveolar macrophages were 
observed at various lipid to protein ratio's when these liposomes were suspended in solution 2. 
To study the influence of possible additional effects of 'environmental' factors in vivo, the 
uptake ofliposomes with SP-C incorporated (SP-C/lipid ratio of 1:100) was studied in vitro. 
At this ratio, SP-C enhanced the uptake; at a lipid concentration of 50 f.!g/ml the uptake of 
SP-C containing liposomes was approximately 6 times greater by both alveolar macrophages 
and alveolar type II cells. These results suggest that in vivo the uptake of SP -C containing lipo-
somes by alveolar cells may be suppressed by some unknown factor(s). 
How the incorporation of SP-C in liposomes may enhance the uptake by alveolar cells? Rice 
et al and Horowitz et al14• 15) have demonstrated previously that SP-C does enhance the uptake 
of lipids in a non-saturable way. In addition, SP -C is known to associate very rapidly with lung 
tissue and alveolar macrophages30· 31l. This increased association, even more rapidly than D PPC, 
might be a possible explanation for an increased uptake of liposomes containing SP-C. 
Although other factors such as the conformation changes observed in liposomes after 
incorporation of SP-C may also affect the binding and uptake of these liposomes by alveolar 
cells as was suggested by Rice et al (14). 
In summary, this study indicates that SP-B has no effect on the uptake ofliposomes in vivo by 
alveolar cells. However, SP-C was shown to enhance the uptake ofliposomes in vivo by alveolar 
cells, an effect which could be further increased by suspending the liposomes in a buffer which 
contained calcium, magnesium and other solutes which are necessary for normal alveolar 
function. Probably, not only these solutes may effect the uptake of the 'SP-C-mediated uptake' 
of liposomes, but also other factors. Since we were able to demonstrate in vitro in the presence 
of physiological concentrations of calcium and magnesium that the 'SP-C-mediated uptake' of 
liposomes is much higher by alveolar cells than in vivo, suggesting that in vivo the uptake 
appears to be down-regulated. The precise mechanism of this possible down-regulation of the 
uptake is not known but may include cell-to cell contact and unknown soluble factors. 
The results of the current study, absence of effects of SP-B and increased uptake due to SP-C, 
might be useful in clinical practice; nowadays, more and more exogenous surfactant 
preparations contain surfactant proteins B and C, as these proteins have been demonstrated to 
increase efficiency of the surfactant32l. 
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To date it is widely accepted that small 'inactive' surfactant aggregates are removed from the 
alveolar space by alveolar cells33• 34l. Exogenous surfactant is surface active and consists mainly 
of large 'active' surfactant aggregates. However, after various breathing cycles the exogenous 
surfactant will become small inactive surfactant aggregates and need to be recycled. The 
presence of SP-B in these aggregates will probably not influence the uptake of these liposomes 
by alveolar type II cells, the first step in the recyling. On the other hand, inclusion of SP-C in 
exogenous surfactant in either the absence or presence of calcium and other solutes may even 
enhance the recycling of the surfactant by increasing the uptake of surfactant by the alveolar 
cells. Therefore, variations in the SP-B concentrations of exogenous surfactant will probably 
have litde influence on the recyling of surfactant though variations in the SP-C concentrations 
may stimulate the recyling. However, it is nowadays unknown whether situation is beneficial 
for the therapy of respiratory failure, an enhanced recycling or not. 
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Abstract 
Using flow cytometry, the effect of exogenous surfactant on the uptake of fluorescent labeled 
surfactant-like liposomes was studied in vivo and in vitro. Healthy adult rats were intra-
tracheally instilled with exogenous surfactant (non-sonicated active or sonicated, inactive) and 
labeled liposomes. Cell-associated fluorescence of the alveolar type II cells and alveolar 
macrophages was compared with those derived from animals that received only labeled lipo-
somes. In vitro, alveolar cells were incubated with labeled liposomes and sonicated or non 
sonicated surfactant, or with large or small aggregates, or no surfactant at all. 
In vitro, uptake of labeled liposomes by alveolar cells was increased by large, active surfactant 
aggregates. In vivo, both sonicated and nonsonicated surfactant decreased uptake of labeled 
liposomes by decreasing the percentage cells involved in the uptake in healthy lungs. These 
results suggest a feedback mechanism; recycling is decreased due to a decrease in uptake, 
because healthy lungs do not need additional surfactant. This feedback mechanism is likely to 
be absent in vitro because environmental factors (e.g. hormonal inflammatory or nerval 
parameters) are not present, which might explain the differences between in vivo and in vitro 
effect of exogenous surfactant on the uptake. 
Introduction 
Surfactant metabolism is a complex mechanism of production, secretion, uptake and recycling 
needed to maintain normal lung function. Disturbances in this complex system are associated 
with diseases such as neonatal RDS and adult ARDS1-4l. Exogenous surfactant therapy has 
become widely accepted in the treatment of RDS and is even under consideration for the 
treatment of ARDS5l. Nevertheless, the effects of the administration of exogenous surfactant 
on the endogenous surfactant metabolism are still under discussion, because there are conflic-
ting results on the influence of large amounts of exogenous surfactant6-'0l. The uptake of 
inactive surfactant is known to be essential in the surfactant metabolism: especially in neonates 
rely on recycling for >90%, indicating the need for uptake of inactivated surfactant' 0 • In 
contrast, in adult rabbits only 50% of the endogenous alveolar surfactant is produced by 
recyling'2l. 
However, most studies have focused on the production or secretion of endogenous surfactant 
and little is known on the effect on the uptake. Therefore the current study investigates the 
effects of exogenous surfactant on the uptake of labeled surfactant-like liposomes by alveolar 
cells both in vivo and in vitro in healthy adult rats. 
Materials and methods 
Ethical Guidelines 
This study was approved by the Institutional Animal Committee at the Erasmus MC 
Rotterdam. 
Liposome preparation 
Small-unilamellar fluorescent labeled surfactant-like liposomes, contammg dipalmitoyl 
phosphatidylcholine (DPPC), phosphatidyl choline (PC), phosphatidylglycerol (PG), 
phosphatidyl inositol (PI), and phosphatidyl ethanolamine (PE) labeled in the head group 
with rhodamine (Rhodamine DHPE; Molecular Probes, Leiden, The Netherlands) and 
cholesterol in a weight ratio of 55:21:8:2:6:8 were prepared as previously described13l. 
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Preparation of exogenous surfoctant 
Exogenous natural surfactant (HL-10, Leo Pharmaceuticals Products, Ballerup, Denmark), 
isolated as described by Gommers et al. 141, was suspended in warmed saline (37"C) to a 
concentration of 50 mg/ml for in vivo experiments and 25 mg/ml for in vitro experiments. In 
vivo, exogenous surfactant was administered at a dosage of 150 mg/kg. Exogenous surfactant 
was suspended in the liposome suspension resulting in a suspension containing 50 mg/ml 
exogenous surfactant and 1 mg/ml fluorescent labeled liposomes (liposome to surfactant ratio 
1:50). 
To study the effect of inactivated surfactant, suspended surfactant was sonicated for 2 min on 
ice using an ultrasonic disintegrator (Branson Sonifier 250, Danbury, USA) which resulted in 
a significantly higher surface tension and absence of dynamic properties as determined by 
Wilhelmy balance as compared to the non-sonicated surfactant (data not shown). 
Intratracheal instillation of liposomes 
The studies were performed with male Sprague-Dawley rats (IFFA Credo, The Netherlands) 
with a bodyweight of314 ± 18 g; the animals were randomly divided in 3 groups. Two groups 
received, respectively, exogenous surfactant containing fluorescent labeled liposomes (SurfLipo 
group) or sonicated surfactant containing fluorescent labeled liposomes (SonSurfLipo group). 
This mixture of exogenous surfactant and labeled liposomes was administered using a 
technique previously described by Verbrugge et al. 151 • One group of animals did not receive any 
exogenous surfactant prior to ventilation (Normal group). 
The animals underwent surgical procedures and mechanical ventilation as previously 
described131 • During mechanical ventilation, arterial blood gases were measured with conven-
tional methods (ABL 555, Radiometer, Copenhagen, Denmark) at start of ventilation, and 
every 30 min thereafter. The Normal group received fluorescent labeled liposomes immediately 
at start of ventilation as previously described13l. One hour after instillation of the fluorescent 
labeled liposomes, the animals were sacrificed by exsanguination via the abdominal aorta and 
the alveolar cells were isolated to determine the cell-associated fluorescence. Untreated control 
animals were sacrificed immediately after anesthesia and their isolated alveolar type II cells and 
alveolar macrophages were used to correct for auto-fluorescence. 
Isolation of alveolar type II cells and alveolar macrophages 
Alveolar cells were isolated as previously described using enzymatic digestion using elastase131 • 
Prior to isolation of the cells, the thorax was opened and the blood cells were removed from 
the lungs by perfusing the pulmonary artery with saline (3TC) supplemented with 20 IE 
heparin per ml (Leo Pharma, Weesp, The Netherlands). The lungs were removed from the 
thoracic cavity en bloc and lavaged with 10 ml of solution 1 [140 mM NaCl, 5 mM KCl, 2.5 
mM Na2HP04.2H20, 10 mM HEPES (N-2-hydroxyethylpiperazine-N'-2-ethaesulfonic 
acid), 6 mM glucose, 0.2 mM EGTA (ethylene glycol-bis- (~-amino ethyl ether) N,N'-tetra-
acetic acid), pH 7.40] at 22"C. This procedure was repeated four times. The lung lavages were 
pooled per animal and centrifuged (100x g; 10 min; 4°C). The cellular pellet, i.e. alveolar 
macrophages, were suspended in solution 2 to a concentration of2x106 cells/ml and stored on 
ice until further use. The alveolar type II cells were isolated according to Dobbs et al. 161 • 
Alveolar type II cells were suspended in solution 2 at a concentration of 2x106 cells/ml and 
stored on ice until further use. Alveolar macrophages were identified using monoclonal 
antibodies specific for rat macrophages (ED9) and alveolar type II cells were identified using 
an alkaline phosphatase assay as described by Edelson et al. 171 • The average yield of alveolar type 
II cells was 15xl 06 a purity of 81 ± 6% and 4,8xl 06 alveolar macro phages with a purity of 90 
± 3% per rat. 
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In vitro assay on the uptake of fluorescent-labeled liposomes and exogenous suifactant 
Alveolar type II cells and alveolar macrophages were isolated from untreated animals as 
described above and were suspended in solution 2 (140 mM NaCl, 5 mM KCl, 2.5 mM 
phosphate buffer, 10 mM HEPES, 6 mM glucose, 2.0 mM CaC12 and 1.3 mM MgS04) to a 
concentration of 2x106 cells/ml. A total of 3x105 cells was incubated with 25 rl 0.5 mg/ml 
fluorescent labeled liposomes and different concentrations of exogenous surfactant (25 mg/rnl) 
resulting in the indicated liposome/surfactant ratio, at 3TC in a shaking water bath. Prior to 
the incubation, exogenous surfactant was either sonicated for 2 min, or not, as indicated. The 
total incubation volume was 0.5 ml. After 1 hour, the incubation was terminated by addition 
of2 ml of ice-cold PBS. The cell suspension was centrifuged at 100x gfor 10 min at 4·c. The 
supernatant was removed and the cells were suspended in 2 ml of ice-cold PBS and centrifuged 
again. This wash procedure was repeated twice. Finally, the pellet was resuspended in 200 rl 
cold PBS and cell-associated fluorescence was determined as described below. 
Discrimination of small and large aggregates 
To study if the large (pelleted surfactant fraction after centrifugation at 27,000x gfor 15 min) 
or small (supernatant of surfactant fraction after centrifugation at 27,000x g for 15 min) 
aggregates within the exogenous surfactant suspension were responsible for a possible effect on 
the uptake, the following experiment was performed. A total of 3*105 alveolar cells, isolated 
from untreated animals, were incubated with fluorescent labeled liposomes and exogenous 
surfactant according to Figure 1. The total volume of the incubation was 500 ]ll. 
In all6 groups, after 1 hour, the incubation was stopped by adding 2 ml ice-cold PBS. The cell 
suspension was washed as described above and, finally, the pellet was resuspended in 200 rl 
cold PBS and cell-associated fluorescence was determined as described below. 
Flow cytometry 
Cell-associated fluorescence of the alveolar type II cells and alveolar macro phages as a measure 
for internali~ed liposomes was determined using flow cytometry (FACSCalibur, Becton 
Dickinson, Mountain View, CA, USA) as previously described13J. 
Localization of cell-associated fluorescence 
To inspect the localization of the cell-associated fluorescence confocal micrographs of alveolar 
cells were obtained using a confocal microscope (Zeiss LSM 510, Carl Zeiss Jena, Germany). 
Images were created with 63x 1.4 n.a. plan apochromat objective and standard photo-
multiplier tubes dedicated to the appropriate excitation and emission spectra of rhodamine 
(excitation 543 nm and emission 572 nm). Images of alveolar cells were serial sectioned with 
an interval of 0.5 Jlm, to distinguish cell-membrane associated fluorescence from true 
intracellular fluorescence. 
Statistical analysis 
Differences between different groups was analyzed using an AN OVA followed by a Bonferonni 
post-hoc test. Differences between the sonicated and non-sonicated surfactant in vitro were 
analyzed using an independent t-test. Differences were considered significant at a p <0.05. 
Values are expressed as mean± SEM. 
Results 
Prior to the experiments surface activity of surfactant suspended in the suspension containing 
fluorescent labeled liposomes was determined and ensured to be unaffected (data not shown). 
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Influence of exogenous surfactant on the uptake in vitro 
The influence of exogenous surfactant on the uptake of liposomes in vitro was studied by 
incubating alveolar cells with 25 jlg/ml of fluorescent labeled liposomes and increasing 
concentrations of exogenous surfactant. The addition of exogenous surfactant (non-sonicated) 
induced an apparent increase in uptake by alveolar type II cells, with a significant maximum 
at a liposome to surfactant ratio of 1:50 compared to the uptake of liposomes in the absence 
of surfactant (Fig 2A). Also, the number of alveolar type II cells involved in the uptake was 
increased at the same liposome to surfactant ratio (Fig. 2B). When the exogenous surfactant is 
sonicated, the uptake ofliposomes by alveolar type II cells, as well as the number of these cells 
involved in the uptake, is significantly decreased (Fig 2A+2B). 
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Figure 2. Effect of active exogenous surfactant on uptake in vitro 
Alveolar type II cells (A, B) and alveolar macrophages (C, D) of untreated animals were 
isolated and a total of3*105 cells were incubated with 25 ]lg/ml fluorescent labeled lipo-
somes for 1 hour at 3TC. Exogenous surfactant, either sonicated inactive (solid line) or 
non-sonicated active (dotted line), was added to the incubation at the indicated 
surfactant to liposome ratio. Mean cell-associated fluorescence (A, C) as well as the 
percentage of cells with a fluorescence higher than auto-fluorescence (B, D) were deter-
mined. The cell-associated fluorescence was expressed as the percentage of the cell-
associated fluorescence in the absence of exogenous surfactant. Values are expressed as 
mean ± SEM (n = 4 incubations). * indicates a significant difference compared to the 
incubation without exogenous surfactant (p<0.05). # indicates a significant difference 
between a similar incubation with non-sonicated surfactant (p<0.05). 
The addition of exogenous surfactant demonstrated a similar effect on the uptake ofliposomes 
by alveolar macrophages as was observed for alveolar type II cells; again, a significant increase 
at a liposome to surfactant ratio of 1:50. However, the percentage alveolar macro phages taking 
up liposomes was significantly decreased at a liposome to surfactant ratio of 1:20 and 1:100, 
although at a liposome to surfactant ratio of 1:50 no significant difference compared to 
Normal group (no surfactant) was observed (Fig 2D). Sanification of the exogenous surfactant 
induced a significant decreae in mean fluorescence and number of alveolar cells participating 
in the uptake starting at surfactant ratio of 1:50 and higher (Fig 2D). 
Effect of large and small surfactant aggregates on uptake 
The results of the experiments suggest a possible role/ effect of the large aggregates present in 
exogenous surfactant. To determine whether the uptake was stimulated by the large or small 
aggregates of surfactant, experiments were performed as shown in Figure 1. 
Addition of exogenous surfactant in a fluorescent liposome/surfactant ratio of 1:50 (Group 1) 
resulted in a significant increase in uptake of fluorescent labeled liposomes by alveolar type II 
cells (Fig. 3A) and alveolar macrophages (Fig. 3C), as well as an increase in the number of 
alveolar type II cells involved in the uptake (Fig. 3B). In Group 2, treated with 'large aggre-
gates', an increase in the uptake of fluorescent labeled liposomes by alveolar type II cells (Fig. 
3A) was observed, as well as an increase in the number of alveolar type II cells involved in the 
uptake, in comparison to the incubation without any surfactant preparation (Normal) (Fig. 
3B). Also, the addition of these 'large' aggregates to alveolar macrophages resulted in a similar 
significant increase in the uptake of fluorescent liposomes (Fig. 3C) although the number of 
macrophages taking up liposomes was unaffected (Fig. 3D). In Group 3, containing 'small' 
aggregates, no effects on the uptake of fluorescent labeled liposomes or on the cell number 
involved in the uptake was observed for alveolar cells (Fig. 3). 
In order to determine whether the fluorescent liposomes associate with the surfactant large 
aggregates and thereby facilitating uptake of this whole complex or large aggregates stimulate 
the uptake of small aggregates by alveolar cells, exogenous surfactant was suspended in a 
suspension containing fluorescent labeled liposomes (Group 4 and 5) which was followed by 
centrifugation. Of the resulting pellet and supernatant a total amount of 50 pl was added to 
the incubation. The addition of the pellet (Group 4) resulted in a significantly lower cell-
associated fluorescence of both alveolar type II cells and alveolar macrophages (Fig. 3A, C). In 
addition, the percentage of cells that were involved in the uptake of fluorescent liposomes was 
also significantly lower in comparison to normalliposomes. 
On the other hand, the addition of the supernatant (Group 5), did not affect the uptake of 
labeled liposomes by either alveolar type II cells or alveolar macrophages, as all values, mean 
cell-associated fluorescence and number of cells taking up liposomes did not differ significantly 
from those derived by the addition of only fluorescent labeled liposomes (Normal). 
Effect of exogenous surfactant on the uptake in vivo 
To study if the effects of exogenous surfactant on the uptake of surfactant-like liposomes were 
also present in vivo, healthy, ventilated rats were intratracheally instilled with fluorescent 
labeled liposomes and exogenous surfactant. 
Exogenous surfactant was suspended in a suspension containing fluorescent labeled liposomes 
(1 mg/ml) to a liposome to surfactant ratio of 1:50. 
Instillation of this suspension in ventilated animals did not affect the uptake of labeled lipo-
somes, compared to the uptake of the same labeled liposomes without exogenous surfactant 
(Fig 4A). However, the percentage alveolar type II cells involved in the uptake was significantly 
decreased compared to the 'normal' liposomes, that is without exogenous surfactant (Fig 4B). 
On the other hand, the uptake of this suspension containing both exogenous surfactant and 
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Figure 3. Effect of large and small suifactant aggregates on uptake in vitro 
Alveolar cells were isolated from untreated animals and a total of 3*105 alveolar type II 
cells (A, B) or alveolar macrophages (C, D) were incubated at 3TC for one hour. The 
'Normal' group received only 25 jlg/ml fluorescent labeled liposomes. Exogenous 
surfactant was added in a liposome to surfactant ratio of 1:50 (Group 1) together with 
25 jlg/rnl fluorescent labeled liposomes. Centrifuged surfactant (27,000*g) was added in 
a similar liposome to surfactant ratio of 1:50 (pellet of the surfactant in Group 2, super-
natant in Group 3). A mixture of fluorescent labeled liposomes and exogenous surfactant 
in (again) a liposome to surfactant ratio of 1:50 was centrifuged and both pellet (Group 
4) and supernatant (Group 5) were incubated with alveolar cells. Flow cytometry was 
used to determine cell-associated fluorescence (A, C) and percentage of cells involved in 
the uptake of the labeled liposomes (B, D) (n = 5 incubations per group; values are 
expressed as mean± SEM). *indicates a significant difference compared with the Normal 
group. 
labeled liposomes did not influence the uptake by alveolar macrophages or the percentage 
alveolar macrophages involved in the uptake when compared to the normal liposomes (Fig. 
4C, D). 
More interestingly, however, when the same experiments were repeated with sonicated, 
inactivated, exogenous surfactant, similar results were found. The administration of a 
suspension containing sonicated surfactant and labeled liposomes did not change the uptake 
of labeled liposomes by alveolar type II cells or alveolar macrophages in comparison to the 
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Figure 4. Effect of exogenous natural surfactant on uptake in vivo 
The animals were randomly divided into 3 groups. All animals were intratracheally 
instilled with fluorescent labeled liposomes (3 mg/kg). Depending on the group, either 
exogenous natural surfactant (Surf)(150 mg/kg) or sonicated exogenous surfactant 
(SonSurf)(150 mg/kg) was intratracheally administered together with the liposomes 
(SurfLipo, SonSurfLipo). One additional group received no surfactant (Normal). One 
hour after instillation of the fluorescent labeled liposomes, the animals were sacrificed 
and alveolar cells were isolated. Cell associated fluorescence (A, C) and percentage of cells 
involved in the uptake ofliposomes (B, D) was determined using flow cytometry (n = 5 
animals per group; values expressed as mean± SEM). *indicates a significant difference 
compared to the normalliposomes. 
uptake of only labeled liposomes. Nevertheless, both the percentage of alveolar type II cells and 
alveolar macro phages involved in the uptake of labeled liposomes was significantly decreased 
by the addition of sonicated surfactant, compared to the percentage of alveolar cells taking part 
in the uptake when using 'normal' liposomes (Fig. 4B, D). 
Localization of cell-associated fluorescence 
To ascertain that the cell-associated fluorescence was located within the cell rather than 
binding to the outer membrane of the cell, confocal laser microscopy was used. The confocal 
scans through the middle of the cell show a punctuate fluorescence throughout the cell limited 
to its circumference with the exception of its nucleus, demonstrating the intracellular presence 
of the fluorescent liposomes for both alveolar type II cell (Fig 5A) and alveolar macrophage 
(Fig. 5B). 
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Figure 5. Localization of cell-associated fluorescence 
Both alveolar type II cells (A) and alveolar macrophages (B) were isolated from untreated 
animals and incubated with 25 jlg/ml fluorescent labeled liposomes and exogenous 
surfactant (liposome/surfactant ratio 1:5 0). One hour after incubation, cells were washed 
3 times with cold PBS and the cells were mounted on glass coverslips. 
Discussion 
Pulmonary surfactant has been widely accepted to be essential for normal breathing, that is 
with physiological pressures. Surfactant facilitates this by providing a dynamic, low surface 
tension at the alveolocapillary membrane in the lung. Unfortunately, this endogenous 
surfactant can be absent or decreased, as in premature infants, or inactivated by a variety of 
causes, leading to respiratory failure. The use of exogenous surfactant is nowadays widely 
accepted in clinical practice, mostly in neonates, though its use in adults is under investi-
gation51, and improves outcome significantly. 
The administration of large amounts of exogenous surfactant might influence the surfactant 
metabolism, possibly via a feedback mechanism. The endogenous surfactant metabolism 
consists of production, secretion, formation of lipid monolayer, turnover, re-uptake and 
recycling. Several studies have focused on the effects of exogenous surfactant on the produc-
tion and secretion16-191. However, little is known about the influence of large amounts of 
exogenous surfactant on the uptake, as the few studies performed focused on the clearance of 
the surfactant or individual components and their results are contradictory18· 20-251. This re-
uptake of surfactant lipids has been demonstrated to be essential, especially in neonates, who 
have been demonstrated to rely on recycling for >90%, indicating the need for uptake of 
inactivated surfactant111. 
Pulmonary surfactant consists oflarge and small aggregates; it is thought that the large aggregates 
are surface active and lower surface tension. These 'large' aggregates are then turned over into 
'small' aggregates, which are incapable of providing a variable surface tension and are cleared from 
the alveolar space by alveolar type II cells and alveolar macrophages and, if possible, recycled. 
In the current study we investigated the effects of exogenous surfactant on the uptake of lipo-
somes with a composition similar to small aggregates, both in vitro and in vivo. In addition, 
we studied whether any effects caused by exogenous surfactant were induced by large or small 
aggregates. 
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From the in vitro experiments it can be concluded that exogenous surfactant influences the 
uptake oflabeled liposomes. The addition of exogenous surfactant in a liposome to surfactant 
ratio of 1:50 increases the uptake in both alveolar type II cells and alveolar macro phages. More 
specifically, the 'large' aggregates enhance the uptake of fluorescent labeled surfactant-like lipo-
somes. However, it has been demonstrated that DPPC liposomes associate with large aggre-
gates20, though in the current experiments it is unlikely that the large aggregates associated 
with the fluorescent labeled liposomes. We demonstrated that addition of a suspension 
(created by centrifuging a solution containing exogenous surfactant and fluorescent liposomes 
and resuspending the pellet), to alveolar cells induced a significantly lower cell-associated 
fluorescence of these alveolar cells compared to alveolar cells incubated with only fluorescent 
labeled liposomes. 
This stimulation of the uptake of labeled liposomes by alveolar cells by exogenous surfactant 
was also investigated in vivo. Interestingly, the cellular uptake of labeled liposomes was 
unaffected by the administration of exogenous surfactant. However, the percentage alveolar 
type II cells was significantly decreased compared to normal liposomes. Thus, it might be 
suggested that in vivo, exogenous surfactant downregulates the uptake by decreasing the 
percentage of cells involved in the uptake and most likely recycling; a negative feedback 
mechanism. It has been demonstrated that in injured lungs surfactant synthesis is increased27• 
28), and in addition uptake is increased in injured lungs29). In injured lungs, surfactant function 
is decreased, which has to be compensated for. Additional surfactant in healthy animals may 
lead to a downregulation of the surfactant metabolism, with less need for recycling; de novo 
synthesis is sufficient as only little new surfactant is needed. In vitro, however, de novo synthe-
sis is unlikely because no substrate is available and the cells rely on recycling and thus uptake. 
Surfactant stimulates the cell to produce surfactant, ensuring a constant amount of surfactant 
in the 'alveolar' space. This stimulation is induced by the large aggregates, as demonstrated in 
the current study. 
The instillation of sonicated surfactant induces an effect similar to surface active surfactant. 
However, the in vitro experiments suggested competition between sonicated surfactant and 
labeled liposomes. Therefore, an explanation for the in vivo results is more complex. It is 
unlikely that only competition between the sonicated surfactant and labeled liposomes takes 
place as only the number of cells involved in the uptake is decreased, whereas the uptake per 
cell remains at the same level. This unexpected behavior of sonicated surfactant underlines the 
hypothesis of feedback mechanisms via hormonal, inflammatory or nerval parameters, present 
in vivo though absent in vitro. However, further studies are needed to clarifY the feedback 
mechanism(s) in vivo and the effects of exogenous surfactant in diseased lungs. 
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Abstract 
Background: The in vivo effect on uptake of liposomes by synthetic SP-B analogues was 
investigated by measuring their effect on the uptake of surfactant-like liposomes by alveolar 
cells. Native SP-B and four SP-B analogues were included: monomeric and dimeric SP-B1_25 
(Cys-11>Ala-11), both these peptides have surface tension lowering activities though the 
dimeric form is more active, and monomeric and dimeric Serine SP-B1_25 (Cys-11>Ala-11 and 
Arg-12>Ser-12) which do not have surface tension lowering activities. 
Method: Healthy, mechanically ventilated rats received intratracheally various SP-B peptides 
(SP-B/lipid ratio 1:33 w/w) incorporated in surfactant-like liposomes (consisting of DPPC, 
PC, PG, PI, cholesterol and fluorescent labeled PE in a weight ratio of 55:21:8:2:8:6). One 
hour after instillation, alveolar macrophages (AM) and alveolar type II (ATII) cells were 
isolated and cell-associated fluorescence was determined using flow cytometry. Confocal laser 
microscopy was performed to ensure internalization of the liposomes rather than association 
of the liposome with the outer cell membrane. 
Results: The amount of cell-associated fluorescence of AM was the same for all liposome 
preparations, including the four with SP-B peptides as well as the controlliposome preparation 
which did not contain SP-B. However, cell-associated fluorescence of ATII cells in the presence 
ofliposomes incorporated with the serine SP-B peptides was reduced by 40% compared to the 
control liposomes. Confocal microscopy demonstrated the internalization of all liposome 
preparations by AM and ATII cells. 
Conclusion: Uptake ofliposomes by ATII cells ofliposomes with monomeric and dimeric SP-
B1_25 was similar to the uptake ofliposomes with native SP-B, but decreased by the addition 
of serine SP-B. The incorporation of SP-B analogues results in an increased uptake of these 
liposomes by alveolar macrophages for monomeric SP-B1_25 and serine dimeric SP-B1_25 
whereas dSP-B1_25 results in a decreased uptake. 
Therefore, mutant SP-B peptides, such as serine SP-B, may depress surfactant recycling and 
thus affect surfactant metabolism. 
Introduction 
Pulmonary surfactant is essential for normal breathing, and its absence leads to respiratory 
failure. The presence of endogenous surfactant in the lung is dependent upon a very complex 
system of production, secretion, formation of lipid monolayer, turnover, re-uptake and 
recycling. Briefly, after secretion, surfactant unfolds to tubular myelin that is incorporated into 
the lipid monolayer. During respiration the surfactant in the lipid monolayer is turned over 
from large surface active aggregates into small inactive surfactant aggregates1· 31 • These small 
aggregates are removed from the alveolar space by both alveolar macrophages and alveolar type 
II cells. As de novo synthesis is insufficient to compensate the loss of surfactant, especially in 
neonates, these small aggregates are recycled by the alveolar type II cells. 
The uptake of small aggregates is influenced by several factors, such as environmental ones41 , 
lipid constitution and surfactant proteins, mainly SP-A, SP-B and SP-C. Especially SP-A and 
to a smaller extent SP-C have been demonstrated to stimulate the uptake of surfactant lipids 
by alveolar type II cells and macrophages5· 131 • The effects of SP-B on the uptake are, however, 
more complex; it ahs been shown that SP-B can increase the uptake of liposomes in vitro10• 14-
171, whereas others have demonstrated an inhibition of SP-B on SP-C mediated uptake by 
alveolar type II cells9• 101. 
Exogenous surfactant has been accepted worldwide as a therapy ofRDS in premature and term 
infants, and the use of surfactant therapy for adults is under discussion. Exogenous surfactant 
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is usually derived from lung extracts containing phospholipids and the two hydrophobic 
surfactant proteins SP-B and SP-C; both these surfactant proteins play an important role in 
the surface tension lowering properties of surfactanes-zo) _ Moreover, the need of the two 
proteins is emphasized by the fact that absence of SP-B is lethal2L 22l, whereas SP-C is not but 
mutations in the SP-C gene can be related to interstitial lung diseases23l_ 
Synthetic analogues of SP-B and SP-C based on the known human amino-acid sequence are 
nowadays tested with the aim to develop a completely synthetic surfactant preparation. 
Nevertheless, the effects of the surfactant proteins on the endogenous surfactant metabolism 
remain unknown. 
Our laboratory has been able to formulate and synthesize synthetic SP-B and SP-C peptides, 
which closely mimic the function of natural surfactant proteins24l. The in vivo metabolism and 
the effects on the clearance of these surfactant peptides have yet not been investigated. We 
studied the effect of monomeric and dimeric SP-B1_25 peptides, based on the N-terminal 
segment of human SP-B with an alanine for cysteine substitution at position 11, on the 
uptake of surfactant-like liposomes by alveolar type II cells and alveolar macrophages. The 
SP- B1_25 (Cys-11 > Ala-11) variant disulfide linked homodimer has been the focus of recent 
laboratory studies as it closely mimics the in vitro and in vivo functions of the full-length 
SP-B protein25-27l. 
Materials and methods 
Ethical Guidelines 
This study was approved by the Institutional Animal Care and Use Committee at the Erasmus 
MC- Faculty Rotterdam. 
Porcine SP-B and synthetic SP-B analogues 
Porcine SP-B was isolated from lung lavage and characterized according to standard proce-
dures28l. Monomeric SP-B1_25 peptide was synthesized on a 0.25 mmol scale with an Applied 
Biosystems Model 431A peptide synthesizer using a FastMoc™ strategf9l. The SP-B1_25 
sequence was based on the N-terminal of human SP-B30l with one modification, cysteine in 
position 11 was replaced by alanine (Cys-11 > Ala-11 variant monomer)25-26l. The peptide was 
synthesized with prederivatized Fmoc-Gly resin (CalbiochemNova, La Jolla) or PEG-PA resin 
(Perceptive Biosystems, Old Connecticut Path, MA) and single coupled for all residues. After 
purification by reversephase high performance liquid chromatography, the molecular mass was 
confirmed by fast atom bombardment mass spectroscopy or electro spray mass spectroscopy3°l. 
The SP-B1_25 (Cys-11 > Ala-11) variant disulfide linked homodimer was formed by oxidizing 
the monomeric SP-B1_25 peptide (mSP-B1_25)25'26l. The molecular mass of this dimeric SP-B1_ 
25 peptide (dSP-B1_25)was confirmed by electro spray mass spectroscopy and indicated the 
yield of dimeric product to be essentially 1 00o/o25l. 
Mutant monomeric and dimeric SP-B1_25 peptides were synthesized with site-specific 
substitutions of serine for arginine in positions 12 and 17 and for lysine in positions 16 and 
24 of theN-terminal (Fig. 1). These site-specific substitutions reduce the net cationic charge 
on the molecule without affecting the hydrophobicitf4l. Synthesis, purification and characte-
rization of the serine mutants were done in the same manner as the original peptides. 
All peptides were produced in their native state and then their N-terminal was fluorescent 
labeled on the resin with Bodip~ FL, CASE (N-(4,4-difluoro-5,7-dimethyl-4-bora-3a,4a-
diaza-s-indacene-3-propionyl)cysteic acid, succinimidyl ester, triethylammonium salt) 
(Molecular Probes Inc., Eugene, OR, USA) using a previously reported protocol31l. The N-
terminallabeled peptides were cleaved and deprotected from the resin by Hydrogen Fluoride 
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SP-B1-25 monomer 
Phe-Pro-Ile-Pro-Leu-Pro-Tyr-Cys-Trp-Leu-Ala-Arg-Ala-Leu-Ile-Lys-Arg-Ile-Gln-Ala-
Met-Ile-Pro-Lys-Gly 
SP-B1_25 serine monomer 
Phe-Pro-Ile-Pro-Leu-Pro-Tyr-Cys-Trp-Leu-Ala-Ser-Ala-Leu-Ile-Ser-Ser-Ile-Gln-Ala-
Met-Ile-Pro-Ser-Gly 
Figure 1. Peptide sequences of the SP-B analogues and their serine mutants 
The SP-B1_25 homodimer consists of two SP-B1_25 monomers which are disulfide-linked 
at Cys8. The fluorescent label was inserted in all peptides at theN-terminus, shown on 
the left side of the sequence. 
methodology32l. The crude labeled peptides were then purified by reverse phase HPL06l and 
their mass confirmed by MALDI-TOF mass spectrometry (UCLA mass spectometry facility). 
Liposome preparation 
Surfactant-like liposomes were prepared by mixing the following lipids; dipalmitoyl phosphat-
idylcholine (DPPC), phosphatidyl choline (PC), phosphatidylglycerol (PG), phosphatidyl 
inositol (PI), and phosphatidyl ethanolamine (PE) labeled with Texas-Red in the head group 
(Texas-Red DHPE, Molecular Probes Inc., Leiden, The Netherlands) and cholesterol in a 
weight ratio of 55:21:8:2:6:8 and the indicated surfactant proteins at a protein/lipid concen-
tration of 3:100 wt:wt. Subsequently, this mixture was dried under a stream of nitrogen. The 
lipids were purchased from Sigma (Zwijndrecht, The Netherlands), unless stated otherwise. 
The liposomes were suspended in PBS at a concentration of 0.5 mg lipids/ml (in vitro 
experiments) or 1 mg/ml (in vivo experiments) using glass pearls and vortexing. Immediately 
prior to use, the liposome suspension was sonicated for 2 min on ice using an ultrasonic 
disintegrator (Branson Sonifier 250, Danbury, CT, USA) to prepare small unilamellar lipo-
somes4l. The size of the liposomes was determined by dynamic light scattering at 25"C with a 
Malvern 4700 system using a 25 mW He-Ne laser (NEC, Tokyo, Japan) and the auto measure 
version 3.2 software (Malvern Ltd, UK). As a measure of particle size distribution of the 
dispersion, the system reports a polydispersity index (p.d.). This index ranges from 0.0 for a 
monodisperse and up to 1.0 for an entirely polydisperse dispersion. After ultrasonification the 
liposomes size ranged from 140 to 165 nm and the polydispersity index ranged from 0.2 to 
0.35. 
Intratracheal instillation of fluorescent liposomes 
The studies were performed with male Sprague-Dawley rats (IFFA Credo, The Netherlands) 
with a bodyweight of 318 ± 16 g. After induction of anesthesia with a mixture of nitrous oxide 
(66%), oxygen (33%) and isoflurane (1-2%), a sterile polyethylene catheter (0.8 mm o.d.) was 
inserted into one of the carotid arteries. The animals were then tracheotomized and a sterile 
metal cannula was inserted into the trachea. 
After these surgical procedures, gaseous anesthesia was ended and replaced with an intra-
peritoneal injection of pentobarbital sodium (60 mg/ml, Nembutal®, Algin BV, Maassluis, The 
Netherlands) at a dose of 30 mg/kg bodyweight every hour. 
Muscle relaxation was induced and maintained by an hourly intramuscular injection of 
pancuronium bromide (2 mg/kg, Pavulon; Organon Technika, Boxtel, The Netherlands). The 
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animals were then mechanically ventilated with a Servo® ventilator 900C (Siemens-Elema, 
Solna, Sweden) set to pressure control mode using a frequency of 30/min, an inspiratory/ 
expiratory ratio of 1:2, a positive end-expiratory pressure (PEEP) of 2 em H 20, a peak 
inspiratory pressure (PIP) of 12 em H 20 and Fi02 was set to 1. 
Before instillation of the labeled liposomes, PEEP was increased to 6 em H 20 and PIP was 
increased to 26 em H 20. After disconnection from the ventilator, the liposomes were 
administered intratracheally at the indicated dosage. The suspension of liposomes (1 mg 
lipids/ml) was administered as a bolus of3 ml!kg followed by a bolus of air (12 ml!kg), directly 
into the endothracheal tube via a syringe, and the animals were immediately reconnected to 
the ventilator. Thirty minutes after instillation of the liposomes PEEP was reduced to 2 em 
H 20 and PIP to 12 em H 20. 
Arterial blood gas values were measured with conventional methods (ABL 555, Radiometer, 
Copenhagen, Denmark) at the start of ventilation, immediately after instillation of the lipo-
somes and every 30 minutes thereafter. After one hour of ventilation the animals were sacri-
ficed by exsanguination via the abdominal aorta and the alveolar type II cells and alveolar 
macrophages were isolated to determine the cell-associated fluorescence. Untreated animals 
were sacrificed immediately after anesthesia and their isolated alveolar type II cells and alveolar 
macrophages were used to correct for auto-fluorescence. 
Isolation of alveolar type II cells and alveolar macrophages 
Prior to isolation of the cells, the thorax was opened and blood was removed from the lungs 
by perfusing the pulmonary artery with warmed saline (3TC) supplemented with 20 IE 
heparin per ml (Leo Pharma, Weesp, The Netherlands). The lungs were removed en bloc from 
the thoracic cavity and lavaged with 10 ml of solution 1 [140 mM NaCl, 5 mM KCl, 2.5 mM 
Na2HP04.2H20, 10 mM HEPES (N-2-hydroxyethylpiperazine-N'-2-ethaesulfonic acid), 6 
mM glucose, 0.2 mM EGTA (ethylene glycol-bis- (~-amino ethyl ether) N,N'-tetra-acetic 
acid), pH 7.40] at 3TC. This procedure was repeated four times. The lung lavages were pooled 
per animal and centrifuged (100x g; 10 min; 4oC). The cellular pellet, i.e. alveolar macro-
phages, was suspended in solution 2 [140 mM NaCl, 5 mM KCl, 2.5 mM Na2HP04.2H20, 
10 mM HEPES, 6 mM glucose, 2.0 mM CaC12 and 1.3 mM MgS04] to a concentration of 
2x106 cells/ml and stored on ice until further use. The alveolar type II cells were isolated accor-
ding to Dobbs et al.33l, using enzymatic digestion as previously described. Alveolar type II cells 
were suspended in solution 2 at a concentration of 2x106 cells/ml and stored on ice until 
further use. Alveolar macrophages were identified using monoclonal antibodies specific for rat 
macrophages (ED9) and alveolar type II cells were identified using an alkaline phosphatase 
assay as described by Edelson et al. 34l. The average yield of alveolar type II cells was 16x1 06 with 
a purity of 80 ± 5% and 5x1 06 alveolar macro phages with a purity of 92 ± 5% per rat. 
In vitro uptake ofSP-B peptide 
Alveolar cells of untreated animals were isolated as described above and suspended in solution 
2 to a concentration of2x106 cells/ml. A total of3x105 cells were incubated with the indicated 
concentration of the specified liposomes at 3TC (final volume 500 f.!l) in a shaking water 
bath. After 1 hour, the incubation was terminated by addition of 2 ml of ice-cold PBS ( 4 o C). 
The cell-suspension was centrifuged at 100 x g for 10 min at 4°C. The supernatant was 
removed, and the cells were suspended in 2 rnl ice-cold PBS and centrifuged again. This wash 
procedure was repeated twice. Finally, the pellet was resuspended in 200 f.!l of cold PBS, and 
cell-associated fluorescence was determined as described below. 
Flow cytometry 
Cell-associated fluorescence of the alveolar type II cells and alveolar macro phages as a measure 
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for internalized liposomes was determined using flow cytometry (FACSCalibur; Becton 
Dickinson, Mountain View, CA, USA). The cell-associated fluorescence of 15,000 cells was 
determined. Alveolar macrophages and alveolar type II cells derived from untreated control 
animals were used in each experiment to determine the auto-fluorescence of the cells. 
Subsequently, the mean cell-associated fluorescence was determined only for those cells that 
had a higher fluorescence than that caused by auto-fluorescence (gated cells). 
Localization of cell-associated fluorescence 
To localize the cell-associated fluorescence, intracellular or extracellular, confocal laser micro-
graphs were obtained using a confocal microscope (LSM51 ONLO, Carl Zeiss, Jena, Germany). 
Images were created with plan apochromat 63x 1.4 n.a., objectives and photomultiplier tubes 
and filters set at 500-550 nm and 656-615 nm (TexasRed, excitation 596 nm; Bodipy, 
excitation 503 nm HeNe laser). Images of alveolar cells were serially sectioned pinhole at 1 airy 
unit with an interval of 0.5 ~-tm to distinguish cell membrane-associated fluorescence from the 
intracellular fluorescence. 
Statistical analysis 
Differences between the 6 groups that received liposomes with a different composition were 
analyzed using an ANOVA followed by a Bonferroni post-hoc test. Blood gas values were 
analyzed using a repeated measurement ANOVA. Differences were considered statistically 
significant at a p <0.05. Values are expressed as mean± SEM. 
Results 
Effect ofSP-B1_25 on the uptake ofliposomes by alveolar cells in vitro 
After isolation from untreated animals, alveolar cells were incubated with different concen-
trations of liposomes. In these liposomes, native SP-B (nSP-B), monomeric SP-B1_25 or 
dimeric SP-B1_25 was included in a protein to lipid ratio of 3:100. After 1 hour the incubation 
was stopped and cell-associated fluorescence was determined. 
The incorporation of SP-B (or derivations) in the fluorescent labeled liposomes did not 
influence the uptake of these liposomes by alveolar cells (Fig. 2 A, C). Nor was the percentage 
of cells involved in the uptake affected by the inclusion of proteins in the liposome (Fig 2 B, 
D). 
Effect ofSP-B1_25 analogues containing liposomes on the gas exchange 
The inclusion of SP-B1_25 analogues in the labeled liposomes did not affect gas-exchange. 
Arterial blood gas values remained at healthy levels after instillation (results not shown). 
Effect of SP-B 1-25 peptides on the uptake by alveolar cells in vivo 
To study the effect of SP-B analogues, the different SP-B peptides were incorporated in 
fluorescent labeled liposomes at a protein to lipid concentration of 3:100 wt:wt. The uptake 
by alveolar type II cells oflabeled liposomes was significantly increased with the incorporation 
of dSP-B1_25 whereas the inclusion of other SP-B analogues did not affect uptake (Fig. 3A). 
However, the percentage of alveolar type II cells involved in the uptake decreased when dSP-
B1_25 was incorporated, while the inclusion of mSP-B1_25 increased the percentage of alveolar 
type II cells (Fig. 3B). Such an effect of the inclusion on the percentage of cells involved in the 
uptake of labeled liposomes was also observed for alveolar macrophages. The percentage 
alveolar macrophages taking part in the uptake was significantly decreased with the inclusion 
of dSP-B 1_25 in the liposome. In addition, the incorporation of serine mSP-B1_25 also 
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decreased the amount of alveolar macrophages taking up labeled liposomes (Fig. 3D). 
Interestingly, the uptake per alveolar macrophage was not affected by the incorporation of 
dSP-B 1_25 or serine mSP-B 1_25, but was significantly increased due to the incorporation of 
mSP-B 1_25 or serine dSP-B 1_25 (Fig. 3C). These results raise the question as to how total 
uptake was affected by inclusion of the SP-B analogues, and therefore total cell-associated 
fluorescence was determined, which takes into consideration both the uptake per cell as well 
as the percentage of cells involved in the uptake. These data demonstrate a decreased uptake 
ofliposomes with serine SP-B1_25 analogues by alveolar type II cells (Fig. 4A). The incorpora-
tion of serine mSP-B 1_25 did not influence uptake by alveolar macrophages. However, 
inclusion of serine dSP-B 1_25 resulted in a significant increase in uptake of labeled liposomes 
by alveolar macrophages similar to the increase caused by mSP-B 1_25 (Fig 4B), whereas 
enclosure of dSP-B 1_25 in the labeled liposomes resulted in a decreased uptake by alveolar 
macrophages. 
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Figure 2. Effect of nSP-B, mSP-B 1_25 and dSP-B 1_25 on the alveolar cell uptake in vitro 
Alveolar cells were isolated from untreated animals and incubated for 1 hour at 3TC 
with the indicated concentrations of fluorescent liposomes dependent on the group 
containing native SP-B (nSP-B), monomeric SP-B1_25 (mSP-B 1_25) or dimeric SP-B1_25 
(dSP-B1_25) or no proteins (normal). The SP-B proteins were included in a protein to 
lipid ratio of 3:100. The mean cell-associated fluorescence of gated alveolar type II cells 
(A) and alveolar macrophages (C) was determined. In addition, the percentage gated 
alveolar type II cells (B) and alveolar macrophages (D) were determined. No significant 
differences were observed at any concentration (n = 4 incubations at every concentration; 
values are mean ± SEM). 
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Figure 3. Effect ofSP-B and SP-B analogues on the alveolar cell uptake in vivo 
Fluorescent labeled liposomes with native SP-B (nSP-B), monomeric SP-B1_25 (mSP-B 1_ 
25), dimeric SP-B1_25 (dSP-B1_25), serine monomeric SP-B1_25 (serine mSP-B 1_25) or 
serine dimeric SP-B1_25 (serine dSP-B 1_25) incorporated at a protein to lipid ratio of 
3:100 were intratracheally instilled in ventilated rats. After one hour, alveolar type II cells 
(A, B) and alveolar macrophages were isolated (C, D), and cell-associated fluorescence 
(A, C) and percentage cells involved in the uptake (B, D) were determined. (n = 4 rats 
per group; values are mean± SEM); *, p<O.OS versus normal 
Localization of cell-associated fluorescence caused by SP-B1_25 
To ascertain that the cell-associated fluorescence was located within the cell rather than 
binding to the outer membrane of the cell, confocal laser scanning microscopy was used. One 
hour after intratracheal instillation of the liposomes containing mSP-B 1_25 or dSP-B 1_25 in 
mechanically ventilated rats, the alveolar cells were isolated and confocal scans were made. 
These confocal scans through the middle of the cell show a punctuate fluorescence throughout 
the cell limited to its circumference with the exception of its nucleus, demonstrating the 
intracellular presence of the fluorescent liposomes (Fig 5 and 6). 
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Figure 4. Effect of SP-B1_25 on total 
uptake of liposomes 
Fluorescent labeled liposomes with native 
SP-B (nSP-B), monomeric SP-B1_25 (mSP-
B1_25), dimeric SP-B1_25 (dSP-Bl-25), 
serine monomeric SP-B1_25 (serine mSP-
B1_25) or serine dimeric SP-B1_25 (serine 
dSP-B1_25) incorporated at a protein to 
lipid ratio of 3:100 were intratracheally 
instilled in ventilated rats. After one 
hour, alveolar type II cells (A) and 
alveolar macrophages (B) were isolated, 
and total cell-associated fluorescence was 
determined. (n = 4 rats per group; values 
are mean ± SEM); *, p<0.05 versus 
normal 
SP-B is essential for the biophysical properties of pulmonary surfactant. SP-B is a 79 amino 
acid, cysteine rich hydrophobic protein found in pulmonary surfactant as an 18 kDa dimer. It 
is synthesized in the endoplasmic reticulum of the alveolar type II cell as a large precursor 
protein of 42 kDa. This precursor SP-B is transported via the Golgi complex and the 
multivesicular bodies to the lamellar bodies while it undergoes proteolytic processing to the 
mature 9 kDa protein. In the lamellar bodies SP-B combines with the other surfactant proteins 
and lipids. The lamellar bodies are secreted into the alveolar space, where they provide 
functional surfactant for the air-water interface. The surfactant metabolism in vivo has recently 
been reviewed35l. In the adult lung SP-B is cleared more rapidly from the alveoli than saturated 
phosphatidylcholine36l. In the developing lung, the clearance of phospholipids and SP-A is in 
general much slower than in the adult lun~7' 38l. The clearance of SP-A, B, and C has been 
studied in adult (rabbit) lungs36· 37• 39l, the clearance of SP-B in newborn rabbits40l and that of 
SP-C in preterm lambs41l. The surfactant proteins are not only cleared from the alveolar space 
but may also play a role in the clearance of surfactant lipids from the alveolar space. Both SP-
A and SP-C have been shown to stimulate the uptake. The effects of SP-B are more complex, 
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Figure 5. Localization of cell-associated fluorescence of SP-B1_25 
Mechanically ventilated rats were intratracheally instilled with fluorescent labeled lipo-
somes containing either monomeric SP-B1_25 (A, C) or dimeric SP-B1_25 (B, D). One 
hour after instillation alveolar macrophages (C, D) and alveolar type II cells (A, B) were 
isolated and confocal scans were made. All scans were made using the same microscopic 
settings. 
at physiological amounts it does not affect uptake, though at high concentrations SP-B 
stimulates the clearance of labeled liposomes. In our laboratory, synthetic analogues of SP-B 
have been designed, and their function in lowering surface tension has been demonstrated25l. 
However, the effects of this synthetic SP-B on the clearance are not yet clarified. In the current 
study the effect of the incorporation of SP-B analogues on the uptake oflabeled liposomes was 
studied both in vivo and in vitro. 
First, the effects of the synthetic SP-B fragments on the uptake of labeled liposomes were 
studied in vitro and after comparison with nSP-B, it can be concluded that the incorporation 
of 3% SP-B or SP-B analogues does not influence the uptake by alveolar cells nor the percen-
tage of cells involved in the uptake. However, significant differences between in vitro and in 
vivo studies have been demonstrated, and thus similar experiments were performed in vivo. 
Incorporation of nSP-B in the liposomes did not influence the uptake of these liposomes by 
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Figure 6. Localization of cell-associated fluorescence of serine SP-B 1_25 
Mechanically ventilated rats were intratracheally instilled with fluorescent labeled lipo-
somes containing either monomeric serine SP-B1_25 (A, C) or dimeric serine SP-B1_25 (B, 
D). One hour after instillation alveolar macrophages (C, D) and alveolar type II cells (A, 
B) were isolated and confocal scans were made. All scans were made using the same 
microscopic settings. 
alveolar type II cells or alveolar macrophages as was expected based on previous studies. Then, 
with regard to the synthetic SP-B analogues, the inclusion of mSP-B 1_25 did not influence the 
uptake of the liposomes by alveolar type II cells, though it did result in an increased uptake of 
the labeled liposomes by alveolar macrophages. However, the percentage of alveolar type II 
cells involved in the uptake was significantly increased when mSP-B 1_25 was incorporated, 
whereas the percentage of alveolar macrophages, taking up these liposomes was unaffected. 
Overall, the incorporation of mSP-B1_25 increases the uptake of labeled liposomes by alveolar 
macrophages, whereas the uptake by alveolar type II cells did not differ significantly from the 
uptake of normalliposomes. The incorporation of dSP-B 1_25 induced an increased uptake of 
labeled liposomes by alveolar type II cells, whereas the percentage alveolar type II cells involved 
in the uptake decreased significantly compared with the normalliposomes and liposomes with 
SP-B incorporated. The inclusion of dSP-B 1_25 in the liposome did not affect the uptake per 
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alveolar macrophage, though the percentage of alveolar macrophages involved in the clearance 
of these liposomes decreased significantly, resulting in an overall reduced clearance of lipo-
somes with dSP-B 1_25 in comparison to liposomes without a surfactant protein or with nSP-
B. 
From these results it can be concluded that surface active analogs of SP-B can influence the 
contribution of alveolar macrophages on the clearance of surfactant-like liposomes. 
These synthetic surfactant proteins, based on human native SP-B were developed with the aim 
to produce a completely synthetic surfactant. Both mSP-B1_25 and dSP-B-1-25 have been 
demonstrated to improve lung function though dSP-B-1-25 was more efficient than mSP-B-
1-2542· 43l suggesting a legitimate use of these proteins in exogenous surfactant. The results of 
the current study demonstrate that the use of dSP-B-1-25 is preferable to mSP-B-1-25; the 
first is not only more surface active25l but surfactant-like liposomes with dSP-B-1-25 incorpo-
rated are also less taken up by alveolar macrophages and thus more liposomes are available for 
clearance and recycling by alveolar type II cells. Incorporation of mSP-B-1-25 stimulates the 
uptake of these liposomes by alveolar macrophages, so these liposomes will be more readily 
removed from the lung. 
The two mutant SP-B1_25 analogues, serine mSP-B1_25 and serine dSP-B 1_25, are less surface 
active and in addition they inhibit the uptake of surfactant-like liposomes as demonstrated in 
the present study. These results underline the hypothesis that the hydrophobic surfactant 
proteins, SP-B and SP-C influence the uptake by alveolar macrophages and alveolar type II 
cells, via interaction with the surfactant lipids. SP-B has been demonstrated to interact with 
PG, the second major lipid after PC44•45l. In addition, this phospholipid has been demonstrated 
to influence the uptake by alveolar type II cells and alveolar macrophages (submitted data.) 46l. 
In summary, the current study demonstrates that the more surface active synthetic SP-B 
analogues do not interfere with the normal surfactant metabolism and can thus be used in 
exogenous surfactant therapy. In addition, the results underline the hypothesis that the effects 
of SP-B on the uptake by alveolar cells are mediated by interactions with the surfactant lipids, 
though an interaction does not necessarily imply an enhanced surface tension lowering activity. 
Further studies are needed to establish how these synthetic surfactant proteins influence the 
uptake in diseased animals (as a synthetic exogenous surfactant preparation will be used as a 
therapeutic intervention for respiratory failure) and their effects on recycling of surfactant. 
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Summary 
Pulmonary surfactant is essential for normal breathing and disturbance of the surfactant 
system, caused for example by diseases, is associated with respiratory failure. In order to 
determine the pathophysiological deviation within the surfactant system, the normal 
physiology of the surfactant metabolism has to be clear. Because little is known about the 
uptake of surfactant by alveolar cells even in healthy animals, the studies presented in this 
thesis are performed using healthy adult animals. 
Chapter 1 provides an overview on the uptake of pulmonary surfactant by alveolar type II cells 
and alveolar macrophages and its regulating factors. First the discovery of and the need for 
pulmonary surfactant are discussed, followed by a description of the composition of 
pulmonary surfactant: 90% lipids (dipalmitoylphosphatidylcholine, phosphatidylcholine, 
phosphatidylglycerol, phosphatidylinositol, phosphatidylethanolamine, cholesterol) and 1 Oo/o 
surfactant specific proteins, SP-A, SP-B, SP-C and SP-D. Subsequently we describe the 
metabolism of pulmonary surfactant, discuss possible bottlenecks in the metabolism and, more 
specifically, the need for re-uptake of pulmonary surfactant. This is followed by an analysis of 
the literature on methods used to measure the uptake, discussing the advantages and 
disadvantages of the different methods including one developed by our group, as described in 
Chapter 2. · 
We developed a method using fluorescent labeled liposomes (with a composition similar to 
natural surfactant) to measure surfactant uptake. Compared with the methods described in the 
literature, the advantages of our method include: the option to measure both in vivo and in 
vitro and to compare the results, as well as demonstrating uptake or intracellular presence 
rather than cellular adhesion of the fluorescent labeled surfactant-like liposomes. Furthermore, 
in this method a minor component is used to measure the uptake by replacing it with a similar 
fluorescent labeled one, and thus the role of the major phospholipids in the regulation of the 
uptake can be studied, which is discussed in more detail in Chapter 3. 
Fluorescent labeled liposomes, composed of 86% of the studied phospholipid and 14% of 
fluorescent labeled phosphatidylethanolamine and cholesterol, were used to investigate the 
effect of dipalmitoylphosphatidylcholine, phosphatidylcholine, phosphatidylglycerol and 
phosphatidylinositol in vitro. The results showed an increased uptake of negatively charged 
lipids in comparison to neutrally charged lipids and surfactant-like liposomes. In addition, 
from competition experiments studying phosphatidylglycerol and dipalmitoylphosphatidyl-
choline or phosphatidylinositol, it was concluded that the lipids are incorporated by alveolar 
cells via the same pathway. 
In Chapter 4, this method is used to determine the effect of the second major phospholipid, 
phosphatidylglycerol, on the uptake in vivo. It was demonstrated that a high concentration of 
phosphatidylglycerol leads to a decrease of alveolar macrophages in the broncho-alveolar 
lavage. More interestingly, large amounts of phosphatidylglycerol induce severe deterioration 
of lung mechanics, as demonstrated by a deterioration of blood gas values. Histological 
samples showing diffuse alveolar damage support the hypothesis of severe surfactant 
dysfunction leading to respiratory failure. These results imply a possible fundamental role of 
phosphatidylglycerol in the surfactant metabolism apart from the surfactant proteins. 
Although the role of surfactant proteins, especially SP-A, on the uptake of surfactant has been 
studied extensively, the effects of the hydrophobic proteins SP-B and SP-C on the clearance of 
surfactant-like liposomes in vivo were studied for the first time by our group. 
Chapter 5 presents the results of these experiments. The presence of SP-B is unlikely to 
influence uptake, though inclusion of SP-C in combination with divalent cations and other 
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solutes is indeed capable of influencing the uptake. These surfactant proteins SP-B and SP-C 
are nowadays commonly present in therapeutically applied exogenous surfactant. Though 
exogenous surfactant is used worldwide as a therapeutic life-saving intervention in neonates or 
infants suffering respiratory distress syndrome, its effect on the endogenous surfactant 
metabolism is not yet clarified. 
Chapter 6 presents a study on the effect of exogenous surfactant on the uptake of surfactant-
like liposomes in healthy adult animals. In vitro, large surface active surfactant aggregates were 
demonstrated to increase the uptake of small surface inactive aggregates whereas in vivo uptake 
was decreased by the presence of exogenous surfactant. However, the specific mechanisms 
underlying these results have to be further elucidated. Because the costs of exogenous 
surfactant are high and the supply limited, the options to produce a synthetic surfactant are 
discussed, especially the use of synthetic SP-B analogues. However, these mimics of SP-B 
should not interfere with the endogenous metabolism and should have a similar function. 
Therefore, in Chapter 7, the effects of SP-B analogues on the uptake of surfactant-like lipo-
somes are studied. The results demonstrated that, the uptake of liposomes by alveolar type II 
cells ofliposomes with monomeric and dimeric SP-B1-25 (Cys-11>Ala-ll) was similar to the 
uptake of liposomes with native SP-B. However, the incorporation of serine SP-B (Cys-
11>Ala-11 and Arg-12>Ser-12), known to have little surface tension lowering activity, resulted 
in a decreased uptake of these labeled liposomes. The incorporation of SP-B analogues results 
in an increased uptake of these liposomes by alveolar macrophages for monomeric SP-B-1-25 
and serine dimeric SP-B-1-25, whereas dimeric SP-B-1-25 results in a decreased uptake. From 
these results it was concluded that mutant SP-B peptides, such as serine SP-B, may depress 
surfactant recycling and thus affect surfactant metabolism. 
The work presented in this thesis demonstrates the viability of studying the uptake of 
surfactant with fluorescent labeled liposomes. The results underline the need to study 
surfactant uptake both in vivo and in vitro, as well as the influence of composition on uptake, 
the effect of natural hydrophobic surfactant proteins SP-B and SP-C as well as synthetic SP-B 
analogues, and finally the influence of exogenous surfactant in healthy animals. It is essential 
to further explore the uptake of surfactant, for example in diseased animals, to clarify 
regulating factors and finally develop a disease-specific surfactant, whose composition depends 
on the underlying disease. 
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Sam en vatting 
De aanwezigheid van long surfactant is essentieel voor een normale ademhaling en wordt 
gewaarborgd via een complex metabolisme. Verstoringen van het surfactant systeem, door 
ziekten of onrijpe longen, zijn verbonden met respiratoir falen. Om patho-f}rsiologische 
afurijkingen binnen het surfactant systeem te kunnen bepalen, is het noodzakelijk dat de 
normale fYsiologie van het surfactant metabolisme bekend is. Over de opname van surfactant 
door alveolaire cellen is weinig bekend, ook niet in gezonde dieren. Dat is de reden dat de 
studies zoals beschreven in dit proefschrift uitgevoerd zijn in gezonde dieren. In Hoofdstuk 1 
wordt een overzicht geven van de opname van pulmonaal surfactant door zowel alveolaire type 
II cellen als alveolaire macrofagen en de regulerende factoren van dit proces. Ten eerste wordt 
de ontdekking en het belang van surfactant beschreven, wat vervolgens verder gaat in een 
beschrijving van de chemie van surfactant. Surfactant is opgebouwd uit 90% lipiden (metals 
belangrijkste: dipalmitoylphosphatidylcholine, phosphatidylcholine, phosphatidylglycerol, 
phosphatidylinositol, phosphatidylethanolamine en cholesterol) en 10% surfactant specifieke 
eiwitten; SP-A, SP-B, SP-C en SP-D. Daaropvolgend wordt de productie van de componenten 
of meer algemeen het metabolisme van pulmonaal surfactant beschreven. Mogelijke knel-
punten binnen het metabolisme worden aangestipt en de noodzaak van bepaalde onderdelen 
binnen het complex van surfactant metabolisme benadrukt, in het bijzonder de noodzaak van 
heropname van pulmonaal surfactant. 
Hierna worden de beschikbare methoden op het gebied van het meten van de opname van 
surfactant en de voor- en nadelen van elk van de methodes beschreven aan de hand van de 
literatuur, waarna in Hoofdstuk 2 de methode zoals die ontwikkeld is door onze groep 
beschreven wordt. 
Deze bestaat uit het meten van de opname van lipiden door alveolaire cellen met behulp van 
fluorescent gelabelde liposomes en flow-cytometrie. Deze methode, waarbij cel-geassocieerde 
fluorescentie gebruikt wordt als maat voor de opname van fluorescent gelabelde liposomen, 
heeft een aantal voordelen ten opzichte van andere methoden (bijvoorbeeld radioactiviteit): 
zoals de mogelijkheid om zowel in vivo als in vitro te meten en deze resultaten met elkaar te 
vergelijken, alsook het aan tonen dat de fluorescentie wordt veroorzaakt door intracellulaire 
aanwezigheid en niet door 'kleven' aan het celmembraan. Bovendien maken de meeste 
methoden gebruik van gelabeld dipalmitoylphosphatidylcholine, een van de meest essentiele 
lipiden, terwijl onze methode een andere lipid gebruikt als tracer, namelijk phosphatidylet-
hanolamine een lipid dat slechts in geringe mate voorkomt in pulmonaal surfactant (8 
gewichtsprocenten). Het labelen van een niet-essentieellipid maakt het mogelijk de rol van 
'essentiele' lipiden te onderzoeken. 
In Hoofdstuk 3 wordt beschreven hoe met behulp van gemodificeerde liposomen, die voor 
86% bestaand uit het te bestuderen lipid, fluorescent gelabeld phosphatidylethanolamine en 
cholesterol, het effect van dipalmitoylphosphatidylcholine, phosphatidylcholine, phosphati-
dylglycerol en phosphatidylinositol bepaald kan worden. Uit de resultaten van deze 
experimenten kan geconcludeerd worden dat negatief geladen lipiden beter/sneller opgenomen 
worden dan neutraal geladen lipden of surfactant-achtige liposomen. Daarnaast wezen 
competitie experimenten met phosphatidylglycerol en dipalmitoylphosphatidylcholine of 
phosphatidylinositol aan dat deze lipiden opgenomen worden via dezelfde weg, echter dat er 
een voorkeur bestaat voor 'negatief' geladen lipiden. 
In Hoofdstuk 4 wordt dit verder onderzocht door het effect van phosphatidylglycerol, het op 
2 na belangrijkste lipid, in vivo te bestuderen. Daaruit kwam naar voren dat hoge concentraties 
phosphatidylglycerolleiden tot een afname in het aantal alveolaire macrofagen in broncho-
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alveolaire lavage. Tevens en niet geheel onbelangrijk, induceert een verhoogde concentratie 
phosphatidylglycerol een verslechtering van de arteriele oxygenatie als ook diffuse alveolaire 
schade zoals op histologische coupes aangetoond werd. Het dient opgemerkt te worden dat de 
aanwezigheid van co-factoren, als calcium en magnesium, in het liposoom deze negatieve 
effecten van phosphatidylglycerol kan voorkomen. Hiermee is aangetoond dat naast de in de 
literatuur beschreven surfactant specifieke eiwitten, met name SP-A, de lipid samenstelling 
eveneens een rol speelt in de regulatie van de opname van surfactant, in het bijzonder 
phosphatidylglycerol. Echter, de rol van de hydrofobe eiwitten op de opname van surfactant 
in vivo is niet bekend. 
In Hoofdstuk 5 worden de resultaten beschreven van de experimenten zoals die uitgevoerd 
zijn om de rol van SP-B en/of SP-C op de heropname van surfactant te bestuderen. Het 
hydrofobe SP-B, essentieel voor de surfactant functie aangezien afwezigheid bij geboorte leidt 
tot directe dood, lijkt geen effect op de opname van surfactant te hebben, SP-C daarentegen, 
voornamelijk in de aanwezigheid van eerder genoemde factoren als calcium en magnesium, 
kan de opname daadwerkelijk bei:nvloeden. Deze twee surfactant eiwitten, SP-B en SP-C, 
worden heden ten dage toegevoegd aan exogeen surfactant, zoals dat gebruikt wordt in 
klinische toepassing. Ofschoon exogeen surfactant therapie wereldwijd geaccepteerd is als een 
levensreddende interventie in neonaten en kinderen leidend aan Respiratory Distress 
Syndrome (RDS), ongeacht de oorzaak, zijn de effecten van exogeen surfactant op het 
endogene surfactant metabolisme nog niet geheel opgehelderd. 
In Hoofdstuk 6 van dit proefschrift wordt het effect van exogeen surfactant op de opname van 
op surfactant lijkende liposomen in gezonde dieren bestudeerd, alsook in vitro. In deze laatste 
situaties werd aangetoond dat de grote, oppervlakte-actieve aggregaten van surfactant de 
opname van fluorescent gelabelde kleine aggregaten verhoogd. Aan de andere kant, in vivo, 
leidde de aanwezigheid van exogeen surfactant tot een verlaging van de opname van lipo-
somen. De onderliggende mechanismen van deze tegenstrijdige effecten van exogeen 
surfactant op de opname zullen verder onderzocht moeten worden, ofschoon duidelijk is dat 
'omgevingsfactoren' een rol spelen. 
De kosten van exogeen surfactant zijn hoog en derhalve wordt er gezocht naar een mogelijk-
heid om een synthetisch surfactant, alsook synthetische varianten/mimics van SP-B te produ-
ceren. Echter, deze synthetische peptiden mogen het endogene metabolisme logischerwijs niet 
bei:nvloeden. 
Recent, zijn een aantal SP-B analogen ontwikkeld en in Hoofdstuk 7 wordt hun effect op de 
opname van surfactant-achtige liposomen bestudeert en beschreven dat monomerisch en 
dimerisch SP-B-1-25 de opname door alveolaire type II cellen niet bei:nvloed, maar het 
vervangen van aminozuren door serine leid tot de 'serine' variant van SP-B-1-25 en geeft een 
verminderde opname door type II cellen. Met het oog op alveolaire macrofagen valt op dat de 
aanwezigheid van monomerisch SP-B-1-25 of serine dimerisch SP-B-1-25 leidt tot een 
verhoogde opname van de liposomen; de aanwezigheid van dimerisch SP-B-1-25 in het lipo-
soom daarentegen leidt tot een verminderde opname van deze liposomen door alveolaire 
macrofagen. Uit deze resultaten kan geconcludeerd worden dat mutant SP-B peptide, zoals de 
'serine variant', de surfactant recycling kan verminderen en dus een effect zou kunnen hebben 
op het endogene surfactant metabolisme. 
Tot slot kan uit de resultaten zoals beschreven in dit proefschrift geconcludeerd worden dat het 
gebruik van fluorescent gelabelde liposomen een goede methode is om surfactant opname door 
alveolaire cellen te meten met een aantal voordelen ten opzichte van de tot op heden gebruikte 
methoden. Met behulp van deze methode is aangetoond dat er essentiele verschillen bestaan 
tussen de in vivo en in vitro situatie en dat de opname van surfactant niet alleen bepaald wordt 
door surfactant specifieke eiwitten maar zeker ook door haar lipid samenstelling. Ten aanzien 
van het effect van exogeen surfactant op de opname en mogelijk dus het endogene metabo-
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lisme moet aangestipt worden dat er in vitro een stimulatie van de opname gezien werd terwijl 
in vivo de opname verminderde; echter de onderliggende mechanismen hiervan zijn niet 
bekend. Met het oog op de ontwikkeling van een synthetisch surfactant moet gemeld worden 
dat het gebruik van surfactant eiwit analogen mogelijk is, ofschoon variaties in aminozuren 
zouden kunnen leiden tot een verandert metabolisme van het specifieke eiwit, zoals aan-
getoond voor de varianten, c.q. synthetische analogen van SP-B. 
Het werk dat gepresenteerd wordt in dit proefschrift laat zien dat de opname van surfactant 
gemeten kan worden met fluorescent gelabelde liposomen; en onderstreept de noodzaak om 
zowel in vivo als in vitro te meten, laat een effect van samenstelling op de opname zien, demon-
streert het effect van de natuurlijk hydrofobe eiwitten SP-B en SP-C als ook van synthetische 
SP-B analogen op de opname en tot slot het effect van exogeen surfactant op de opname in 
gezonde dieren. Het is essentieel om de opname van surfactant verder te onderzoeken, 
bijvoorbeeld in zieke dieren, met het oog op opheldering van regulerende factoren en uit-
eindelijk de ontwikkeling van een ziekte specifiek surfactant, waarbij haar samenstelling 
afhankelijk is van het onderliggend lijden. 
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